1
|
Dietzsch AN, Al-Hasani H, Altschmied J, Bottermann K, Brendler J, Haendeler J, Horn S, Kaczmarek I, Körner A, Krause K, Landgraf K, Le Duc D, Lehmann L, Lehr S, Pick S, Ricken A, Schnorr R, Schulz A, Strnadová M, Velluva A, Zabri H, Schöneberg T, Thor D, Prömel S. Dysfunction of the adhesion G protein-coupled receptor latrophilin 1 (ADGRL1/LPHN1) increases the risk of obesity. Signal Transduct Target Ther 2024; 9:103. [PMID: 38664368 PMCID: PMC11045723 DOI: 10.1038/s41392-024-01810-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2023] [Revised: 03/04/2024] [Accepted: 03/20/2024] [Indexed: 04/28/2024] Open
Abstract
Obesity is one of the diseases with severe health consequences and rapidly increasing worldwide prevalence. Understanding the complex network of food intake and energy balance regulation is an essential prerequisite for pharmacological intervention with obesity. G protein-coupled receptors (GPCRs) are among the main modulators of metabolism and energy balance. They, for instance, regulate appetite and satiety in certain hypothalamic neurons, as well as glucose and lipid metabolism and hormone secretion from adipocytes. Mutations in some GPCRs, such as the melanocortin receptor type 4 (MC4R), have been associated with early-onset obesity. Here, we identified the adhesion GPCR latrophilin 1 (ADGRL1/LPHN1) as a member of the regulating network governing food intake and the maintenance of energy balance. Deficiency of the highly conserved receptor in mice results in increased food consumption and severe obesity, accompanied by dysregulation of glucose homeostasis. Consistently, we identified a partially inactivating mutation in human ADGRL1/LPHN1 in a patient suffering from obesity. Therefore, we propose that LPHN1 dysfunction is a risk factor for obesity development.
Collapse
Affiliation(s)
- André Nguyen Dietzsch
- Rudolf Schönheimer Institute of Biochemistry, Medical Faculty, Leipzig University, Leipzig, Germany
| | - Hadi Al-Hasani
- Institute for Clinical Biochemistry and Pathobiochemistry, Medical Faculty, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University Düsseldorf, Düsseldorf, Germany
- German Center for Diabetes Research (DZD e.V.), Munich-Neuherberg, Germany
| | - Joachim Altschmied
- Cardiovascular Degeneration, Clinical Chemistry and Laboratory Diagnostics, Medical Faculty, University Hospital and Heinrich Heine University Düsseldorf, Düsseldorf, Germany
- Cardiovascular Research Institute (CARID), Medical Faculty, University Hospital and Heinrich Heine University Düsseldorf, Düsseldorf, Germany
| | - Katharina Bottermann
- Cardiovascular Research Institute (CARID), Medical Faculty, University Hospital and Heinrich Heine University Düsseldorf, Düsseldorf, Germany
- Institute of Pharmacology, Medical Faculty, University Hospital and Heinrich Heine University Düsseldorf, Düsseldorf, Germany
| | - Jana Brendler
- Institute of Anatomy, Medical Faculty, Leipzig University, Leipzig, Germany
| | - Judith Haendeler
- Cardiovascular Degeneration, Clinical Chemistry and Laboratory Diagnostics, Medical Faculty, University Hospital and Heinrich Heine University Düsseldorf, Düsseldorf, Germany
- Cardiovascular Research Institute (CARID), Medical Faculty, University Hospital and Heinrich Heine University Düsseldorf, Düsseldorf, Germany
| | - Susanne Horn
- Rudolf Schönheimer Institute of Biochemistry, Medical Faculty, Leipzig University, Leipzig, Germany
| | - Isabell Kaczmarek
- Rudolf Schönheimer Institute of Biochemistry, Medical Faculty, Leipzig University, Leipzig, Germany
| | - Antje Körner
- Center for Pediatric Research, Hospital for Children and Adolescents, Medical Faculty, Leipzig University, Leipzig, Germany
- Helmholtz Institute for Metabolic, Obesity and Vascular Research (HI-MAG) of the Helmholtz Zentrum München at the University of Leipzig and University Hospital Leipzig, Leipzig, Germany
| | - Kerstin Krause
- Department of Endocrinology, Nephrology, Rheumatology, Leipzig University Medical Center, Leipzig, Germany
| | - Kathrin Landgraf
- Center for Pediatric Research, Hospital for Children and Adolescents, Medical Faculty, Leipzig University, Leipzig, Germany
| | - Diana Le Duc
- Institute of Human Genetics, Leipzig University Medical Center, Leipzig, Germany
| | - Laura Lehmann
- Institute of Cell Biology, Department of Biology, Heinrich Heine University Düsseldorf, Düsseldorf, Germany
| | - Stefan Lehr
- Institute for Clinical Biochemistry and Pathobiochemistry, Medical Faculty, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University Düsseldorf, Düsseldorf, Germany
- German Center for Diabetes Research (DZD e.V.), Munich-Neuherberg, Germany
| | - Stephanie Pick
- Institute of Cell Biology, Department of Biology, Heinrich Heine University Düsseldorf, Düsseldorf, Germany
| | - Albert Ricken
- Institute of Anatomy, Medical Faculty, Leipzig University, Leipzig, Germany
| | - Rene Schnorr
- Institute of Cell Biology, Department of Biology, Heinrich Heine University Düsseldorf, Düsseldorf, Germany
| | - Angela Schulz
- Rudolf Schönheimer Institute of Biochemistry, Medical Faculty, Leipzig University, Leipzig, Germany
| | - Martina Strnadová
- Rudolf Schönheimer Institute of Biochemistry, Medical Faculty, Leipzig University, Leipzig, Germany
| | - Akhil Velluva
- Institute of Human Genetics, Leipzig University Medical Center, Leipzig, Germany
| | - Heba Zabri
- Institute of Pharmacology, Medical Faculty, University Hospital and Heinrich Heine University Düsseldorf, Düsseldorf, Germany
| | - Torsten Schöneberg
- Rudolf Schönheimer Institute of Biochemistry, Medical Faculty, Leipzig University, Leipzig, Germany
- School of Medicine, University of Global Health Equity, Kigali, Rwanda
| | - Doreen Thor
- Rudolf Schönheimer Institute of Biochemistry, Medical Faculty, Leipzig University, Leipzig, Germany.
| | - Simone Prömel
- Institute of Cell Biology, Department of Biology, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
| |
Collapse
|
2
|
Springer C, Binsch C, Weide D, Toska L, Cremer AL, Backes H, Scheel AK, Espelage L, Kotzka J, Sill S, Kurowski A, Kim D, Karpinski S, Schnurr TM, Hansen T, Hartwig S, Lehr S, Cames S, Brüning J, Lienhard M, Herwig R, Börno S, Timmermann B, Al-Hasani H, Chadt A. Depletion of TBC1D4 improves the metabolic exercise response by overcoming genetically induced peripheral insulin resistance. Diabetes 2024:db230463. [PMID: 38608276 DOI: 10.2337/db23-0463] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/05/2024] [Accepted: 04/02/2024] [Indexed: 04/14/2024]
Abstract
The RabGTPase-activating protein (RabGAP) TBC1D4 (=AS160) represents a key component in the regulation of glucose transport into skeletal muscle and white adipose tissue (WAT) and is therefore crucial during the development of insulin resistance and type-2 diabetes. Increased daily activity has been shown to be associated with improved postprandial hyperglycemia in allele carriers of a loss-of-function variant in the human TBC1D4 gene. Using conventional Tbc1d4-deficient mice (D4KO) fed a high-fat diet (HFD), we show that already a moderate endurance exercise training leads to substantially improved glucose and insulin tolerance and enhanced expression levels of markers for mitochondrial activity and browning in WAT from D4KO animals. Importantly, in vivo and ex vivo analyses of glucose uptake revealed increased glucose clearance in interscapular brown adipose tissue (iBAT) and WAT from trained D4KO mice. Thus, chronic exercise is able to overcome the genetically induced insulin resistance caused by the Tbc1d4-depletion. Gene variants in TBC1D4 may be relevant in future precision medicine as determinants of exercise response.
Collapse
Affiliation(s)
- Christian Springer
- Institute for Clinical Biochemistry and Pathobiochemistry, German Diabetes Center (DDZ), Leibniz-Center for Diabetes Research at the Heinrich Heine University, Medical faculty, Düsseldorf
- German Center for Diabetes Research, Partner Düsseldorf, München-Neuherberg, Germany
| | - Christian Binsch
- Institute for Clinical Biochemistry and Pathobiochemistry, German Diabetes Center (DDZ), Leibniz-Center for Diabetes Research at the Heinrich Heine University, Medical faculty, Düsseldorf
- German Center for Diabetes Research, Partner Düsseldorf, München-Neuherberg, Germany
| | - Deborah Weide
- Institute for Clinical Biochemistry and Pathobiochemistry, German Diabetes Center (DDZ), Leibniz-Center for Diabetes Research at the Heinrich Heine University, Medical faculty, Düsseldorf
- German Center for Diabetes Research, Partner Düsseldorf, München-Neuherberg, Germany
| | - Laura Toska
- Institute for Clinical Biochemistry and Pathobiochemistry, German Diabetes Center (DDZ), Leibniz-Center for Diabetes Research at the Heinrich Heine University, Medical faculty, Düsseldorf
- German Center for Diabetes Research, Partner Düsseldorf, München-Neuherberg, Germany
| | - Anna Lena Cremer
- Institute for Neuronal Control of Brain Metabolism, Max Planck Institute for Metabolism Research, Cologne, Germany
| | - Heiko Backes
- Institute for Neuronal Control of Brain Metabolism, Max Planck Institute for Metabolism Research, Cologne, Germany
| | - Anna K Scheel
- Institute for Clinical Biochemistry and Pathobiochemistry, German Diabetes Center (DDZ), Leibniz-Center for Diabetes Research at the Heinrich Heine University, Medical faculty, Düsseldorf
- German Center for Diabetes Research, Partner Düsseldorf, München-Neuherberg, Germany
| | - Lena Espelage
- Institute for Clinical Biochemistry and Pathobiochemistry, German Diabetes Center (DDZ), Leibniz-Center for Diabetes Research at the Heinrich Heine University, Medical faculty, Düsseldorf
- German Center for Diabetes Research, Partner Düsseldorf, München-Neuherberg, Germany
| | - Jörg Kotzka
- Institute for Clinical Biochemistry and Pathobiochemistry, German Diabetes Center (DDZ), Leibniz-Center for Diabetes Research at the Heinrich Heine University, Medical faculty, Düsseldorf
| | - Sebastian Sill
- Institute for Clinical Biochemistry and Pathobiochemistry, German Diabetes Center (DDZ), Leibniz-Center for Diabetes Research at the Heinrich Heine University, Medical faculty, Düsseldorf
- German Center for Diabetes Research, Partner Düsseldorf, München-Neuherberg, Germany
| | - Anette Kurowski
- Institute for Clinical Biochemistry and Pathobiochemistry, German Diabetes Center (DDZ), Leibniz-Center for Diabetes Research at the Heinrich Heine University, Medical faculty, Düsseldorf
| | - Daebin Kim
- Institute for Clinical Biochemistry and Pathobiochemistry, German Diabetes Center (DDZ), Leibniz-Center for Diabetes Research at the Heinrich Heine University, Medical faculty, Düsseldorf
| | - Sandra Karpinski
- Institute for Clinical Biochemistry and Pathobiochemistry, German Diabetes Center (DDZ), Leibniz-Center for Diabetes Research at the Heinrich Heine University, Medical faculty, Düsseldorf
| | - Theresia M Schnurr
- Section of Metabolic Genetics, Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
| | - Torben Hansen
- Section of Metabolic Genetics, Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
| | - Sonja Hartwig
- Institute for Clinical Biochemistry and Pathobiochemistry, German Diabetes Center (DDZ), Leibniz-Center for Diabetes Research at the Heinrich Heine University, Medical faculty, Düsseldorf
- German Center for Diabetes Research, Partner Düsseldorf, München-Neuherberg, Germany
| | - Stefan Lehr
- Institute for Clinical Biochemistry and Pathobiochemistry, German Diabetes Center (DDZ), Leibniz-Center for Diabetes Research at the Heinrich Heine University, Medical faculty, Düsseldorf
- German Center for Diabetes Research, Partner Düsseldorf, München-Neuherberg, Germany
| | - Sandra Cames
- Institute for Clinical Biochemistry and Pathobiochemistry, German Diabetes Center (DDZ), Leibniz-Center for Diabetes Research at the Heinrich Heine University, Medical faculty, Düsseldorf
- German Center for Diabetes Research, Partner Düsseldorf, München-Neuherberg, Germany
| | - Jens Brüning
- Institute for Neuronal Control of Brain Metabolism, Max Planck Institute for Metabolism Research, Cologne, Germany
| | | | - Ralf Herwig
- Max-Planck-Institue for Molecular Genetics, Berlin, Germany
| | - Stefan Börno
- Max-Planck-Institue for Molecular Genetics, Berlin, Germany
| | | | - Hadi Al-Hasani
- Institute for Clinical Biochemistry and Pathobiochemistry, German Diabetes Center (DDZ), Leibniz-Center for Diabetes Research at the Heinrich Heine University, Medical faculty, Düsseldorf
- German Center for Diabetes Research, Partner Düsseldorf, München-Neuherberg, Germany
| | - Alexandra Chadt
- Institute for Clinical Biochemistry and Pathobiochemistry, German Diabetes Center (DDZ), Leibniz-Center for Diabetes Research at the Heinrich Heine University, Medical faculty, Düsseldorf
- German Center for Diabetes Research, Partner Düsseldorf, München-Neuherberg, Germany
| |
Collapse
|
3
|
Große-Segerath L, Follert P, Behnke K, Ettich J, Buschmann T, Kirschner P, Hartwig S, Lehr S, Korf-Klingebiel M, Eberhard D, Lehwald-Tywuschik N, Al-Hasani H, Knoefel WT, Heinrich S, Levkau B, Wollert KC, Scheller J, Lammert E. Identification of myeloid-derived growth factor as a mechanically-induced, growth-promoting angiocrine signal for human hepatocytes. Nat Commun 2024; 15:1076. [PMID: 38316785 PMCID: PMC10844291 DOI: 10.1038/s41467-024-44760-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2022] [Accepted: 01/02/2024] [Indexed: 02/07/2024] Open
Abstract
Recently, we have shown that after partial hepatectomy (PHx), an increased hepatic blood flow initiates liver growth in mice by vasodilation and mechanically-triggered release of angiocrine signals. Here, we use mass spectrometry to identify a mechanically-induced angiocrine signal in human hepatic endothelial cells, that is, myeloid-derived growth factor (MYDGF). We show that it induces proliferation and promotes survival of primary human hepatocytes derived from different donors in two-dimensional cell culture, via activation of mitogen-activated protein kinase (MAPK) and signal transducer and activator of transcription 3 (STAT3). MYDGF also enhances proliferation of human hepatocytes in three-dimensional organoids. In vivo, genetic deletion of MYDGF decreases hepatocyte proliferation in the regenerating mouse liver after PHx; conversely, adeno-associated viral delivery of MYDGF increases hepatocyte proliferation and MAPK signaling after PHx. We conclude that MYDGF represents a mechanically-induced angiocrine signal and that it triggers growth of, and provides protection to, primary mouse and human hepatocytes.
Collapse
Affiliation(s)
- Linda Große-Segerath
- Heinrich Heine University Düsseldorf, Faculty of Mathematics and Natural Sciences, Institute of Metabolic Physiology, 40225, Düsseldorf, Germany
- Institute for Vascular and Islet Cell Biology, German Diabetes Center (DDZ), Leibniz Center for Diabetes Research at Heinrich Heine University, 40225, Düsseldorf, Germany
- German Center for Diabetes Research (DZD e.V.), Helmholtz Zentrum München, 85764, Neuherberg, Germany
| | - Paula Follert
- Heinrich Heine University Düsseldorf, Faculty of Mathematics and Natural Sciences, Institute of Metabolic Physiology, 40225, Düsseldorf, Germany
| | - Kristina Behnke
- Institute of Biochemistry and Molecular Biology II, Medical Faculty and University Hospital Düsseldorf, Heinrich Heine University Düsseldorf, 40225, Düsseldorf, Germany
| | - Julia Ettich
- Institute of Biochemistry and Molecular Biology II, Medical Faculty and University Hospital Düsseldorf, Heinrich Heine University Düsseldorf, 40225, Düsseldorf, Germany
| | - Tobias Buschmann
- Institute for Molecular Medicine III, Medical Faculty and University Hospital Düsseldorf, Heinrich Heine University Düsseldorf, 40225, Düsseldorf, Germany
| | - Philip Kirschner
- Heinrich Heine University Düsseldorf, Faculty of Mathematics and Natural Sciences, Institute of Metabolic Physiology, 40225, Düsseldorf, Germany
| | - Sonja Hartwig
- German Center for Diabetes Research (DZD e.V.), Helmholtz Zentrum München, 85764, Neuherberg, Germany
- Institute for Clinical Biochemistry and Pathobiochemistry, German Diabetes Center (DDZ), Leibniz Center for Diabetes Research at Heinrich Heine University, Medical Faculty, 40225, Düsseldorf, Germany
| | - Stefan Lehr
- German Center for Diabetes Research (DZD e.V.), Helmholtz Zentrum München, 85764, Neuherberg, Germany
- Institute for Clinical Biochemistry and Pathobiochemistry, German Diabetes Center (DDZ), Leibniz Center for Diabetes Research at Heinrich Heine University, Medical Faculty, 40225, Düsseldorf, Germany
| | - Mortimer Korf-Klingebiel
- Division of Molecular and Translational Cardiology, Department of Cardiology and Angiology, Hannover Medical School, 30625, Hannover, Germany
| | - Daniel Eberhard
- Heinrich Heine University Düsseldorf, Faculty of Mathematics and Natural Sciences, Institute of Metabolic Physiology, 40225, Düsseldorf, Germany
| | - Nadja Lehwald-Tywuschik
- Department of General, Visceral, Thorax and Pediatric Surgery, Medical Faculty and University Hospital Düsseldorf, Heinrich Heine University Düsseldorf, 40225, Düsseldorf, Germany
| | - Hadi Al-Hasani
- German Center for Diabetes Research (DZD e.V.), Helmholtz Zentrum München, 85764, Neuherberg, Germany
- Institute for Clinical Biochemistry and Pathobiochemistry, German Diabetes Center (DDZ), Leibniz Center for Diabetes Research at Heinrich Heine University, Medical Faculty, 40225, Düsseldorf, Germany
| | - Wolfram Trudo Knoefel
- Department of General, Visceral, Thorax and Pediatric Surgery, Medical Faculty and University Hospital Düsseldorf, Heinrich Heine University Düsseldorf, 40225, Düsseldorf, Germany
| | - Stefan Heinrich
- Department of General, Visceral and Transplantation Surgery, University Hospital Center Mainz, 55131, Mainz, Germany
| | - Bodo Levkau
- Institute for Molecular Medicine III, Medical Faculty and University Hospital Düsseldorf, Heinrich Heine University Düsseldorf, 40225, Düsseldorf, Germany
| | - Kai C Wollert
- Division of Molecular and Translational Cardiology, Department of Cardiology and Angiology, Hannover Medical School, 30625, Hannover, Germany
| | - Jürgen Scheller
- Institute of Biochemistry and Molecular Biology II, Medical Faculty and University Hospital Düsseldorf, Heinrich Heine University Düsseldorf, 40225, Düsseldorf, Germany
| | - Eckhard Lammert
- Heinrich Heine University Düsseldorf, Faculty of Mathematics and Natural Sciences, Institute of Metabolic Physiology, 40225, Düsseldorf, Germany.
- Institute for Vascular and Islet Cell Biology, German Diabetes Center (DDZ), Leibniz Center for Diabetes Research at Heinrich Heine University, 40225, Düsseldorf, Germany.
- German Center for Diabetes Research (DZD e.V.), Helmholtz Zentrum München, 85764, Neuherberg, Germany.
| |
Collapse
|
4
|
van Meijel RLJ, Vliex LMM, Hartwig S, Lehr S, Al-Hasani H, Blaak EE, Goossens GH. The impact of mild hypoxia exposure on myokine secretion in human obesity. Int J Obes (Lond) 2023; 47:520-527. [PMID: 36997723 DOI: 10.1038/s41366-023-01294-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/17/2022] [Revised: 02/22/2023] [Accepted: 03/10/2023] [Indexed: 04/01/2023]
Abstract
BACKGROUND/OBJECTIVE Compelling evidence indicates that myokines act in an autocrine, paracrine and endocrine manner to alter metabolic homeostasis. The mechanisms underlying exercise-induced changes in myokine secretion remain to be elucidated. Since exercise acutely decreases oxygen partial pressure (pO2) in skeletal muscle (SM), the present study was designed to test the hypothesis that (1) hypoxia exposure impacts myokine secretion in primary human myotubes and (2) exposure to mild hypoxia in vivo alters fasting and postprandial plasma myokine concentrations in humans. METHODS Differentiated primary human myotubes were exposed to different physiological pO2 levels for 24 h, and cell culture medium was harvested to determine myokine secretion. Furthermore, we performed a randomized single-blind crossover trial to investigate the impact of mild intermittent hypoxia exposure (MIH: 7-day exposure to 15% O2, 3x2h/day vs. normoxia: 21% O2) on in vivo SM pO2 and plasma myokine concentrations in 12 individuals with overweight and obesity (body-mass index ≥ 28 kg/m2). RESULTS Hypoxia exposure (1% O2) increased secreted protein acidic and rich in cysteine (SPARC, p = 0.043) and follistatin like 1 (FSTL1, p = 0.021), and reduced leukemia inhibitory factor (LIF) secretion (p = 0.009) compared to 3% O2 in primary human myotubes. In addition, 1% O2 exposure increased interleukin-6 (IL-6, p = 0.004) and SPARC secretion (p = 0.021), whilst reducing fatty acid binding protein 3 (FABP3) secretion (p = 0.021) compared to 21% O2. MIH exposure in vivo markedly decreased SM pO2 (≈40%, p = 0.002) but did not alter plasma myokine concentrations. CONCLUSIONS Hypoxia exposure altered the secretion of several myokines in primary human myotubes, revealing hypoxia as a novel modulator of myokine secretion. However, both acute and 7-day MIH exposure did not induce alterations in plasma myokine concentrations in individuals with overweight and obesity. CLINICAL TRIALS IDENTIFIER This study is registered at the Netherlands Trial Register (NL7120/NTR7325).
Collapse
Affiliation(s)
- Rens L J van Meijel
- Department of Human Biology, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University Medical Center+, Maastricht, The Netherlands
| | - Lars M M Vliex
- Department of Human Biology, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University Medical Center+, Maastricht, The Netherlands
| | - Sonja Hartwig
- Institute for Clinical Biochemistry and Pathobiochemistry, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University, Medical Faculty, Duesseldorf, Germany
- German Center for Diabetes Research, Partner Duesseldorf, München-Neuherberg, Duesseldorf, Germany
| | - Stefan Lehr
- Institute for Clinical Biochemistry and Pathobiochemistry, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University, Medical Faculty, Duesseldorf, Germany
- German Center for Diabetes Research, Partner Duesseldorf, München-Neuherberg, Duesseldorf, Germany
| | - Hadi Al-Hasani
- Institute for Clinical Biochemistry and Pathobiochemistry, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University, Medical Faculty, Duesseldorf, Germany
- German Center for Diabetes Research, Partner Duesseldorf, München-Neuherberg, Duesseldorf, Germany
| | - Ellen E Blaak
- Department of Human Biology, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University Medical Center+, Maastricht, The Netherlands
| | - Gijs H Goossens
- Department of Human Biology, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University Medical Center+, Maastricht, The Netherlands.
| |
Collapse
|
5
|
Roeder J, Liu J, Doch I, Ruschhaupt M, Christmann A, Grill E, Helmke H, Hohmann S, Lehr S, Frackenpohl J, Yang Z. Abscisic acid agonists suitable for optimizing plant water use. Front Plant Sci 2023; 13:1071710. [PMID: 36743550 PMCID: PMC9894685 DOI: 10.3389/fpls.2022.1071710] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 10/16/2022] [Accepted: 12/28/2022] [Indexed: 06/18/2023]
Abstract
Climate change and overexploitation of groundwater resources cause constraints on water demand for agriculture, thus threatening crop productivity. For future food security, there is an urgent need for crops of high water use efficiency combined with high crop productivity, i.e. having high water productivity. High water productivity means efficient biomass accumulation at reduced transpiration. Recent studies show that plants are able to optimize carbon uptake per water transpired with little or no trade-off in yield. The phytohormone abscisic acid (ABA) plays a pivotal role in minimizing leaf transpiration and mediating enhanced water productivity. Hence, ABA and more chemically stable ABA agonists have the potential to improve crop water productivity. Synthesis, screening, and identification of suitable ABA agonists are major efforts currently undertaken. In this study, we used yeast expressing the plant ABA signal pathway to prescreen ABA-related cyano cyclopropyl compounds (CCPs). The yeast analysis allowed testing the ABA agonists for general toxicity, efficient uptake, and specificity in regulating different ABA receptor complexes. Subsequently, promising ABA-mimics were analyzed in vitro for ligand-receptor interaction complemented by physiological analyses. Several CCPs activated ABA signaling in yeast and plant cells. CCP1, CCP2, and CCP5 were by an order of magnitude more efficient than ABA in minimizing transpiration of Arabidopsis plants. In a progressive drought experiment, CCP2 mediated an increase in water use efficiency superior to ABA without trade-offs in biomass accumulation.
Collapse
Affiliation(s)
- Jan Roeder
- Department of Botany, Technical University of Munich, Freising, Germany
| | - Jinghui Liu
- Department of Botany, Technical University of Munich, Freising, Germany
| | - Isabel Doch
- Department of Botany, Technical University of Munich, Freising, Germany
| | - Moritz Ruschhaupt
- Department of Botany, Technical University of Munich, Freising, Germany
| | | | - Erwin Grill
- Department of Botany, Technical University of Munich, Freising, Germany
| | - Hendrik Helmke
- Research and Development, Weed Control Research, Division Crop Science, Bayer AG, Frankfurt am Main, Germany
| | - Sabine Hohmann
- Research and Development, Weed Control Research, Division Crop Science, Bayer AG, Frankfurt am Main, Germany
| | - Stefan Lehr
- Research and Development, Weed Control Research, Division Crop Science, Bayer AG, Frankfurt am Main, Germany
| | - Jens Frackenpohl
- Research and Development, Weed Control Research, Division Crop Science, Bayer AG, Frankfurt am Main, Germany
| | - Zhenyu Yang
- Department of Botany, Technical University of Munich, Freising, Germany
| |
Collapse
|
6
|
Lehr S, Felber F, Tantcheva-Poor I, Keßler C, Eming R, Nyström A, Rizzi M, Kiritsi D. 065 Evaluating pathogenicity of skin autoantibodies in hereditary epidermolysis bullosa hints towards predisposition of autoimmunity. J Invest Dermatol 2022. [DOI: 10.1016/j.jid.2022.09.074] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
7
|
Ostendorf Y, Rolauer L, Pasch N, Schaefer H, Heitmann S, Petzsch P, Poschmann G, Hartwig S, Lehr S, Koehrer K, Fischer JW, Grandoch M. Neutrophils as major drivers of increased atherosclerosis in a murine model of chronic colitis. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.3042] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Recent findings showed a higher risk of premature atherosclerosis and cardiovascular events in patients with inflammatory bowel disease (IBD) especially during acute flare of the chronic disease. The underlying mechanisms remain to be defined since traditional risk factors such as hypercholesterinemia are not present in these patients.
Purpose
The present study aimed to unravel the underlying pathomechanisms of enhanced atherogenesis and -progression in a murine model of colitis.
Methods
Chronic colitis was induced in male Apolipoprotein E-deficient mice (Apoe−/−) using dextran sodium sulphate (DSS) in drinking water for 2,3 or 5 cycles, while the control group received regular drinking water. Each cycle consisted of 6 days DSS application and two weeks of recovery. Aortic atherosclerotic plaque burden was determined by en face Oil Red O staining and immune cell subsets were analysed by flow cytometry in the circulation, the bone marrow, and the aorta. Neutrophil depletion was performed via i.p injection of a Ly6G-depleting antibody or respective isotype control. Bone marrow-derived neutrophils were further analysed by transcriptome analysis.
Results
Similar to IBD patients, mice with chronic colitis exhibited an increased aortic plaque burden after 15 weeks of treatment despite the absence of classical risk factors. Over time, both circulating and aortic neutrophils showed an oscillatory detection pattern with the first significant increase after the 2nd DSS administration whereby the second increase after the 3rd DSS cycle was even stronger. Also, pro-inflammatory cytokines were elevated in the plasma and specifically G-CSF showed the same oscillatory pattern with increased plasma level already after the 2nd DSS administration and an even stronger increase after the 3rd thereby pointing towards alterations in bone marrow hematopoiesis. In line, flow cytometric analyses confirmed a greater rise of hematopoietic stem and even myeloid progenitor cells compared with the 2nd DSS application in IBD mice after 3rd treatment. scRNA-Seq analysis of progenitor cells revealed changes in cell differentiation towards neutrophils and upregulation of proinflammatory genes in isolated neutrophils of DSS-treated mice. These neutrophils showed also a more adhesive phenotype revealed by increased mRNA expression of Glg1 and Selplg. Accordingly, also Sele mRNA was increased in the aorta. The reduction of circulating neutrophils by an anti-Ly6G antibody during the acute phases of colitis reduced the aortic plaque burden compared to isotype treaded mice.
Conclusion
The current findings suggest detrimental effects of chronic colitis on atherogenesis and -progression in Apoe−/− mice via increased differentiation of myeloid cells into neutrophils and the promotion of a more adhesive and proinflammatory phenotype. These modified neutrophils may act as initiators of atherogenesis by promoting the invasion of immune cells into the aortic wall.
Funding Acknowledgement
Type of funding sources: None.
Collapse
Affiliation(s)
- Y Ostendorf
- University Hospital Duesseldorf , Duesseldorf , Germany
| | - L Rolauer
- University Hospital Duesseldorf , Duesseldorf , Germany
| | - N Pasch
- University Hospital Duesseldorf , Duesseldorf , Germany
| | - H Schaefer
- University Hospital Duesseldorf , Duesseldorf , Germany
| | - S Heitmann
- University Hospital Duesseldorf , Duesseldorf , Germany
| | - P Petzsch
- Heinrich Heine University , Duesseldorf , Germany
| | - G Poschmann
- Heinrich Heine University , Duesseldorf , Germany
| | - S Hartwig
- Heinrich Heine University , Duesseldorf , Germany
| | - S Lehr
- Heinrich Heine University , Duesseldorf , Germany
| | - K Koehrer
- Heinrich Heine University , Duesseldorf , Germany
| | - J W Fischer
- University Hospital Duesseldorf , Duesseldorf , Germany
| | - M Grandoch
- University Hospital Duesseldorf , Duesseldorf , Germany
| |
Collapse
|
8
|
Selig JI, Japes F, Kueppers C, Hartwig S, Lehr S, Fischer JW, Lichtenberg A, Akhyari P, Barth M. Hyperglycaemia-induced degeneration of bioprosthetic valve tissue and the pivotal role of the extracellular matrix molecule biglycan. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.2901] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background/Introduction
Bioprosthetic valve degeneration is a growing clinical challenge in our aging society. Especially type 2 diabetes mellitus represents a risk factor for bioprosthetic valve deterioration with likewise worldwide rising prevalence. The proteoglycan biglycan has been shown to be associated with degenerative changes of the valve in diabetic patients even though underlying mechanisms are yet unknown.
Purpose
The impact of hyperglycaemia on bioprosthetic valve tissue was analysed in an established mouse model of ectopic calcification. Thereby, the role of biglycan in bioprosthetic valve degeneration was assessed in biglycan-deficient mice (Bgn-/0) in comparison to wild type littermates (WT).
Methods
Hyperglycaemia was induced in six weeks old mice by intraperitoneal injection of streptozotocin (STZ; 55 mg/kg body weight) on five consecutive days. Blood glucose concentration was verified two weeks after treatment and bioprosthetic valve material was implanted subcutaneously. After eight weeks, phenotype of invading cells and extracellular matrix remodelling of implants were analysed with histochemical and immunohistological staining. Furthermore, gene expression of invading cells, circulating cytokines in blood plasma and calcium accumulation in the tissue were quantified.
Results
STZ treatment significantly increased blood glucose levels in both genotype groups (WT-STZ: 156 mg/dl; WT+STZ: 353 mg/dl; Bgn-/0-STZ: 142 mg/dl; Bgn-/0+STZ: 396 mg/dl). Immunohistological staining identified most of cells invading the bioprosthetic tissue and the surrounded capsule as Mac2-positive and partly positive for vimentin, whereas alpha smooth muscle actin and von Willebrand factor were only detectable sporadically. Movat pentachrome staining exhibited an altered extracellular matrix composition of collagen and proteoglycans due to hyperglycaemia, while the elastin amount remained stable. Gene expression analysis showed an increased expression of the proteoglycan decorin in hyperglycaemic mice (WT-STZ: 0.55; WT+STZ: 1.13; Bgn-/0-STZ: 0.51; Bgn-/0+STZ: 1.70). Circulating cytokines (IL-1β, IL-2, IL-5, IL-10, INF-γ, TNF-α, GM-CSF) were influenced neither by hyperglycaemia nor by the genotype of the mice. Alizarin and von Kossa staining exhibited small to moderate calcium deposits in the bioprosthetic valve tissue. A colorimetric assay showed a significantly increased calcium accumulation in WT with hyperglycaemia versus normoglycemic WT (WT-STZ: 8.96 μg/mg; WT+STZ: 18.54 μg/mg), an observation that was lost in Bgn-/0 (Bgn-/0-STZ: 9.84 μg/mg; Bgn-/0+STZ: 12.97 μg/mg).
Conclusion
Hyperglycaemia significantly promotes destructive remodelling in bioprosthetic valve material. Biglycan-deficiency limits degenerative processes associated with diabetes, suggesting that biglycan as a component of the extracellular matrix has an adverse effect in diabetes-associated bioprosthetic valve deterioration.
Funding Acknowledgement
Type of funding sources: Foundation. Main funding source(s): Dr. Rusche grant of the German Heart Foundation and the German Society for Thoracic and Cardiovascular Surgery
Collapse
Affiliation(s)
- J I Selig
- University Hospital Duesseldorf, Department of Cardiac Surgery , Duesseldorf , Germany
| | - F Japes
- University Hospital Duesseldorf, Department of Cardiac Surgery , Duesseldorf , Germany
| | - C Kueppers
- University Hospital Duesseldorf, Department of Cardiac Surgery , Duesseldorf , Germany
| | - S Hartwig
- German Diabetes Center, Institute of Clinical Biochemistry and Pathobiochemistry , Duesseldorf , Germany
| | - S Lehr
- German Diabetes Center, Institute of Clinical Biochemistry and Pathobiochemistry , Duesseldorf , Germany
| | - J W Fischer
- University Hospital Duesseldorf, Institute for Pharmacology and Clinical Pharmacology , Duesseldorf , Germany
| | - A Lichtenberg
- University Hospital Duesseldorf, Department of Cardiac Surgery , Duesseldorf , Germany
| | - P Akhyari
- University Hospital Duesseldorf, Department of Cardiac Surgery , Duesseldorf , Germany
| | - M Barth
- University Hospital Duesseldorf, Department of Cardiac Surgery , Duesseldorf , Germany
| |
Collapse
|
9
|
Piroth M, Gorski DJ, Hundhausen C, Petz A, Gorressen S, Semmler D, Zabri H, Hartwig S, Lehr S, Kelm M, Jung C, Fischer JW. Hyaluronan Synthase 3 is Protective After Cardiac Ischemia-Reperfusion by preserving the T cell Response. Matrix Biol 2022; 112:116-131. [PMID: 35998871 DOI: 10.1016/j.matbio.2022.08.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2022] [Revised: 08/02/2022] [Accepted: 08/18/2022] [Indexed: 10/15/2022]
Abstract
Dysregulated extracellular matrix (ECM) is a hallmark of adverse cardiac remodeling after myocardial infarction (MI). Previous work from our laboratory suggests that synthesis of the major ECM component hyaluronan (HA) may be beneficial for post-infarct healing. Here, we aimed to investigate the mechanisms of hyaluronan synthase 3 (HAS3) in cardiac healing after MI. Mice with genetic deletion of Has3 (Has3 KO) and wildtype mice (WT) underwent 45 minutes of ischemia with subsequent reperfusion (I/R), followed by monitoring of heart function and analysis of tissue remodeling for up to three weeks. Has3 KO mice exhibited impaired cardiac function as evidenced by a reduced ejection fraction. Accordingly, Has3 deficiency also resulted in an increased scar size. Cardiac fibroblast activation and CD68+ macrophage counts were similar between genotypes. However, we found a significant decrease in CD4 T cells in the hearts of Has3 KO mice seven days post-MI, in particular reduced numbers of CD4+CXCR3+ Th1 and CD4+CD25+ Treg cells. Furthermore, Has3 deficient cardiac T cells were less activated and more apoptotic as shown by decreased CD69+ and increased annexin V+ cells, respectively. In vitro assays using activated splenic CD3 T cells demonstrated that Has3 deficiency resulted in reduced expression of the main HA receptor CD44 and diminished T cell proliferation. T cell transendothelial migration was similar between genotypes. Of note, analysis of peripheral blood from patients with ST-elevation myocardial infarction (STEMI) revealed that HAS3 is the predominant HAS isoenzyme also in human T cells. In conclusion, our data suggest that HAS3 is required for mounting a physiological T cell response after MI to support cardiac healing. Therefore, our study may serve as a foundation for the development of novel strategies targeting HA-matrix to preserve T cell function after MI.
Collapse
Affiliation(s)
- Marco Piroth
- Institute for Pharmacology, University Hospital Düsseldorf, Heinrich-Heine-University Düsseldorf, Germany
| | - Daniel J Gorski
- Institute for Pharmacology, University Hospital Düsseldorf, Heinrich-Heine-University Düsseldorf, Germany
| | - Christian Hundhausen
- Institute for Pharmacology, University Hospital Düsseldorf, Heinrich-Heine-University Düsseldorf, Germany
| | - Anne Petz
- Institute for Pharmacology, University Hospital Düsseldorf, Heinrich-Heine-University Düsseldorf, Germany
| | - Simone Gorressen
- Institute for Pharmacology, University Hospital Düsseldorf, Heinrich-Heine-University Düsseldorf, Germany
| | - Dominik Semmler
- Institute for Pharmacology, University Hospital Düsseldorf, Heinrich-Heine-University Düsseldorf, Germany
| | - Heba Zabri
- Institute for Pharmacology, University Hospital Düsseldorf, Heinrich-Heine-University Düsseldorf, Germany
| | - Sonja Hartwig
- German Diabetes Center at the Heinrich-Heine-University Düsseldorf, Leibniz Center for Diabetes Research
| | - Stefan Lehr
- German Diabetes Center at the Heinrich-Heine-University Düsseldorf, Leibniz Center for Diabetes Research
| | - Malte Kelm
- Cardiology, Pulmonology and Vascular Medicine, Medical Faculty of the Heinrich Heine University Düsseldorf
| | - Christian Jung
- Cardiology, Pulmonology and Vascular Medicine, Medical Faculty of the Heinrich Heine University Düsseldorf
| | - Jens W Fischer
- Institute for Pharmacology, University Hospital Düsseldorf, Heinrich-Heine-University Düsseldorf, Germany.
| |
Collapse
|
10
|
Fahlbusch P, Nikolic A, Hartwig S, Jacob S, Kettel U, Köllmer C, Al-Hasani H, Lehr S, Müller-Wieland D, Knebel B, Kotzka J. Adaptation of Oxidative Phosphorylation Machinery Compensates for Hepatic Lipotoxicity in Early Stages of MAFLD. Int J Mol Sci 2022; 23:ijms23126873. [PMID: 35743314 PMCID: PMC9224893 DOI: 10.3390/ijms23126873] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2022] [Revised: 06/18/2022] [Accepted: 06/18/2022] [Indexed: 12/10/2022] Open
Abstract
Alterations in mitochondrial function are an important control variable in the progression of metabolic dysfunction-associated fatty liver disease (MAFLD), while also noted by increased de novo lipogenesis (DNL) and hepatic insulin resistance. We hypothesized that the organization and function of a mitochondrial electron transport chain (ETC) in this pathologic condition is a consequence of shifted substrate availability. We addressed this question using a transgenic mouse model with increased hepatic insulin resistance and DNL due to constitutively active human SREBP-1c. The abundance of ETC complex subunits and components of key metabolic pathways are regulated in the liver of these animals. Further omics approaches combined with functional assays in isolated liver mitochondria and primary hepatocytes revealed that the SREBP-1c-forced fatty liver induced a substrate limitation for oxidative phosphorylation, inducing enhanced complex II activity. The observed increased expression of mitochondrial genes may have indicated a counteraction. In conclusion, a shift of available substrates directed toward activated DNL results in increased electron flows, mainly through complex II, to compensate for the increased energy demand of the cell. The reorganization of key compounds in energy metabolism observed in the SREBP-1c animal model might explain the initial increase in mitochondrial function observed in the early stages of human MAFLD.
Collapse
Affiliation(s)
- Pia Fahlbusch
- Institute of Clinical Biochemistry and Pathobiochemistry, German Diabetes Center at the Heinrich-Heine-University Duesseldorf, Leibniz Center for Diabetes Research, 40225 Duesseldorf, Germany; (P.F.); (A.N.); (S.H.); (S.J.); (U.K.); (C.K.); (H.A.-H.); (S.L.); (J.K.)
- German Center for Diabetes Research (DZD), Partner Duesseldorf, 40225 Duesseldorf, Germany
| | - Aleksandra Nikolic
- Institute of Clinical Biochemistry and Pathobiochemistry, German Diabetes Center at the Heinrich-Heine-University Duesseldorf, Leibniz Center for Diabetes Research, 40225 Duesseldorf, Germany; (P.F.); (A.N.); (S.H.); (S.J.); (U.K.); (C.K.); (H.A.-H.); (S.L.); (J.K.)
- German Center for Diabetes Research (DZD), Partner Duesseldorf, 40225 Duesseldorf, Germany
| | - Sonja Hartwig
- Institute of Clinical Biochemistry and Pathobiochemistry, German Diabetes Center at the Heinrich-Heine-University Duesseldorf, Leibniz Center for Diabetes Research, 40225 Duesseldorf, Germany; (P.F.); (A.N.); (S.H.); (S.J.); (U.K.); (C.K.); (H.A.-H.); (S.L.); (J.K.)
- German Center for Diabetes Research (DZD), Partner Duesseldorf, 40225 Duesseldorf, Germany
| | - Sylvia Jacob
- Institute of Clinical Biochemistry and Pathobiochemistry, German Diabetes Center at the Heinrich-Heine-University Duesseldorf, Leibniz Center for Diabetes Research, 40225 Duesseldorf, Germany; (P.F.); (A.N.); (S.H.); (S.J.); (U.K.); (C.K.); (H.A.-H.); (S.L.); (J.K.)
| | - Ulrike Kettel
- Institute of Clinical Biochemistry and Pathobiochemistry, German Diabetes Center at the Heinrich-Heine-University Duesseldorf, Leibniz Center for Diabetes Research, 40225 Duesseldorf, Germany; (P.F.); (A.N.); (S.H.); (S.J.); (U.K.); (C.K.); (H.A.-H.); (S.L.); (J.K.)
| | - Cornelia Köllmer
- Institute of Clinical Biochemistry and Pathobiochemistry, German Diabetes Center at the Heinrich-Heine-University Duesseldorf, Leibniz Center for Diabetes Research, 40225 Duesseldorf, Germany; (P.F.); (A.N.); (S.H.); (S.J.); (U.K.); (C.K.); (H.A.-H.); (S.L.); (J.K.)
| | - Hadi Al-Hasani
- Institute of Clinical Biochemistry and Pathobiochemistry, German Diabetes Center at the Heinrich-Heine-University Duesseldorf, Leibniz Center for Diabetes Research, 40225 Duesseldorf, Germany; (P.F.); (A.N.); (S.H.); (S.J.); (U.K.); (C.K.); (H.A.-H.); (S.L.); (J.K.)
- German Center for Diabetes Research (DZD), Partner Duesseldorf, 40225 Duesseldorf, Germany
- Medical Faculty, Heinrich-Heine-University Düsseldorf, 40225 Düsseldorf, Germany
| | - Stefan Lehr
- Institute of Clinical Biochemistry and Pathobiochemistry, German Diabetes Center at the Heinrich-Heine-University Duesseldorf, Leibniz Center for Diabetes Research, 40225 Duesseldorf, Germany; (P.F.); (A.N.); (S.H.); (S.J.); (U.K.); (C.K.); (H.A.-H.); (S.L.); (J.K.)
- German Center for Diabetes Research (DZD), Partner Duesseldorf, 40225 Duesseldorf, Germany
| | - Dirk Müller-Wieland
- Clinical Research Centre, Department of Internal Medicine I, University Hospital Aachen, 52074 Aachen, Germany;
| | - Birgit Knebel
- Institute of Clinical Biochemistry and Pathobiochemistry, German Diabetes Center at the Heinrich-Heine-University Duesseldorf, Leibniz Center for Diabetes Research, 40225 Duesseldorf, Germany; (P.F.); (A.N.); (S.H.); (S.J.); (U.K.); (C.K.); (H.A.-H.); (S.L.); (J.K.)
- German Center for Diabetes Research (DZD), Partner Duesseldorf, 40225 Duesseldorf, Germany
- Correspondence: ; Tel.: +49-211-3382-536
| | - Jörg Kotzka
- Institute of Clinical Biochemistry and Pathobiochemistry, German Diabetes Center at the Heinrich-Heine-University Duesseldorf, Leibniz Center for Diabetes Research, 40225 Duesseldorf, Germany; (P.F.); (A.N.); (S.H.); (S.J.); (U.K.); (C.K.); (H.A.-H.); (S.L.); (J.K.)
- German Center for Diabetes Research (DZD), Partner Duesseldorf, 40225 Duesseldorf, Germany
| |
Collapse
|
11
|
Dille M, Nikolic A, Wahlers N, Fahlbusch P, Jacob S, Hartwig S, Lehr S, Kabra D, Klymenko O, Al-Hasani H, Kotzka J, Knebel B. Long-term adjustment of hepatic lipid metabolism after chronic stress and the role of FGF21. Biochim Biophys Acta Mol Basis Dis 2022; 1868:166286. [PMID: 34624498 DOI: 10.1016/j.bbadis.2021.166286] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2021] [Revised: 09/27/2021] [Accepted: 10/01/2021] [Indexed: 12/14/2022]
Abstract
Chronic stress leads to post-traumatic stress disorder (PTSD) and metabolic disorders including fatty liver. We hypothesized that stress-induced molecular mechanisms alter energy metabolism, thereby promoting hepatic lipid accumulation even after a stress-free recovery period. In this context, we investigated fibroblast growth factor-21 (FGF21) as protective for energy and glucose homeostasis. FGF21 knockout mice (B6.129S6(SJL)-Fgf21tm1.2Djm; FGF21KO) and control mice (C57BL6; WT) were subjected to chronic variable stress. Mice were examined directly after acute intervention (Cvs) and long-term after 3 months of recovery (3mCvs). In WT, Cvs reduced insulin sensitivity and hepatic lipid accumulation, whilst fatty acid uptake increased. FGF21KO mice responded to Cvs with improved glucose tolerance, insulin resistance but liver triglycerides and plasma lipids were unaltered. Hepatic gene expression was specifically altered by genotype and stress e.g. by PPARa and SREBP-1 regulated genes. The stress-induced alteration of hepatic metabolism persisted after stress recovery. In hepatocytes at 3mCvs, differential gene regulation and secreted proteins indicated a genotype specific progression of liver dysfunction. Overall, at 3mCvs FGF21 was involved in maintaining mitochondrial activity, attenuating de novo lipogenesis, increased fatty acid uptake and histone acetyltransferase activity. Glucocorticoid release and binding to the FGF21 promoter may contribute to prolonged FGF21 release and protection against hepatic lipid accumulation. In conclusion, we showed that stress favors fatty liver disease and FGF21 protected against hepatic lipid accumulation after previous chronic stress loading by i) restored physiological function, ii) modulated gene expression via DNA-modifying enzymes, and iii) maintained energy metabolism.
Collapse
Affiliation(s)
- Matthias Dille
- Institute for Clinical Biochemistry und Pathobiochemistry, German Diabetes-Center, Leibniz Center for Diabetes Research at Heinrich-Heine-University, Düsseldorf, Germany; German Center for Diabetes Research (DZD), München-Neuherberg, Germany
| | - Aleksandra Nikolic
- Institute for Clinical Biochemistry und Pathobiochemistry, German Diabetes-Center, Leibniz Center for Diabetes Research at Heinrich-Heine-University, Düsseldorf, Germany; German Center for Diabetes Research (DZD), München-Neuherberg, Germany
| | - Natalie Wahlers
- Institute for Clinical Biochemistry und Pathobiochemistry, German Diabetes-Center, Leibniz Center for Diabetes Research at Heinrich-Heine-University, Düsseldorf, Germany; German Center for Diabetes Research (DZD), München-Neuherberg, Germany
| | - Pia Fahlbusch
- Institute for Clinical Biochemistry und Pathobiochemistry, German Diabetes-Center, Leibniz Center for Diabetes Research at Heinrich-Heine-University, Düsseldorf, Germany; German Center for Diabetes Research (DZD), München-Neuherberg, Germany
| | - Sylvia Jacob
- Institute for Clinical Biochemistry und Pathobiochemistry, German Diabetes-Center, Leibniz Center for Diabetes Research at Heinrich-Heine-University, Düsseldorf, Germany; German Center for Diabetes Research (DZD), München-Neuherberg, Germany
| | - Sonja Hartwig
- Institute for Clinical Biochemistry und Pathobiochemistry, German Diabetes-Center, Leibniz Center for Diabetes Research at Heinrich-Heine-University, Düsseldorf, Germany; German Center for Diabetes Research (DZD), München-Neuherberg, Germany
| | - Stefan Lehr
- Institute for Clinical Biochemistry und Pathobiochemistry, German Diabetes-Center, Leibniz Center for Diabetes Research at Heinrich-Heine-University, Düsseldorf, Germany; German Center for Diabetes Research (DZD), München-Neuherberg, Germany
| | - Dhiraj Kabra
- Institute for Clinical Biochemistry und Pathobiochemistry, German Diabetes-Center, Leibniz Center for Diabetes Research at Heinrich-Heine-University, Düsseldorf, Germany; German Center for Diabetes Research (DZD), München-Neuherberg, Germany
| | - Oleksiy Klymenko
- Institute for Clinical Biochemistry und Pathobiochemistry, German Diabetes-Center, Leibniz Center for Diabetes Research at Heinrich-Heine-University, Düsseldorf, Germany; German Center for Diabetes Research (DZD), München-Neuherberg, Germany
| | - Hadi Al-Hasani
- Institute for Clinical Biochemistry und Pathobiochemistry, German Diabetes-Center, Leibniz Center for Diabetes Research at Heinrich-Heine-University, Düsseldorf, Germany; German Center for Diabetes Research (DZD), München-Neuherberg, Germany; Medical Faculty, Heinrich-Heine-University, Düsseldorf, Germany
| | - Jörg Kotzka
- Institute for Clinical Biochemistry und Pathobiochemistry, German Diabetes-Center, Leibniz Center for Diabetes Research at Heinrich-Heine-University, Düsseldorf, Germany; German Center for Diabetes Research (DZD), München-Neuherberg, Germany
| | - Birgit Knebel
- Institute for Clinical Biochemistry und Pathobiochemistry, German Diabetes-Center, Leibniz Center for Diabetes Research at Heinrich-Heine-University, Düsseldorf, Germany; German Center for Diabetes Research (DZD), München-Neuherberg, Germany.
| |
Collapse
|
12
|
Apostolopoulou M, Mastrototaro L, Hartwig S, Pesta D, Straßburger K, de Filippo E, Jelenik T, Karusheva Y, Gancheva S, Markgraf D, Herder C, Nair KS, Reichert AS, Lehr S, Müssig K, Al-Hasani H, Szendroedi J, Roden M. Metabolic responsiveness to training depends on insulin sensitivity and protein content of exosomes in insulin-resistant males. Sci Adv 2021; 7:eabi9551. [PMID: 34623918 PMCID: PMC8500512 DOI: 10.1126/sciadv.abi9551] [Citation(s) in RCA: 17] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/02/2023]
Abstract
High-intensity interval training (HIIT) improves cardiorespiratory fitness (VO2max), but its impact on metabolism remains unclear. We hypothesized that 12-week HIIT increases insulin sensitivity in males with or without type 2 diabetes [T2D and NDM (nondiabetic humans)]. However, despite identically higher VO2max, mainly insulin-resistant (IR) persons (T2D and IR NDM) showed distinct alterations of circulating small extracellular vesicles (SEVs) along with lower inhibitory metabolic (protein kinase Cε activity) or inflammatory (nuclear factor κB) signaling in muscle of T2D or IR NDM, respectively. This is related to the specific alterations in SEV proteome reflecting down-regulation of the phospholipase C pathway (T2D) and up-regulated antioxidant capacity (IR NDM). Thus, SEV cargo may contribute to modulating the individual metabolic responsiveness to exercise training in humans.
Collapse
Affiliation(s)
- Maria Apostolopoulou
- Department of Endocrinology and Diabetology, Medical Faculty and University Hospital, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany
- Institute for Clinical Diabetology, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany
- German Center for Diabetes Research, Partner Düsseldorf, München-Neuherberg, Germany
| | - Lucia Mastrototaro
- Institute for Clinical Diabetology, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany
- German Center for Diabetes Research, Partner Düsseldorf, München-Neuherberg, Germany
| | - Sonja Hartwig
- German Center for Diabetes Research, Partner Düsseldorf, München-Neuherberg, Germany
- Institute for Clinical Biochemistry and Pathobiochemistry German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany
| | - Dominik Pesta
- Institute for Clinical Diabetology, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany
- German Center for Diabetes Research, Partner Düsseldorf, München-Neuherberg, Germany
| | - Klaus Straßburger
- German Center for Diabetes Research, Partner Düsseldorf, München-Neuherberg, Germany
- Institute for Biometrics and Epidemiology, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany
| | - Elisabetta de Filippo
- Institute for Clinical Diabetology, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany
- German Center for Diabetes Research, Partner Düsseldorf, München-Neuherberg, Germany
| | - Tomas Jelenik
- Institute for Clinical Diabetology, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany
- German Center for Diabetes Research, Partner Düsseldorf, München-Neuherberg, Germany
| | - Yanislava Karusheva
- Institute for Clinical Diabetology, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany
- German Center for Diabetes Research, Partner Düsseldorf, München-Neuherberg, Germany
| | - Sofiya Gancheva
- Department of Endocrinology and Diabetology, Medical Faculty and University Hospital, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany
- Institute for Clinical Diabetology, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany
- German Center for Diabetes Research, Partner Düsseldorf, München-Neuherberg, Germany
| | - Daniel Markgraf
- Institute for Clinical Diabetology, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany
- German Center for Diabetes Research, Partner Düsseldorf, München-Neuherberg, Germany
| | - Christian Herder
- Department of Endocrinology and Diabetology, Medical Faculty and University Hospital, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany
- Institute for Clinical Diabetology, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany
- German Center for Diabetes Research, Partner Düsseldorf, München-Neuherberg, Germany
| | - K. Sreekumaran Nair
- Division of Endocrinology, Diabetes and Nutrition, Mayo Clinic, Rochester, MN, USA
| | - Andreas S. Reichert
- Institute of Biochemistry and Molecular Biology I, Medical Faculty and University Hospital Düsseldorf, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany
| | - Stefan Lehr
- German Center for Diabetes Research, Partner Düsseldorf, München-Neuherberg, Germany
- Institute for Clinical Biochemistry and Pathobiochemistry German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany
| | - Karsten Müssig
- Department of Endocrinology and Diabetology, Medical Faculty and University Hospital, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany
- Institute for Clinical Diabetology, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany
- German Center for Diabetes Research, Partner Düsseldorf, München-Neuherberg, Germany
| | - Hadi Al-Hasani
- German Center for Diabetes Research, Partner Düsseldorf, München-Neuherberg, Germany
- Institute for Clinical Biochemistry and Pathobiochemistry German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany
| | - Julia Szendroedi
- Department of Endocrinology and Diabetology, Medical Faculty and University Hospital, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany
- Institute for Clinical Diabetology, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany
- German Center for Diabetes Research, Partner Düsseldorf, München-Neuherberg, Germany
- Department of Internal Medicine, Heidelberg University, Heidelberg, Germany
| | - Michael Roden
- Department of Endocrinology and Diabetology, Medical Faculty and University Hospital, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany
- Institute for Clinical Diabetology, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany
- German Center for Diabetes Research, Partner Düsseldorf, München-Neuherberg, Germany
- Corresponding author.
| |
Collapse
|
13
|
Kohlmorgen C, Gerfer S, Feldmann K, Twarock S, Hartwig S, Lehr S, Klier M, Krüger I, Helten C, Keul P, Kahl S, Polzin A, Elvers M, Flögel U, Kelm M, Levkau B, Roden M, Fischer JW, Grandoch M. Dapagliflozin reduces thrombin generation and platelet activation: implications for cardiovascular risk reduction in type 2 diabetes mellitus. Diabetologia 2021; 64:1834-1849. [PMID: 34131781 PMCID: PMC8245397 DOI: 10.1007/s00125-021-05498-0] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/14/2020] [Accepted: 02/11/2021] [Indexed: 12/15/2022]
Abstract
AIMS/HYPOTHESIS People with diabetes have an increased cardiovascular risk with an accelerated development of atherosclerosis and an elevated mortality rate after myocardial infarction. Therefore, cardioprotective effects of glucose-lowering therapies are of major importance for the pharmacotherapy of individuals with type 2 diabetes. For sodium-glucose cotransporter 2 inhibitors (SGLT2is), in addition to a reduction in blood glucose, beneficial effects on atherosclerosis, obesity, renal function and blood pressure have been observed. Recent results showed a reduced risk of worsening heart failure and cardiovascular deaths under dapagliflozin treatment irrespective of the diabetic state. However, the underlying mechanisms are yet unknown. Platelets are known drivers of atherosclerosis and atherothrombosis and disturbed platelet activation has also been suggested to occur in type 2 diabetes. Therefore, the present study investigates the impact of the SGLT2i dapagliflozin on the interplay between platelets and inflammation in atherogenesis. METHODS Male, 8-week-old LDL-receptor-deficient (Ldlr-/-) mice received a high-fat, high-sucrose diabetogenic diet supplemented without (control) or with dapagliflozin (5 mg/kg body weight per day) for two time periods: 8 and 25 weeks. In a first translational approach, eight healthy volunteers received 10 mg dapagliflozin/day for 4 weeks. RESULTS Dapagliflozin treatment ameliorated atherosclerotic lesion development, reduced circulating platelet-leucocyte aggregates (glycoprotein [GP]Ib+CD45+: 29.40 ± 5.94 vs 17.00 ± 5.69 cells, p < 0.01; GPIb+lymphocyte antigen 6 complex, locus G+ (Ly6G): 8.00 ± 2.45 vs 4.33 ± 1.75 cells, p < 0.05) and decreased aortic macrophage infiltration (1.31 ± 0.62 vs 0.70 ± 0.58 ×103 cells/aorta, p < 0.01). Deeper analysis revealed that dapagliflozin decreased activated CD62P-positive platelets in Ldlr-/- mice fed a diabetogenic diet (3.78 ± 1.20% vs 2.83 ± 1.06%, p < 0.01) without affecting bleeding time (85.29 ± 37.27 vs 89.25 ± 16.26 s, p = 0.78). While blood glucose was only moderately affected, dapagliflozin further reduced endogenous thrombin generation (581.4 ± 194.6 nmol/l × min) × 10-9 thrombin vs 254.1 ± 106.4 (nmol/l × min) × 10-9 thrombin), thereby decreasing one of the most important platelet activators. We observed a direct inhibitory effect of dapagliflozin on isolated platelets. In addition, dapagliflozin increased HDL-cholesterol levels. Importantly, higher HDL-cholesterol levels (1.70 ± 0.58 vs 3.15 ± 1.67 mmol/l, p < 0.01) likely contribute to dapagliflozin-mediated inhibition of platelet activation and thrombin generation. Accordingly, in line with the results in mice, treatment with dapagliflozin lowered CD62P-positive platelet counts in humans after stimulation by collagen-related peptide (CRP; 88.13 ± 5.37% of platelets vs 77.59 ± 10.70%, p < 0.05) or thrombin receptor activator peptide-6 (TRAP-6; 44.23 ± 15.54% vs 28.96 ± 11.41%, p < 0.01) without affecting haemostasis. CONCLUSIONS/INTERPRETATION We demonstrate that dapagliflozin-mediated atheroprotection in mice is driven by elevated HDL-cholesterol and ameliorated thrombin-platelet-mediated inflammation without interfering with haemostasis. This glucose-independent mechanism likely contributes to dapagliflozin's beneficial cardiovascular risk profile.
Collapse
Affiliation(s)
- Christina Kohlmorgen
- Institute of Pharmacology and Clinical Pharmacology, Medical Faculty and University Hospital of Düsseldorf, Heinrich-Heine University Düsseldorf, Düsseldorf, Germany
- Cardiovascular Research Institute Düsseldorf (CARID), Medical Faculty and University Hospital of Düsseldorf, Heinrich-Heine University Düsseldorf, Düsseldorf, Germany
| | - Stephen Gerfer
- Institute of Pharmacology and Clinical Pharmacology, Medical Faculty and University Hospital of Düsseldorf, Heinrich-Heine University Düsseldorf, Düsseldorf, Germany
- Cardiovascular Research Institute Düsseldorf (CARID), Medical Faculty and University Hospital of Düsseldorf, Heinrich-Heine University Düsseldorf, Düsseldorf, Germany
- Department of Cardiothoracic Surgery, Heart Center, University Hospital of Cologne, University of Cologne, Cologne, Germany
| | - Kathrin Feldmann
- Institute of Pharmacology and Clinical Pharmacology, Medical Faculty and University Hospital of Düsseldorf, Heinrich-Heine University Düsseldorf, Düsseldorf, Germany
- Cardiovascular Research Institute Düsseldorf (CARID), Medical Faculty and University Hospital of Düsseldorf, Heinrich-Heine University Düsseldorf, Düsseldorf, Germany
| | - Sören Twarock
- Institute of Pharmacology and Clinical Pharmacology, Medical Faculty and University Hospital of Düsseldorf, Heinrich-Heine University Düsseldorf, Düsseldorf, Germany
- Cardiovascular Research Institute Düsseldorf (CARID), Medical Faculty and University Hospital of Düsseldorf, Heinrich-Heine University Düsseldorf, Düsseldorf, Germany
| | - Sonja Hartwig
- Institute for Clinical Biochemistry and Pathobiochemistry, German Diabetes Center, Leibniz Center for Diabetes Research at the Heinrich-Heine University Düsseldorf, Düsseldorf, Germany
- German Center for Diabetes Research (DZD), München-Neuherberg, Germany
| | - Stefan Lehr
- Institute for Clinical Biochemistry and Pathobiochemistry, German Diabetes Center, Leibniz Center for Diabetes Research at the Heinrich-Heine University Düsseldorf, Düsseldorf, Germany
- German Center for Diabetes Research (DZD), München-Neuherberg, Germany
| | - Meike Klier
- Division of Vascular and Endovascular Surgery, Experimental Vascular Medicine, Heinrich-Heine University Medical Center, Medical Faculty and University Hospital of Düsseldorf, Heinrich-Heine University Düsseldorf, Düsseldorf, Germany
| | - Irena Krüger
- Division of Vascular and Endovascular Surgery, Experimental Vascular Medicine, Heinrich-Heine University Medical Center, Medical Faculty and University Hospital of Düsseldorf, Heinrich-Heine University Düsseldorf, Düsseldorf, Germany
| | - Carolin Helten
- Cardiovascular Research Institute Düsseldorf (CARID), Medical Faculty and University Hospital of Düsseldorf, Heinrich-Heine University Düsseldorf, Düsseldorf, Germany
- Division of Cardiology, Pulmonology, and Vascular Medicine Medical Faculty, University Hospital of Düsseldorf, Heinrich-Heine University Düsseldorf, Düsseldorf, Germany
| | - Petra Keul
- Institute for Molecular Medicine III and University Hospital Düsseldorf, Heinrich-Heine University Düsseldorf, Düsseldorf, Germany
| | - Sabine Kahl
- German Center for Diabetes Research (DZD), München-Neuherberg, Germany
- Institute for Clinical Diabetology, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich-Heine University Düsseldorf, Düsseldorf, Germany
| | - Amin Polzin
- Cardiovascular Research Institute Düsseldorf (CARID), Medical Faculty and University Hospital of Düsseldorf, Heinrich-Heine University Düsseldorf, Düsseldorf, Germany
- Division of Cardiology, Pulmonology, and Vascular Medicine Medical Faculty, University Hospital of Düsseldorf, Heinrich-Heine University Düsseldorf, Düsseldorf, Germany
| | - Margitta Elvers
- Division of Vascular and Endovascular Surgery, Experimental Vascular Medicine, Heinrich-Heine University Medical Center, Medical Faculty and University Hospital of Düsseldorf, Heinrich-Heine University Düsseldorf, Düsseldorf, Germany
| | - Ulrich Flögel
- Cardiovascular Research Institute Düsseldorf (CARID), Medical Faculty and University Hospital of Düsseldorf, Heinrich-Heine University Düsseldorf, Düsseldorf, Germany
- Division of Cardiology, Pulmonology, and Vascular Medicine Medical Faculty, University Hospital of Düsseldorf, Heinrich-Heine University Düsseldorf, Düsseldorf, Germany
- Experimental Cardiovascular Imaging, Institute of Molecular Cardiology, Medical Faculty and University Hospital of Düsseldorf, Heinrich-Heine University Düsseldorf, Düsseldorf, Germany
| | - Malte Kelm
- Cardiovascular Research Institute Düsseldorf (CARID), Medical Faculty and University Hospital of Düsseldorf, Heinrich-Heine University Düsseldorf, Düsseldorf, Germany
- Division of Cardiology, Pulmonology, and Vascular Medicine Medical Faculty, University Hospital of Düsseldorf, Heinrich-Heine University Düsseldorf, Düsseldorf, Germany
| | - Bodo Levkau
- Institute for Molecular Medicine III and University Hospital Düsseldorf, Heinrich-Heine University Düsseldorf, Düsseldorf, Germany
| | - Michael Roden
- German Center for Diabetes Research (DZD), München-Neuherberg, Germany
- Institute for Clinical Diabetology, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich-Heine University Düsseldorf, Düsseldorf, Germany
- Department of Endocrinology and Diabetology, Medical Faculty and University Hospital of Düsseldorf, Heinrich-Heine University Düsseldorf, Düsseldorf, Germany
| | - Jens W Fischer
- Institute of Pharmacology and Clinical Pharmacology, Medical Faculty and University Hospital of Düsseldorf, Heinrich-Heine University Düsseldorf, Düsseldorf, Germany
- Cardiovascular Research Institute Düsseldorf (CARID), Medical Faculty and University Hospital of Düsseldorf, Heinrich-Heine University Düsseldorf, Düsseldorf, Germany
| | - Maria Grandoch
- Institute of Pharmacology and Clinical Pharmacology, Medical Faculty and University Hospital of Düsseldorf, Heinrich-Heine University Düsseldorf, Düsseldorf, Germany.
- Cardiovascular Research Institute Düsseldorf (CARID), Medical Faculty and University Hospital of Düsseldorf, Heinrich-Heine University Düsseldorf, Düsseldorf, Germany.
| |
Collapse
|
14
|
Post J, Schaffrath A, Gering I, Hartwig S, Lehr S, Shah NJ, Langen KJ, Willbold D, Kutzsche J, Willuweit A. Oral Treatment with RD2RD2 Impedes Development of Motoric Phenotype and Delays Symptom Onset in SOD1 G93A Transgenic Mice. Int J Mol Sci 2021; 22:ijms22137066. [PMID: 34209129 PMCID: PMC8269060 DOI: 10.3390/ijms22137066] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2021] [Revised: 06/25/2021] [Accepted: 06/25/2021] [Indexed: 11/16/2022] Open
Abstract
Neuroinflammation is a pathological hallmark of several neurodegenerative disorders and plays a key role in the pathogenesis of amyotrophic lateral sclerosis (ALS). It has been implicated as driver of disease progression and is observed in ALS patients, as well as in the transgenic SOD1G93A mouse model. Here, we explore and validate the therapeutic potential of the d-enantiomeric peptide RD2RD2 upon oral administration in SOD1G93A mice. Transgenic mice were treated daily with RD2RD2 or placebo for 10 weeks and phenotype progression was followed with several behavioural tests. At the end of the study, plasma cytokine levels and glia cell markers in brain and spinal cord were analysed. Treatment resulted in a significantly increased performance in behavioural and motor coordination tests and a decelerated neurodegenerative phenotype in RD2RD2-treated SOD1G93A mice. Additionally, we observed retardation of the average disease onset. Treatment of SOD1G93A mice led to significant reduction in glial cell activation and a rescue of neurons. Analysis of plasma revealed normalisation of several cytokines in samples of RD2RD2-treated SOD1G93A mice towards the levels of non-transgenic mice. In conclusion, these findings qualify RD2RD2 to be considered for further development and testing towards a disease modifying ALS treatment.
Collapse
Affiliation(s)
- Julia Post
- Institute of Biological Information Processing, Structural Biochemistry (IBI-7), Forschungszentrum Jülich, 52425 Jülich, Germany; (J.P.); (A.S.); (I.G.)
| | - Anja Schaffrath
- Institute of Biological Information Processing, Structural Biochemistry (IBI-7), Forschungszentrum Jülich, 52425 Jülich, Germany; (J.P.); (A.S.); (I.G.)
| | - Ian Gering
- Institute of Biological Information Processing, Structural Biochemistry (IBI-7), Forschungszentrum Jülich, 52425 Jülich, Germany; (J.P.); (A.S.); (I.G.)
| | - Sonja Hartwig
- Institute for Clinical Biochemistry and Pathobiochemistry, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich-Heine-University Düsseldorf, 40225 Düsseldorf, Germany; (S.H.); (S.L.)
- German Center for Diabetes Research, Partner Düsseldorf, 85764 München-Neuherberg, Germany
| | - Stefan Lehr
- Institute for Clinical Biochemistry and Pathobiochemistry, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich-Heine-University Düsseldorf, 40225 Düsseldorf, Germany; (S.H.); (S.L.)
- German Center for Diabetes Research, Partner Düsseldorf, 85764 München-Neuherberg, Germany
| | - N. Jon Shah
- Institute of Neuroscience and Medicine, Medical Imaging Physics (INM-4), Forschungszentrum Jülich, 52425 Jülich, Germany; (N.J.S.); (K.-J.L.)
- Institute of Neuroscience and Medicine 11, INM-11, JARA, Forschungszentrum Jülich, 52425 Jülich, Germany
- JARA-Brain-Translational Medicine, 52062 Aachen, Germany
- Department of Neurology, RWTH Aachen University, 52062 Aachen, Germany
| | - Karl-Josef Langen
- Institute of Neuroscience and Medicine, Medical Imaging Physics (INM-4), Forschungszentrum Jülich, 52425 Jülich, Germany; (N.J.S.); (K.-J.L.)
- Department of Nuclear Medicine, RWTH Aachen University, 52062 Aachen, Germany
| | - Dieter Willbold
- Institute of Biological Information Processing, Structural Biochemistry (IBI-7), Forschungszentrum Jülich, 52425 Jülich, Germany; (J.P.); (A.S.); (I.G.)
- Institut für Physikalische Biologie, Heinrich-Heine-Universität, 40225 Düsseldorf, Germany
- Correspondence: (D.W.); (J.K.); (A.W.); Tel.: +49-2461-612100 (D.W.); +49-2461-619496 (J.K.); +49-2461-6196358 (A.W.); Fax: +49-2461-612023 (D.W.); +49-2461-619497 (J.K.); +49-2461-612302 (A.W.)
| | - Janine Kutzsche
- Institute of Biological Information Processing, Structural Biochemistry (IBI-7), Forschungszentrum Jülich, 52425 Jülich, Germany; (J.P.); (A.S.); (I.G.)
- Correspondence: (D.W.); (J.K.); (A.W.); Tel.: +49-2461-612100 (D.W.); +49-2461-619496 (J.K.); +49-2461-6196358 (A.W.); Fax: +49-2461-612023 (D.W.); +49-2461-619497 (J.K.); +49-2461-612302 (A.W.)
| | - Antje Willuweit
- Institute of Neuroscience and Medicine, Medical Imaging Physics (INM-4), Forschungszentrum Jülich, 52425 Jülich, Germany; (N.J.S.); (K.-J.L.)
- Correspondence: (D.W.); (J.K.); (A.W.); Tel.: +49-2461-612100 (D.W.); +49-2461-619496 (J.K.); +49-2461-6196358 (A.W.); Fax: +49-2461-612023 (D.W.); +49-2461-619497 (J.K.); +49-2461-612302 (A.W.)
| |
Collapse
|
15
|
Abstract
As the powerhouse of the cell, mitochondria, plays a crucial role in many aspects of life, whereby mitochondrial dysfunctions are associated with pathogenesis of many diseases, like neurodegenerative diseases, obesity, cancer, and metabolic as well as cardiovascular disorders. Mitochondria analysis frequently starts with isolation and enrichment procedures, which have become increasingly important in biomedical research. Unfortunately, isolation procedures can easily cause changes in the structural integrity of mitochondria during in vitro handling having impact on their function. This carries the risk that conclusions about isolated mitochondria may be drawn on the basis of experimental artifacts. Here we critically review a commonly used isolation procedure for mitochondria utilizing differential (gradient) centrifugation and depict major challenges to achieve "functional" mitochondria as basis for comprehensive physiological studies.
Collapse
Affiliation(s)
- Stefan Lehr
- Institute for Clinical Biochemistry and Pathobiochemistry, German Diabetes Center at the Heinrich-Heine-University Duesseldorf, Leibniz Center for Diabetes Research, Duesseldorf, Germany.
- German Center for Diabetes Research (DZD e.V.), Neuherberg, Germany.
| | - Sonja Hartwig
- Institute for Clinical Biochemistry and Pathobiochemistry, German Diabetes Center at the Heinrich-Heine-University Duesseldorf, Leibniz Center for Diabetes Research, Duesseldorf, Germany
- German Center for Diabetes Research (DZD e.V.), Neuherberg, Germany
| | - Jorg Kotzka
- Institute for Clinical Biochemistry and Pathobiochemistry, German Diabetes Center at the Heinrich-Heine-University Duesseldorf, Leibniz Center for Diabetes Research, Duesseldorf, Germany
- German Center for Diabetes Research (DZD e.V.), Neuherberg, Germany
| |
Collapse
|
16
|
Bojack G, Baltz R, Dittgen J, Fischer C, Freigang J, Getachew R, Grill E, Helmke H, Hohmann S, Lange G, Lehr S, Porée F, Schmidt J, Schmutzler D, Yang Z, Frackenpohl J. Synthesis and Exploration of Abscisic Acid Receptor Agonists Against Dought Stress by Adding Constraint to a Tetrahydroquinoline‐Based Lead Structure. European J Org Chem 2021. [DOI: 10.1002/ejoc.202100415] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- Guido Bojack
- Research & Development, Weed Control, Division Crop Science Bayer AG Industriepark Höchst 65926 Frankfurt am Main Germany
| | - Rachel Baltz
- Research & Development, Weed Control, Division Crop Science Bayer AG Industriepark Höchst 65926 Frankfurt am Main Germany
| | - Jan Dittgen
- Research & Development, Weed Control, Division Crop Science Bayer AG Industriepark Höchst 65926 Frankfurt am Main Germany
| | - Christian Fischer
- Research & Development, Weed Control, Division Crop Science Bayer AG Industriepark Höchst 65926 Frankfurt am Main Germany
| | - Jörg Freigang
- Research & Development Research Technology, Division Crop Science Bayer AG Alfred-Nobel-Straße 50 40789 Monheim Germany
| | - Rahel Getachew
- Research & Development, Weed Control, Division Crop Science Bayer AG Industriepark Höchst 65926 Frankfurt am Main Germany
| | - Erwin Grill
- Lehrstuhl für Botanik Wissenschaftszentrum Weihenstephan Technische Universität München Emil-Ramann-Straße 4 85354 Freising Germany
| | - Hendrik Helmke
- Research & Development, Weed Control, Division Crop Science Bayer AG Industriepark Höchst 65926 Frankfurt am Main Germany
| | - Sabine Hohmann
- Research & Development, Weed Control, Division Crop Science Bayer AG Industriepark Höchst 65926 Frankfurt am Main Germany
| | - Gudrun Lange
- Research & Development, Weed Control, Division Crop Science Bayer AG Industriepark Höchst 65926 Frankfurt am Main Germany
| | - Stefan Lehr
- Research & Development, Weed Control, Division Crop Science Bayer AG Industriepark Höchst 65926 Frankfurt am Main Germany
| | - Fabien Porée
- Research & Development, Weed Control, Division Crop Science Bayer AG Industriepark Höchst 65926 Frankfurt am Main Germany
| | - Jana Schmidt
- Research & Development, Weed Control, Division Crop Science Bayer AG Industriepark Höchst 65926 Frankfurt am Main Germany
| | - Dirk Schmutzler
- Research & Development, Weed Control, Division Crop Science Bayer AG Industriepark Höchst 65926 Frankfurt am Main Germany
| | - Zhenyu Yang
- Lehrstuhl für Botanik Wissenschaftszentrum Weihenstephan Technische Universität München Emil-Ramann-Straße 4 85354 Freising Germany
| | - Jens Frackenpohl
- Research & Development, Weed Control, Division Crop Science Bayer AG Industriepark Höchst 65926 Frankfurt am Main Germany
| |
Collapse
|
17
|
Eickelschulte S, Hartwig S, Leiser B, Lehr S, Joschko V, Chokkalingam M, Chadt A, Al-Hasani H. AKT/AMPK-mediated phosphorylation of TBC1D4 disrupts the interaction with insulin-regulated aminopeptidase. J Biol Chem 2021; 296:100637. [PMID: 33872597 PMCID: PMC8131924 DOI: 10.1016/j.jbc.2021.100637] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2021] [Revised: 03/29/2021] [Accepted: 04/05/2021] [Indexed: 12/26/2022] Open
Abstract
TBC1D4 is a 160 kDa multidomain Rab GTPase-activating protein (RabGAP) and a downstream target of the insulin- and contraction-activated kinases AKT and AMPK. Phosphorylation of TBC1D4 has been linked to translocation of GLUT4 from storage vesicles (GSVs) to the cell surface. However, its impact on enzymatic activity is not well understood, as previous studies mostly investigated the truncated GAP domain lacking the known phosphorylation sites. In the present study, we expressed and purified recombinant full-length TBC1D4 using a baculovirus system. Size-exclusion chromatography and coimmunoprecipitation experiments revealed that full-length TBC1D4 forms oligomers of ∼600 kDa. Compared with the truncated GAP domain, full-length TBC1D4 displayed similar substrate specificity, but had a markedly higher specific GAP activity toward Rab10. Using high-resolution mass spectrometry, we mapped 19 Ser/Thr phosphorylation sites in TBC1D4. We determined Michaelis–Menten kinetics using in vitro phosphorylation assays with purified kinases and stable isotope-labeled γ-[18O4]-ATP. These data revealed that Ser324 (KM ∼6 μM) and Thr649 (KM ∼25 μM) were preferential sites for phosphorylation by AKT, whereas Ser348, Ser577, Ser595 (KM ∼10 μM), Ser711 (KM ∼79 μM), and Ser764 were found to be preferred targets for AMPK. Phosphorylation of TBC1D4 by AKT or AMPK did not alter the intrinsic RabGAP activity, but did disrupt interaction with insulin-regulated aminopeptidase (IRAP), a resident protein of GSVs implicated in GLUT4 trafficking. These findings provide evidence that insulin and contraction may regulate TBC1D4 function primarily by disrupting the recruitment of the RabGAP to GLUT4 vesicles.
Collapse
Affiliation(s)
- Samaneh Eickelschulte
- Medical Faculty, Institute of Clinical Biochemistry and Pathobiochemistry, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University, Düsseldorf, Germany; German Center for Diabetes Research (DZD), Partner Düsseldorf, München-Neuherberg, Germany
| | - Sonja Hartwig
- Medical Faculty, Institute of Clinical Biochemistry and Pathobiochemistry, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University, Düsseldorf, Germany; German Center for Diabetes Research (DZD), Partner Düsseldorf, München-Neuherberg, Germany
| | - Ben Leiser
- Medical Faculty, Institute of Clinical Biochemistry and Pathobiochemistry, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University, Düsseldorf, Germany
| | - Stefan Lehr
- Medical Faculty, Institute of Clinical Biochemistry and Pathobiochemistry, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University, Düsseldorf, Germany; German Center for Diabetes Research (DZD), Partner Düsseldorf, München-Neuherberg, Germany
| | - Viola Joschko
- Medical Faculty, Institute of Clinical Biochemistry and Pathobiochemistry, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University, Düsseldorf, Germany
| | - Manopriya Chokkalingam
- Medical Faculty, Institute of Clinical Biochemistry and Pathobiochemistry, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University, Düsseldorf, Germany; German Center for Diabetes Research (DZD), Partner Düsseldorf, München-Neuherberg, Germany
| | - Alexandra Chadt
- Medical Faculty, Institute of Clinical Biochemistry and Pathobiochemistry, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University, Düsseldorf, Germany; German Center for Diabetes Research (DZD), Partner Düsseldorf, München-Neuherberg, Germany
| | - Hadi Al-Hasani
- Medical Faculty, Institute of Clinical Biochemistry and Pathobiochemistry, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University, Düsseldorf, Germany; German Center for Diabetes Research (DZD), Partner Düsseldorf, München-Neuherberg, Germany.
| |
Collapse
|
18
|
Gemoll T, Rozanova S, Röder C, Hartwig S, Kalthoff H, Lehr S, ElSharawy A, Habermann J. Protein Profiling of Serum Extracellular Vesicles Reveals Qualitative and Quantitative Differences After Differential Ultracentrifugation and ExoQuick TM Isolation. J Clin Med 2020; 9:jcm9051429. [PMID: 32408476 PMCID: PMC7290673 DOI: 10.3390/jcm9051429] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2020] [Revised: 05/04/2020] [Accepted: 05/07/2020] [Indexed: 12/11/2022] Open
Abstract
Solid tumor biopsies are the current standard for precision medicine. However, the procedure is invasive and not always feasible. In contrast, liquid biopsies, such as serum enriched for extracellular vesicles (EVs) represent a non-invasive source of cancer biomarkers. In this study, we compared two EV isolation methods in the context of the protein biomarker detection in inflammatory bowel disease (IBD) and colorectal cancer (CRC). Using serum samples of a healthy cohort as well as CRC and IBD patients, EVs were isolated by ultracentrifugation and ExoQuick™ in parallel. EV associated protein profiles were compared by multiplex-fluorescence two-dimensional difference gel electrophoresis (2D-DIGE) and subsequent identification by mass spectrometry. Validation of gelsolin (GSN) was performed using fluorescence-quantitative western blot. 2D-DIGE resolved 936 protein spots in all serum-enriched EVs isolated by ultracentrifugation or ExoQuick™. Hereof, 93 spots were differently expressed between isolation approaches. Higher levels of GSN in EVs obtained with ExoQuick™ compared to ultracentrifugation were confirmed by western blot (p = 0.0006). Although patient groups were distinguishable after both EV isolation approaches, sample preparation strongly influences EVs’ protein profile and thus impacts on inter-study reproducibility, biomarker identification and validation. The results stress the need for strict SOPs in EV research before clinical implementation can be reached.
Collapse
Affiliation(s)
- Timo Gemoll
- Section for Translational Surgical Oncology & Biobanking, Department of Surgery, University of Lübeck and University Hospital Schleswig-Holstein, 23562 Lübeck, Germany; (S.R.); (J.H.)
- Correspondence: ; Tel.: +49-0451-500-40431
| | - Svitlana Rozanova
- Section for Translational Surgical Oncology & Biobanking, Department of Surgery, University of Lübeck and University Hospital Schleswig-Holstein, 23562 Lübeck, Germany; (S.R.); (J.H.)
| | - Christian Röder
- Institute for Experimental Cancer Research, University of Kiel, 24105 Kiel, Germany; (C.R.); (H.K.)
| | - Sonja Hartwig
- Institute for Clinical Biochemistry and Pathobiochemistry, German Diabetes Center at the Heinrich-Heine-University Düsseldorf, Leibniz Center for Diabetes Research, 40225 Düsseldorf, Germany; (S.H.); (S.L.)
- German Center for Diabetes Research (DZD), 85764 München-Neuherberg, Germany
| | - Holger Kalthoff
- Institute for Experimental Cancer Research, University of Kiel, 24105 Kiel, Germany; (C.R.); (H.K.)
| | - Stefan Lehr
- Institute for Clinical Biochemistry and Pathobiochemistry, German Diabetes Center at the Heinrich-Heine-University Düsseldorf, Leibniz Center for Diabetes Research, 40225 Düsseldorf, Germany; (S.H.); (S.L.)
- German Center for Diabetes Research (DZD), 85764 München-Neuherberg, Germany
| | - Abdou ElSharawy
- Institute of Clinical Molecular Biology, Center of Molecular Sciences, University of Kiel, 24118 Kiel, Germany;
- Division of Biochemistry, Chemistry Department, Faculty of Sciences, Damietta University, New Damietta City 34511, Egypt
| | - Jens Habermann
- Section for Translational Surgical Oncology & Biobanking, Department of Surgery, University of Lübeck and University Hospital Schleswig-Holstein, 23562 Lübeck, Germany; (S.R.); (J.H.)
- Interdisciplinary Center for Biobanking-Lübeck (ICB-L), University of Lübeck, 23562 Lübeck, Germany
| |
Collapse
|
19
|
Barbosa DM, Fahlbusch P, Herzfeld de Wiza D, Jacob S, Kettel U, Al-Hasani H, Krüger M, Ouwens DM, Hartwig S, Lehr S, Kotzka J, Knebel B. Rhein, a novel Histone Deacetylase (HDAC) inhibitor with antifibrotic potency in human myocardial fibrosis. Sci Rep 2020; 10:4888. [PMID: 32184434 PMCID: PMC7078222 DOI: 10.1038/s41598-020-61886-3] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2019] [Accepted: 03/04/2020] [Indexed: 12/18/2022] Open
Abstract
Although fibrosis depicts a reparative mechanism, maladaptation of the heart due to excessive production of extracellular matrix accelerates cardiac dysfunction. The anthraquinone Rhein was examined for its anti-fibrotic potency to mitigate cardiac fibroblast-to-myofibroblast transition (FMT). Primary human ventricular cardiac fibroblasts were subjected to hypoxia and characterized with proteomics, transcriptomics and cell functional techniques. Knowledge based analyses of the omics data revealed a modulation of fibrosis-associated pathways and cell cycle due to Rhein administration during hypoxia, whereas p53 and p21 were identified as upstream regulators involved in the manifestation of cardiac fibroblast phenotypes. Mechanistically, Rhein acts inhibitory on HDAC classes I/II as enzymatic inhibitor. Rhein-mediated cellular effects were linked to the histone deacetylase (HDAC)-dependent protein stabilization of p53 under normoxic but not hypoxic conditions. Functionally, Rhein inhibited collagen contraction, indicating anti-fibrotic property in cardiac remodeling. This was accompanied by increased abundance of SMAD7, but not SMAD2/3, and consistently SMAD-specific E3 ubiquitin ligase SMURF2. In conclusion, this study identifies Rhein as a novel potent direct HDAC inhibitor that may contribute to the treatment of cardiac fibrosis as anti-fibrotic agent. As readily available drug with approved safety, Rhein constitutes a promising potential therapeutic approach in the supplemental and protective intervention of cardiac fibrosis.
Collapse
Affiliation(s)
- David Monteiro Barbosa
- Institute of Clinical Biochemistry and Pathobiochemistry, German Diabetes Center at the Heinrich-Heine-University Duesseldorf, Leibniz Center for Diabetes Research, Aufm Hennekamp 65, 40225, Duesseldorf, Germany.,German Center for Diabetes Research (DZD), Munich-Neuherberg, Germany.,Medical Faculty, Institute of Cardiovascular Physiology, Heinrich-Heine-University, Duesseldorf, Germany
| | - Pia Fahlbusch
- Institute of Clinical Biochemistry and Pathobiochemistry, German Diabetes Center at the Heinrich-Heine-University Duesseldorf, Leibniz Center for Diabetes Research, Aufm Hennekamp 65, 40225, Duesseldorf, Germany.,German Center for Diabetes Research (DZD), Munich-Neuherberg, Germany
| | - Daniella Herzfeld de Wiza
- Institute of Clinical Biochemistry and Pathobiochemistry, German Diabetes Center at the Heinrich-Heine-University Duesseldorf, Leibniz Center for Diabetes Research, Aufm Hennekamp 65, 40225, Duesseldorf, Germany.,German Center for Diabetes Research (DZD), Munich-Neuherberg, Germany
| | - Sylvia Jacob
- Institute of Clinical Biochemistry and Pathobiochemistry, German Diabetes Center at the Heinrich-Heine-University Duesseldorf, Leibniz Center for Diabetes Research, Aufm Hennekamp 65, 40225, Duesseldorf, Germany.,German Center for Diabetes Research (DZD), Munich-Neuherberg, Germany
| | - Ulrike Kettel
- Institute of Clinical Biochemistry and Pathobiochemistry, German Diabetes Center at the Heinrich-Heine-University Duesseldorf, Leibniz Center for Diabetes Research, Aufm Hennekamp 65, 40225, Duesseldorf, Germany.,German Center for Diabetes Research (DZD), Munich-Neuherberg, Germany
| | - Hadi Al-Hasani
- Institute of Clinical Biochemistry and Pathobiochemistry, German Diabetes Center at the Heinrich-Heine-University Duesseldorf, Leibniz Center for Diabetes Research, Aufm Hennekamp 65, 40225, Duesseldorf, Germany.,German Center for Diabetes Research (DZD), Munich-Neuherberg, Germany.,Medical Faculty, Institute for Clinical Biochemistry and Pathobiochemistry, German Diabetes Center (DDZ), Heinrich-Heine-University, Duesseldorf, Germany
| | - Martina Krüger
- Medical Faculty, Institute of Cardiovascular Physiology, Heinrich-Heine-University, Duesseldorf, Germany
| | - D Margriet Ouwens
- Institute of Clinical Biochemistry and Pathobiochemistry, German Diabetes Center at the Heinrich-Heine-University Duesseldorf, Leibniz Center for Diabetes Research, Aufm Hennekamp 65, 40225, Duesseldorf, Germany.,German Center for Diabetes Research (DZD), Munich-Neuherberg, Germany.,Department of Endocrinology, Ghent University Hospital, Ghent, Belgium
| | - Sonja Hartwig
- Institute of Clinical Biochemistry and Pathobiochemistry, German Diabetes Center at the Heinrich-Heine-University Duesseldorf, Leibniz Center for Diabetes Research, Aufm Hennekamp 65, 40225, Duesseldorf, Germany.,German Center for Diabetes Research (DZD), Munich-Neuherberg, Germany
| | - Stefan Lehr
- Institute of Clinical Biochemistry and Pathobiochemistry, German Diabetes Center at the Heinrich-Heine-University Duesseldorf, Leibniz Center for Diabetes Research, Aufm Hennekamp 65, 40225, Duesseldorf, Germany.,German Center for Diabetes Research (DZD), Munich-Neuherberg, Germany
| | - Jorg Kotzka
- Institute of Clinical Biochemistry and Pathobiochemistry, German Diabetes Center at the Heinrich-Heine-University Duesseldorf, Leibniz Center for Diabetes Research, Aufm Hennekamp 65, 40225, Duesseldorf, Germany.,German Center for Diabetes Research (DZD), Munich-Neuherberg, Germany
| | - Birgit Knebel
- Institute of Clinical Biochemistry and Pathobiochemistry, German Diabetes Center at the Heinrich-Heine-University Duesseldorf, Leibniz Center for Diabetes Research, Aufm Hennekamp 65, 40225, Duesseldorf, Germany. .,German Center for Diabetes Research (DZD), Munich-Neuherberg, Germany.
| |
Collapse
|
20
|
Petz A, Grandoch M, Gorski DJ, Abrams M, Piroth M, Schneckmann R, Homann S, Müller J, Hartwig S, Lehr S, Yamaguchi Y, Wight TN, Gorressen S, Ding Z, Kötter S, Krüger M, Heinen A, Kelm M, Gödecke A, Flögel U, Fischer JW. Cardiac Hyaluronan Synthesis Is Critically Involved in the Cardiac Macrophage Response and Promotes Healing After Ischemia Reperfusion Injury. Circ Res 2020; 124:1433-1447. [PMID: 30916618 DOI: 10.1161/circresaha.118.313285] [Citation(s) in RCA: 41] [Impact Index Per Article: 10.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
RATIONALE Immediate changes in the ECM (extracellular matrix) microenvironment occur after myocardial ischemia and reperfusion (I/R) injury. OBJECTIVE Aim of this study was to unravel the role of the early hyaluronan (HA)-rich ECM after I/R. METHODS AND RESULTS Genetic deletion of Has2 and Has1 was used in a murine model of cardiac I/R. Chemical exchange saturation transfer imaging was adapted to image cardiac ECM post-I/R. Of note, the cardiac chemical exchange saturation transfer signal was severely suppressed by Has2 deletion and pharmacological inhibition of HA synthesis 24 hours after I/R. Has2 KO ( Has2 deficient) mice showed impaired hemodynamic function suggesting a protective role for endogenous HA synthesis. In contrast to Has2 deficiency, Has1-deficient mice developed no specific phenotype compared with control post-I/R. Importantly, in Has2 KO mice, cardiac macrophages were diminished after I/R as detected by 19F MRI (magnetic resonance imaging) of perfluorcarbon-labeled immune cells, Mac-2/Galectin-3 immunostaining, and FACS (fluorescence-activated cell sorting) analysis (CD45+CD11b+Ly6G-CD64+F4/80+cells). In contrast to macrophages, cardiac Ly6Chigh and Ly6Clow monocytes were unaffected post-I/R compared with control mice. Mechanistically, inhibition of HA synthesis led to increased macrophage apoptosis in vivo and in vitro. In addition, α-SMA (α-smooth muscle actin)-positive cells were reduced in the infarcted myocardium and in the border zone. In vitro, the myofibroblast response as measured by Acta2 mRNA expression was reduced by inhibition of HA synthesis and of CD44 signaling. Furthermore, Has2 KO fibroblasts were less able to contract collagen gels in vitro. The effects of HA/CD44 on fibroblasts and macrophages post-I/R might also affect intercellular cross talk because cardiac fibroblasts were activated by monocyte/macrophages and, in turn, protected macrophages from apoptosis. CONCLUSIONS Increased HA synthesis contributes to postinfarct healing by supporting macrophage survival and by promoting the myofibroblast response. Additionally, imaging of cardiac HA by chemical exchange saturation transfer post-I/R might have translational value.
Collapse
Affiliation(s)
- Anne Petz
- From the Institut für Pharmakologie und Klinische Pharmakologie (A.P., M.G., D.J.G., M.A., M.P., R.S., S.H., J.M., S.G., J.W.F.), University Hospital, Heinrich-Heine-University Düsseldorf, Germany.,CARID, Cardiovascular Research Institute Düsseldorf (A.P., M.G., D.J.G., M.A., M.P., R.S., S.H., J.M., S.G., M. Kelm, A.G., U.F., J.W.F.), University Hospital, Heinrich-Heine-University Düsseldorf, Germany
| | - Maria Grandoch
- From the Institut für Pharmakologie und Klinische Pharmakologie (A.P., M.G., D.J.G., M.A., M.P., R.S., S.H., J.M., S.G., J.W.F.), University Hospital, Heinrich-Heine-University Düsseldorf, Germany.,CARID, Cardiovascular Research Institute Düsseldorf (A.P., M.G., D.J.G., M.A., M.P., R.S., S.H., J.M., S.G., M. Kelm, A.G., U.F., J.W.F.), University Hospital, Heinrich-Heine-University Düsseldorf, Germany
| | - Daniel J Gorski
- From the Institut für Pharmakologie und Klinische Pharmakologie (A.P., M.G., D.J.G., M.A., M.P., R.S., S.H., J.M., S.G., J.W.F.), University Hospital, Heinrich-Heine-University Düsseldorf, Germany.,CARID, Cardiovascular Research Institute Düsseldorf (A.P., M.G., D.J.G., M.A., M.P., R.S., S.H., J.M., S.G., M. Kelm, A.G., U.F., J.W.F.), University Hospital, Heinrich-Heine-University Düsseldorf, Germany
| | - Marcel Abrams
- From the Institut für Pharmakologie und Klinische Pharmakologie (A.P., M.G., D.J.G., M.A., M.P., R.S., S.H., J.M., S.G., J.W.F.), University Hospital, Heinrich-Heine-University Düsseldorf, Germany.,CARID, Cardiovascular Research Institute Düsseldorf (A.P., M.G., D.J.G., M.A., M.P., R.S., S.H., J.M., S.G., M. Kelm, A.G., U.F., J.W.F.), University Hospital, Heinrich-Heine-University Düsseldorf, Germany
| | - Marco Piroth
- From the Institut für Pharmakologie und Klinische Pharmakologie (A.P., M.G., D.J.G., M.A., M.P., R.S., S.H., J.M., S.G., J.W.F.), University Hospital, Heinrich-Heine-University Düsseldorf, Germany.,CARID, Cardiovascular Research Institute Düsseldorf (A.P., M.G., D.J.G., M.A., M.P., R.S., S.H., J.M., S.G., M. Kelm, A.G., U.F., J.W.F.), University Hospital, Heinrich-Heine-University Düsseldorf, Germany
| | - Rebekka Schneckmann
- From the Institut für Pharmakologie und Klinische Pharmakologie (A.P., M.G., D.J.G., M.A., M.P., R.S., S.H., J.M., S.G., J.W.F.), University Hospital, Heinrich-Heine-University Düsseldorf, Germany.,CARID, Cardiovascular Research Institute Düsseldorf (A.P., M.G., D.J.G., M.A., M.P., R.S., S.H., J.M., S.G., M. Kelm, A.G., U.F., J.W.F.), University Hospital, Heinrich-Heine-University Düsseldorf, Germany
| | - Susanne Homann
- From the Institut für Pharmakologie und Klinische Pharmakologie (A.P., M.G., D.J.G., M.A., M.P., R.S., S.H., J.M., S.G., J.W.F.), University Hospital, Heinrich-Heine-University Düsseldorf, Germany.,CARID, Cardiovascular Research Institute Düsseldorf (A.P., M.G., D.J.G., M.A., M.P., R.S., S.H., J.M., S.G., M. Kelm, A.G., U.F., J.W.F.), University Hospital, Heinrich-Heine-University Düsseldorf, Germany
| | - Julia Müller
- From the Institut für Pharmakologie und Klinische Pharmakologie (A.P., M.G., D.J.G., M.A., M.P., R.S., S.H., J.M., S.G., J.W.F.), University Hospital, Heinrich-Heine-University Düsseldorf, Germany.,CARID, Cardiovascular Research Institute Düsseldorf (A.P., M.G., D.J.G., M.A., M.P., R.S., S.H., J.M., S.G., M. Kelm, A.G., U.F., J.W.F.), University Hospital, Heinrich-Heine-University Düsseldorf, Germany
| | - Sonja Hartwig
- Institute of Clinical Biochemistry and Pathobiochemistry, German Diabetes Center at the Heinrich-Heine-University Duesseldorf, Leibniz Center for Diabetes Research, Germany (S.H., S.L.).,German Center for Diabetes Research, München-Neuherberg, Germany (S.H., S.L.)
| | - Stefan Lehr
- Institute of Clinical Biochemistry and Pathobiochemistry, German Diabetes Center at the Heinrich-Heine-University Duesseldorf, Leibniz Center for Diabetes Research, Germany (S.H., S.L.).,German Center for Diabetes Research, München-Neuherberg, Germany (S.H., S.L.)
| | - Yu Yamaguchi
- Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA (Y.Y.)
| | - Thomas N Wight
- Matrix Biology Program, Benaroya Research Institute at Virginia Mason, Seattle, WA (T.N.W.)
| | - Simone Gorressen
- From the Institut für Pharmakologie und Klinische Pharmakologie (A.P., M.G., D.J.G., M.A., M.P., R.S., S.H., J.M., S.G., J.W.F.), University Hospital, Heinrich-Heine-University Düsseldorf, Germany.,CARID, Cardiovascular Research Institute Düsseldorf (A.P., M.G., D.J.G., M.A., M.P., R.S., S.H., J.M., S.G., M. Kelm, A.G., U.F., J.W.F.), University Hospital, Heinrich-Heine-University Düsseldorf, Germany
| | - Zhaoping Ding
- Institut für Molekulare Kardiologie (Z.D., U.F.), University Hospital, Heinrich-Heine-University Düsseldorf, Germany
| | - Sebastian Kötter
- Institut für Herz- und Kreislaufphysiologie (S.K., M. Krüger, A.H., A.G.), University Hospital, Heinrich-Heine-University Düsseldorf, Germany
| | - Martina Krüger
- Institut für Herz- und Kreislaufphysiologie (S.K., M. Krüger, A.H., A.G.), University Hospital, Heinrich-Heine-University Düsseldorf, Germany
| | - Andre Heinen
- Institut für Herz- und Kreislaufphysiologie (S.K., M. Krüger, A.H., A.G.), University Hospital, Heinrich-Heine-University Düsseldorf, Germany
| | - Malte Kelm
- CARID, Cardiovascular Research Institute Düsseldorf (A.P., M.G., D.J.G., M.A., M.P., R.S., S.H., J.M., S.G., M. Kelm, A.G., U.F., J.W.F.), University Hospital, Heinrich-Heine-University Düsseldorf, Germany.,Klinik für Kardiologie, Pneumologie und Angiologie (M. Kelm, U.F.), University Hospital, Heinrich-Heine-University Düsseldorf, Germany
| | - Axel Gödecke
- CARID, Cardiovascular Research Institute Düsseldorf (A.P., M.G., D.J.G., M.A., M.P., R.S., S.H., J.M., S.G., M. Kelm, A.G., U.F., J.W.F.), University Hospital, Heinrich-Heine-University Düsseldorf, Germany.,Institut für Herz- und Kreislaufphysiologie (S.K., M. Krüger, A.H., A.G.), University Hospital, Heinrich-Heine-University Düsseldorf, Germany
| | - Ulrich Flögel
- CARID, Cardiovascular Research Institute Düsseldorf (A.P., M.G., D.J.G., M.A., M.P., R.S., S.H., J.M., S.G., M. Kelm, A.G., U.F., J.W.F.), University Hospital, Heinrich-Heine-University Düsseldorf, Germany.,Institut für Molekulare Kardiologie (Z.D., U.F.), University Hospital, Heinrich-Heine-University Düsseldorf, Germany.,Klinik für Kardiologie, Pneumologie und Angiologie (M. Kelm, U.F.), University Hospital, Heinrich-Heine-University Düsseldorf, Germany
| | - Jens W Fischer
- From the Institut für Pharmakologie und Klinische Pharmakologie (A.P., M.G., D.J.G., M.A., M.P., R.S., S.H., J.M., S.G., J.W.F.), University Hospital, Heinrich-Heine-University Düsseldorf, Germany.,CARID, Cardiovascular Research Institute Düsseldorf (A.P., M.G., D.J.G., M.A., M.P., R.S., S.H., J.M., S.G., M. Kelm, A.G., U.F., J.W.F.), University Hospital, Heinrich-Heine-University Düsseldorf, Germany
| |
Collapse
|
21
|
Knebel B, Fahlbusch P, Dille M, Wahlers N, Hartwig S, Jacob S, Kettel U, Schiller M, Herebian D, Koellmer C, Lehr S, Müller-Wieland D, Kotzka J. Fatty Liver Due to Increased de novo Lipogenesis: Alterations in the Hepatic Peroxisomal Proteome. Front Cell Dev Biol 2019; 7:248. [PMID: 31709254 PMCID: PMC6823594 DOI: 10.3389/fcell.2019.00248] [Citation(s) in RCA: 21] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/12/2019] [Accepted: 10/08/2019] [Indexed: 12/15/2022] Open
Abstract
In non-alcoholic fatty liver disease (NAFLD) caused by ectopic lipid accumulation, lipotoxicity is a crucial molecular risk factor. Mechanisms to eliminate lipid overflow can prevent the liver from functional complications. This may involve increased secretion of lipids or metabolic adaptation to ß-oxidation in lipid-degrading organelles such as mitochondria and peroxisomes. In addition to dietary factors, increased plasma fatty acid levels may be due to increased triglyceride synthesis, lipolysis, as well as de novo lipid synthesis (DNL) in the liver. In the present study, we investigated the impact of fatty liver caused by elevated DNL, in a transgenic mouse model with liver-specific overexpression of human sterol regulatory element-binding protein-1c (alb-SREBP-1c), on hepatic gene expression, on plasma lipids and especially on the proteome of peroxisomes by omics analyses, and we interpreted the results with knowledge-based analyses. In summary, the increased hepatic DNL is accompanied by marginal gene expression changes but massive changes in peroxisomal proteome. Furthermore, plasma phosphatidylcholine (PC) as well as lysoPC species were altered. Based on these observations, it can be speculated that the plasticity of organelles and their functionality may be directly affected by lipid overflow.
Collapse
Affiliation(s)
- Birgit Knebel
- Leibniz Center for Diabetes Research, Institute of Clinical Biochemistry and Pathobiochemistry, German Diabetes Center at the Heinrich-Heine-University Duesseldorf, Düsseldorf, Germany
- German Center for Diabetes Research (DZD), Partner Duesseldorf, Düsseldorf, Germany
| | - Pia Fahlbusch
- Leibniz Center for Diabetes Research, Institute of Clinical Biochemistry and Pathobiochemistry, German Diabetes Center at the Heinrich-Heine-University Duesseldorf, Düsseldorf, Germany
- German Center for Diabetes Research (DZD), Partner Duesseldorf, Düsseldorf, Germany
| | - Matthias Dille
- Leibniz Center for Diabetes Research, Institute of Clinical Biochemistry and Pathobiochemistry, German Diabetes Center at the Heinrich-Heine-University Duesseldorf, Düsseldorf, Germany
- German Center for Diabetes Research (DZD), Partner Duesseldorf, Düsseldorf, Germany
| | - Natalie Wahlers
- Leibniz Center for Diabetes Research, Institute of Clinical Biochemistry and Pathobiochemistry, German Diabetes Center at the Heinrich-Heine-University Duesseldorf, Düsseldorf, Germany
- German Center for Diabetes Research (DZD), Partner Duesseldorf, Düsseldorf, Germany
| | - Sonja Hartwig
- Leibniz Center for Diabetes Research, Institute of Clinical Biochemistry and Pathobiochemistry, German Diabetes Center at the Heinrich-Heine-University Duesseldorf, Düsseldorf, Germany
- German Center for Diabetes Research (DZD), Partner Duesseldorf, Düsseldorf, Germany
| | - Sylvia Jacob
- Leibniz Center for Diabetes Research, Institute of Clinical Biochemistry and Pathobiochemistry, German Diabetes Center at the Heinrich-Heine-University Duesseldorf, Düsseldorf, Germany
- German Center for Diabetes Research (DZD), Partner Duesseldorf, Düsseldorf, Germany
| | - Ulrike Kettel
- Leibniz Center for Diabetes Research, Institute of Clinical Biochemistry and Pathobiochemistry, German Diabetes Center at the Heinrich-Heine-University Duesseldorf, Düsseldorf, Germany
- German Center for Diabetes Research (DZD), Partner Duesseldorf, Düsseldorf, Germany
| | - Martina Schiller
- Leibniz Center for Diabetes Research, Institute of Clinical Biochemistry and Pathobiochemistry, German Diabetes Center at the Heinrich-Heine-University Duesseldorf, Düsseldorf, Germany
- German Center for Diabetes Research (DZD), Partner Duesseldorf, Düsseldorf, Germany
| | - Diran Herebian
- Department of General Pediatrics, Neonatology and Pediatric Cardiology, Medical Faculty, University Children’s Hospital, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany
| | - Cornelia Koellmer
- Leibniz Center for Diabetes Research, Institute of Clinical Biochemistry and Pathobiochemistry, German Diabetes Center at the Heinrich-Heine-University Duesseldorf, Düsseldorf, Germany
- German Center for Diabetes Research (DZD), Partner Duesseldorf, Düsseldorf, Germany
| | - Stefan Lehr
- Leibniz Center for Diabetes Research, Institute of Clinical Biochemistry and Pathobiochemistry, German Diabetes Center at the Heinrich-Heine-University Duesseldorf, Düsseldorf, Germany
- German Center for Diabetes Research (DZD), Partner Duesseldorf, Düsseldorf, Germany
| | - Dirk Müller-Wieland
- Department of Internal Medicine I, Clinical Research Centre, University Hospital Aachen, Aachen, Germany
| | - Jorg Kotzka
- Leibniz Center for Diabetes Research, Institute of Clinical Biochemistry and Pathobiochemistry, German Diabetes Center at the Heinrich-Heine-University Duesseldorf, Düsseldorf, Germany
- German Center for Diabetes Research (DZD), Partner Duesseldorf, Düsseldorf, Germany
| |
Collapse
|
22
|
Yang Z, Liu J, Poree F, Schaeufele R, Helmke H, Frackenpohl J, Lehr S, von Koskull-Döring P, Christmann A, Schnyder H, Schmidhalter U, Grill E. Abscisic Acid Receptors and Coreceptors Modulate Plant Water Use Efficiency and Water Productivity. Plant Physiol 2019; 180:1066-1080. [PMID: 30886115 PMCID: PMC6548280 DOI: 10.1104/pp.18.01238] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/15/2018] [Accepted: 03/08/2019] [Indexed: 05/17/2023]
Abstract
Improving the water use efficiency (WUE) of crop plants without trade-offs in growth and yield is considered a utopic goal. However, recent studies on model plants show that partial restriction of transpiration can occur without a reduction in CO2 uptake and photosynthesis. In this study, we analyzed the potentials and constraints of improving WUE in Arabidopsis (Arabidopsis thaliana) and in wheat (Triticum aestivum). We show that the analyzed Arabidopsis wild-type plants consume more water than is required for unrestricted growth. WUE was enhanced without a growth penalty by modulating abscisic acid (ABA) responses either by using overexpression of specific ABA receptors or deficiency of ABA coreceptors. Hence, the plants showed higher water productivity compared with the wild-type plants; that is, equal growth with less water. The high WUE trait was resilient to changes in light intensity and water availability, but it was sensitive to the ambient temperature. ABA application to plants generated a partial phenocopy of the water-productivity trait. ABA application, however, was never as effective as genetic modification in enhancing water productivity, probably because ABA indiscriminately targets all ABA receptors. ABA agonists selective for individual ABA receptors might offer an approach to phenocopy the water-productivity trait of the high WUE lines. ABA application to wheat grown under near-field conditions improved WUE without detectable growth trade-offs. Wheat yields are heavily impacted by water deficit, and our identification of this crop as a promising target for WUE improvement may help contribute to greater food security.
Collapse
Affiliation(s)
- Zhenyu Yang
- Lehrstuhl für Botanik, Technische Universität München, Emil-Ramann-Str. 4, 85354 Freising, Germany
| | - Jinghui Liu
- Lehrstuhl für Botanik, Technische Universität München, Emil-Ramann-Str. 4, 85354 Freising, Germany
| | - Fabien Poree
- Bayer SAS, Toxicology, Toxicology Research, 355, Rue Dostoievski, CS 90153 Valbonne, 06906 Sophia-Antipolis Cedex, France
| | - Rudi Schaeufele
- Lehrstuhl für Grünlandlehre, Technische Universität München, Alte Akademie 12, 85354 Freising, Germany
| | - Hendrik Helmke
- Research and Development, Weed Control Research, Bayer AG, Division Crop Science, Industriepark Höchst, 65926 Frankfurt am Main, Germany
| | - Jens Frackenpohl
- Research and Development, Weed Control Research, Bayer AG, Division Crop Science, Industriepark Höchst, 65926 Frankfurt am Main, Germany
| | - Stefan Lehr
- Research and Development, Weed Control Research, Bayer AG, Division Crop Science, Industriepark Höchst, 65926 Frankfurt am Main, Germany
| | - Pascal von Koskull-Döring
- Research and Development, Weed Control Research, Bayer AG, Division Crop Science, Industriepark Höchst, 65926 Frankfurt am Main, Germany
| | - Alexander Christmann
- Lehrstuhl für Botanik, Technische Universität München, Emil-Ramann-Str. 4, 85354 Freising, Germany
| | - Hans Schnyder
- Lehrstuhl für Grünlandlehre, Technische Universität München, Alte Akademie 12, 85354 Freising, Germany
| | - Urs Schmidhalter
- Lehrstuhl für Pflanzenernährung, Technische Universität München, Emil-Ramann-Straße 2, 85354 Freising, Germany
| | - Erwin Grill
- Lehrstuhl für Botanik, Technische Universität München, Emil-Ramann-Str. 4, 85354 Freising, Germany
| |
Collapse
|
23
|
Knebel B, Fahlbusch P, Poschmann G, Dille M, Wahlers N, Stühler K, Hartwig S, Lehr S, Schiller M, Jacob S, Kettel U, Müller-Wieland D, Kotzka J. Adipokinome Signatures in Obese Mouse Models Reflect Adipose Tissue Health and Are Associated with Serum Lipid Composition. Int J Mol Sci 2019; 20:ijms20102559. [PMID: 31137678 PMCID: PMC6567124 DOI: 10.3390/ijms20102559] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2019] [Revised: 05/21/2019] [Accepted: 05/22/2019] [Indexed: 12/14/2022] Open
Abstract
Adipocyte and hepatic lipid metabolism govern whole-body metabolic homeostasis, whereas a disbalance of de novo lipogenesis (DNL) in fat and liver might lead to obesity, with severe co-morbidities. Nevertheless, some obese people are metabolically healthy, but the “protective” mechanisms are not yet known in detail. Especially, the adipocyte-derived molecular mediators that indicate adipose functionality are poorly understood. We studied transgenic mice (alb-SREBP-1c) with a “healthy” obese phenotype, and obob mice with hyperphagia-induced “sick” obesity to analyze the impact of the tissue-specific DNL on the secreted proteins, i.e., the adipokinome, of the primary adipose cells by label-free proteomics. Compared to the control mice, adipose DNL is reduced in both obese mouse models. In contrast, the hepatic DNL is reduced in obob but elevated in alb-SREBP-1c mice. To investigate the relationship between lipid metabolism and adipokinomes, we formulated the “liver-to-adipose-tissue DNL” ratio. Knowledge-based analyses of these results revealed adipocyte functionality with proteins, which was involved in tissue remodeling or metabolism in the alb-SREBP-1c mice and in the control mice, but mainly in fibrosis in the obob mice. The adipokinome in “healthy” obesity is similar to that in a normal condition, but it differs from that in “sick” obesity, whereas the serum lipid patterns reflect the “liver-to-adipose-tissue DNL” ratio and are associated with the adipokinome signature.
Collapse
Affiliation(s)
- Birgit Knebel
- Institute of Clinical Biochemistry and Pathobiochemistry, German Diabetes Center at the Heinrich-Heine-University Duesseldorf, Leibniz Center for Diabetes Research; 40225 Duesseldorf, Germany.
- German Center for Diabetes Research (DZD), Partner Duesseldorf, 40225 Duesseldorf, Germany.
| | - Pia Fahlbusch
- Institute of Clinical Biochemistry and Pathobiochemistry, German Diabetes Center at the Heinrich-Heine-University Duesseldorf, Leibniz Center for Diabetes Research; 40225 Duesseldorf, Germany.
- German Center for Diabetes Research (DZD), Partner Duesseldorf, 40225 Duesseldorf, Germany.
| | - Gereon Poschmann
- Institute for Molecular Medicine, University Hospital Duesseldorf, Heinrich Heine University Duesseldorf, 40225 Duesseldorf, Germany.
| | - Matthias Dille
- Institute of Clinical Biochemistry and Pathobiochemistry, German Diabetes Center at the Heinrich-Heine-University Duesseldorf, Leibniz Center for Diabetes Research; 40225 Duesseldorf, Germany.
- German Center for Diabetes Research (DZD), Partner Duesseldorf, 40225 Duesseldorf, Germany.
| | - Natalie Wahlers
- Institute of Clinical Biochemistry and Pathobiochemistry, German Diabetes Center at the Heinrich-Heine-University Duesseldorf, Leibniz Center for Diabetes Research; 40225 Duesseldorf, Germany.
- German Center for Diabetes Research (DZD), Partner Duesseldorf, 40225 Duesseldorf, Germany.
| | - Kai Stühler
- Institute for Molecular Medicine, University Hospital Duesseldorf, Heinrich Heine University Duesseldorf, 40225 Duesseldorf, Germany.
- Heinrich-Heine-University Duesseldorf, Molecular Proteomics Laboratory, BMFZ, 40225 Duesseldorf, Germany.
| | - Sonja Hartwig
- Institute of Clinical Biochemistry and Pathobiochemistry, German Diabetes Center at the Heinrich-Heine-University Duesseldorf, Leibniz Center for Diabetes Research; 40225 Duesseldorf, Germany.
- German Center for Diabetes Research (DZD), Partner Duesseldorf, 40225 Duesseldorf, Germany.
| | - Stefan Lehr
- Institute of Clinical Biochemistry and Pathobiochemistry, German Diabetes Center at the Heinrich-Heine-University Duesseldorf, Leibniz Center for Diabetes Research; 40225 Duesseldorf, Germany.
- German Center for Diabetes Research (DZD), Partner Duesseldorf, 40225 Duesseldorf, Germany.
| | - Martina Schiller
- Institute of Clinical Biochemistry and Pathobiochemistry, German Diabetes Center at the Heinrich-Heine-University Duesseldorf, Leibniz Center for Diabetes Research; 40225 Duesseldorf, Germany.
- German Center for Diabetes Research (DZD), Partner Duesseldorf, 40225 Duesseldorf, Germany.
| | - Sylvia Jacob
- Institute of Clinical Biochemistry and Pathobiochemistry, German Diabetes Center at the Heinrich-Heine-University Duesseldorf, Leibniz Center for Diabetes Research; 40225 Duesseldorf, Germany.
- German Center for Diabetes Research (DZD), Partner Duesseldorf, 40225 Duesseldorf, Germany.
| | - Ulrike Kettel
- Institute of Clinical Biochemistry and Pathobiochemistry, German Diabetes Center at the Heinrich-Heine-University Duesseldorf, Leibniz Center for Diabetes Research; 40225 Duesseldorf, Germany.
- German Center for Diabetes Research (DZD), Partner Duesseldorf, 40225 Duesseldorf, Germany.
| | - Dirk Müller-Wieland
- Clinical Research Centre, Department of Internal Medicine I, University Hospital Aachen, 52074 Aachen, Germany.
| | - Jörg Kotzka
- Institute of Clinical Biochemistry and Pathobiochemistry, German Diabetes Center at the Heinrich-Heine-University Duesseldorf, Leibniz Center for Diabetes Research; 40225 Duesseldorf, Germany.
- German Center for Diabetes Research (DZD), Partner Duesseldorf, 40225 Duesseldorf, Germany.
| |
Collapse
|
24
|
Hartwig S, De Filippo E, Göddeke S, Knebel B, Kotzka J, Al-Hasani H, Roden M, Lehr S, Sell H. Exosomal proteins constitute an essential part of the human adipose tissue secretome. Biochim Biophys Acta Proteins Proteom 2018; 1867:140172. [PMID: 30502511 DOI: 10.1016/j.bbapap.2018.11.009] [Citation(s) in RCA: 43] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/30/2018] [Revised: 10/18/2018] [Accepted: 11/23/2018] [Indexed: 01/05/2023]
Abstract
Adipose tissue is an endocrine organ, secreting various adipokines, either directly or via extracellular vesicles, including exosomes. Exosomes are vesicles of 40-150 nm size that represent a novel concept of biomolecule release. We purified exosomes from isolated primary human preadipocytes differentiated to mature adipocytes. The analyses of these exosomal preparations by LC-MS identified 884 proteins, so called exoadipokines. The comparison of exoadipokines with previously identified human exosome-associated proteins in ExoCarta database show an overlap of 817 proteins, but also revealed 67 proteins not assigned to human exosomes, yet. We further compared all exoadipokines to our previously reported reference secretome of human adipose tissue (http://diabesityprot.org/), finding 212 common proteins, whereas 672 proteins were specific for the exosomal fraction. Bioinformatic analyses revealed that the 212 common proteins can be assigned to all major functions of adipose tissue secreted proteins e.g. molecules involved in fibrotic processes or inflammation. In contrast, the exosome-specific proteins were rather assigned to signaling pathways and membrane-mediated processes. In conclusion, the isolation of exosomes allows to further specify the functionality of adipokines and exoadipokines as part of the adipocyte secretome in signaling and interorgan crosstalk.
Collapse
Affiliation(s)
- Sonja Hartwig
- Institute for Clinical Biochemistry and Pathobiochemistry, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University, Duesseldorf, Germany; German Center for Diabetes Research (DZD e.V.), München, Germany
| | - Elisabetta De Filippo
- German Center for Diabetes Research (DZD e.V.), München, Germany; Institute for Clinical Diabetology, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University, Duesseldorf, Germany
| | - Simon Göddeke
- Institute for Clinical Biochemistry and Pathobiochemistry, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University, Duesseldorf, Germany; German Center for Diabetes Research (DZD e.V.), München, Germany
| | - Birgit Knebel
- Institute for Clinical Biochemistry and Pathobiochemistry, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University, Duesseldorf, Germany; German Center for Diabetes Research (DZD e.V.), München, Germany
| | - Jorg Kotzka
- Institute for Clinical Biochemistry and Pathobiochemistry, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University, Duesseldorf, Germany; German Center for Diabetes Research (DZD e.V.), München, Germany
| | - Hadi Al-Hasani
- Institute for Clinical Biochemistry and Pathobiochemistry, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University, Duesseldorf, Germany; German Center for Diabetes Research (DZD e.V.), München, Germany; Institute for Clinical Biochemistry and Pathobiochemistry, German Diabetes Center, Leibniz Center for Diabetes Research, Medical Faculty, Heinrich Heine University, Duesseldorf, Germany
| | - Michael Roden
- German Center for Diabetes Research (DZD e.V.), München, Germany; Institute for Clinical Diabetology, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University, Duesseldorf, Germany; Division of Endocrinology and Diabetology, Medical Faculty, Heinrich Heine University, Duesseldorf, Germany
| | - Stefan Lehr
- Institute for Clinical Biochemistry and Pathobiochemistry, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University, Duesseldorf, Germany; German Center for Diabetes Research (DZD e.V.), München, Germany.
| | - Henrike Sell
- German Center for Diabetes Research (DZD e.V.), München, Germany; Institute for Clinical Diabetology, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University, Duesseldorf, Germany
| |
Collapse
|
25
|
Mafakheri S, Flörke RR, Kanngießer S, Hartwig S, Espelage L, De Wendt C, Schönberger T, Hamker N, Lehr S, Chadt A, Al-Hasani H. AKT and AMP-activated protein kinase regulate TBC1D1 through phosphorylation and its interaction with the cytosolic tail of insulin-regulated aminopeptidase IRAP. J Biol Chem 2018; 293:17853-17862. [PMID: 30275018 DOI: 10.1074/jbc.ra118.005040] [Citation(s) in RCA: 25] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2018] [Revised: 09/18/2018] [Indexed: 12/21/2022] Open
Abstract
In skeletal muscle, the Rab GTPase-activating (GAP) protein TBC1D1 is phosphorylated by AKT and AMP-activated protein kinase (AMPK) in response to insulin and muscle contraction. Genetic ablation of Tbc1d1 or mutation of distinct phosphorylation sites impairs intracellular GLUT4 retention and GLUT4 traffic, presumably through alterations of the activation state of downstream Rab GTPases. Previous studies have focused on characterizing the C-terminal GAP domain of TBC1D1 that lacks the known phosphorylation sites, as well as putative regulatory domains. As a result, it has been unclear how phosphorylation of TBC1D1 would regulate its activity. In the present study, we have expressed, purified, and characterized recombinant full-length TBC1D1 in Sf9 insect cells via the baculovirus system. Full-length TBC1D1 showed RabGAP activity toward GLUT4-associated Rab8a, Rab10, and Rab14, indicating similar substrate specificity as the truncated GAP domain. However, the catalytic activity of the full-length TBC1D1 was markedly higher than that of the GAP domain. Although in vitro phosphorylation of TBC1D1 by AKT or AMPK increased 14-3-3 binding, it did not alter the intrinsic RabGAP activity. However, we found that TBC1D1 interacts through its N-terminal PTB domains with the cytoplasmic domain of the insulin-regulated aminopeptidase, a resident protein of GLUT4 storage vesicles, and this binding is disrupted by phosphorylation of TBC1D1 by AKT or AMPK. In summary, our findings suggest that other regions outside the GAP domain may contribute to the catalytic activity of TBC1D1. Moreover, our data indicate that recruitment of TBC1D1 to GLUT4-containing vesicles and not its GAP activity is regulated by insulin and contraction-mediated phosphorylation.
Collapse
Affiliation(s)
- Samaneh Mafakheri
- From the Institute of Clinical Biochemistry and Pathobiochemistry, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University, Medical Faculty, 40225 Düsseldorf; German Center for Diabetes Research (DZD), 85764 München-Neuherberg, Germany
| | - Ralf R Flörke
- From the Institute of Clinical Biochemistry and Pathobiochemistry, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University, Medical Faculty, 40225 Düsseldorf; German Center for Diabetes Research (DZD), 85764 München-Neuherberg, Germany
| | - Sibylle Kanngießer
- From the Institute of Clinical Biochemistry and Pathobiochemistry, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University, Medical Faculty, 40225 Düsseldorf
| | - Sonja Hartwig
- From the Institute of Clinical Biochemistry and Pathobiochemistry, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University, Medical Faculty, 40225 Düsseldorf; German Center for Diabetes Research (DZD), 85764 München-Neuherberg, Germany
| | - Lena Espelage
- From the Institute of Clinical Biochemistry and Pathobiochemistry, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University, Medical Faculty, 40225 Düsseldorf; German Center for Diabetes Research (DZD), 85764 München-Neuherberg, Germany
| | - Christian De Wendt
- From the Institute of Clinical Biochemistry and Pathobiochemistry, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University, Medical Faculty, 40225 Düsseldorf; German Center for Diabetes Research (DZD), 85764 München-Neuherberg, Germany
| | - Tina Schönberger
- From the Institute of Clinical Biochemistry and Pathobiochemistry, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University, Medical Faculty, 40225 Düsseldorf
| | - Nele Hamker
- From the Institute of Clinical Biochemistry and Pathobiochemistry, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University, Medical Faculty, 40225 Düsseldorf
| | - Stefan Lehr
- From the Institute of Clinical Biochemistry and Pathobiochemistry, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University, Medical Faculty, 40225 Düsseldorf; German Center for Diabetes Research (DZD), 85764 München-Neuherberg, Germany
| | - Alexandra Chadt
- From the Institute of Clinical Biochemistry and Pathobiochemistry, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University, Medical Faculty, 40225 Düsseldorf; German Center for Diabetes Research (DZD), 85764 München-Neuherberg, Germany
| | - Hadi Al-Hasani
- From the Institute of Clinical Biochemistry and Pathobiochemistry, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University, Medical Faculty, 40225 Düsseldorf; German Center for Diabetes Research (DZD), 85764 München-Neuherberg, Germany.
| |
Collapse
|
26
|
Schemmert S, Schartmann E, Zafiu C, Kass B, Hartwig S, Lehr S, Bannach O, Langen KJ, Shah NJ, Kutzsche J, Willuweit A, Willbold D. Aβ Oligomer Elimination Restores Cognition in Transgenic Alzheimer's Mice with Full-blown Pathology. Mol Neurobiol 2018; 56:2211-2223. [PMID: 30003517 PMCID: PMC6394605 DOI: 10.1007/s12035-018-1209-3] [Citation(s) in RCA: 20] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2018] [Accepted: 06/26/2018] [Indexed: 11/05/2022]
Abstract
Oligomers of the amyloid-β (Aβ) protein are suspected to be responsible for the development and progression of Alzheimer’s disease. Thus, the development of compounds that are able to eliminate already formed toxic Aβ oligomers is very desirable. Here, we describe the in vivo efficacy of the compound RD2, which was developed to directly and specifically eliminate toxic Aβ oligomers. In a truly therapeutic, rather than a preventive study, oral treatment with RD2 was able to reverse cognitive deficits and significantly reduce Aβ pathology in old-aged transgenic Alzheimer’s Disease mice with full-blown pathology and behavioral deficits. For the first time, we demonstrate the in vivo target engagement of RD2 by showing a significant reduction of Aβ oligomers in the brains of RD2-treated mice compared to placebo-treated mice. The correlation of Aβ elimination in vivo and the reversal of cognitive deficits in old-aged transgenic mice support the hypothesis that Aβ oligomers are relevant not only for disease development and progression, but also offer a promising target for the causal treatment of Alzheimer’s disease.
Collapse
Affiliation(s)
- Sarah Schemmert
- Institute of Complex Systems, Structural Biochemistry (ICS-6), Forschungszentrum Jülich, 52425, Jülich, Germany
| | - Elena Schartmann
- Institute of Complex Systems, Structural Biochemistry (ICS-6), Forschungszentrum Jülich, 52425, Jülich, Germany
| | - Christian Zafiu
- Institute of Complex Systems, Structural Biochemistry (ICS-6), Forschungszentrum Jülich, 52425, Jülich, Germany
| | - Bettina Kass
- Institute of Complex Systems, Structural Biochemistry (ICS-6), Forschungszentrum Jülich, 52425, Jülich, Germany
| | - Sonja Hartwig
- Institute of Clinical Biochemistry and Pathobiochemistry, German Diabetes Center at the Heinrich Heine University Düsseldorf, Leibniz Centre for Diabetes Research, Düsseldorf, Germany.,German Center for Diabetes Research (DZD), Partner Düsseldorf, Germany
| | - Stefan Lehr
- Institute of Clinical Biochemistry and Pathobiochemistry, German Diabetes Center at the Heinrich Heine University Düsseldorf, Leibniz Centre for Diabetes Research, Düsseldorf, Germany.,German Center for Diabetes Research (DZD), Partner Düsseldorf, Germany
| | - Oliver Bannach
- Institute of Complex Systems, Structural Biochemistry (ICS-6), Forschungszentrum Jülich, 52425, Jülich, Germany
| | - Karl-Josef Langen
- Institute of Neuroscience and Medicine, Medical Imaging Physics (INM-4), Forschungszentrum Jülich, 52425, Jülich, Germany.,Clinic for Nuclear Medicine, RWTH Aachen University, Aachen, Germany
| | - Nadim Joni Shah
- Institute of Neuroscience and Medicine, Medical Imaging Physics (INM-4), Forschungszentrum Jülich, 52425, Jülich, Germany.,Department of Neurology, Faculty of Medicine, JARA, RWTH Aachen University, Aachen, Germany
| | - Janine Kutzsche
- Institute of Complex Systems, Structural Biochemistry (ICS-6), Forschungszentrum Jülich, 52425, Jülich, Germany
| | - Antje Willuweit
- Institute of Neuroscience and Medicine, Medical Imaging Physics (INM-4), Forschungszentrum Jülich, 52425, Jülich, Germany.
| | - Dieter Willbold
- Institute of Complex Systems, Structural Biochemistry (ICS-6), Forschungszentrum Jülich, 52425, Jülich, Germany. .,Institut für Physikalische Biologie, Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Germany.
| |
Collapse
|
27
|
Jelenik T, Dille M, Müller-Lühlhoff S, Kabra DG, Zhou Z, Binsch C, Hartwig S, Lehr S, Chadt A, Peters EMJ, Kruse J, Roden M, Al-Hasani H, Castañeda TR. FGF21 regulates insulin sensitivity following long-term chronic stress. Mol Metab 2018; 16:126-138. [PMID: 29980484 PMCID: PMC6158095 DOI: 10.1016/j.molmet.2018.06.012] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/17/2018] [Revised: 06/12/2018] [Accepted: 06/15/2018] [Indexed: 12/22/2022] Open
Abstract
Objective Post-traumatic stress disorder (PTSD) increases type 2 diabetes risk, yet the underlying mechanisms are unclear. We investigated how early-life exposure to chronic stress affects long-term insulin sensitivity. Methods C57Bl/6J mice were exposed to chronic variable stress for 15 days (Cvs) and then recovered for three months without stress (Cvs3m). Results Cvs mice showed markedly increased plasma corticosterone and hepatic insulin resistance. Cvs3m mice exhibited improved whole-body insulin sensitivity along with enhanced adipose glucose uptake and skeletal muscle mitochondrial function and fatty acid oxidation. Plasma FGF21 levels were substantially increased and associated with expression of genes involved in fatty acid oxidation and formation of brown-like adipocytes. In humans, serum FGF21 levels were associated with stress coping long time after the exposure. Conclusions Early-life exposure to chronic stress leads to long term improvements in insulin sensitivity, oxidative metabolism and adipose tissue remodeling. FGF21 contributes to a physiological memory mechanism to maintain metabolic homeostasis. Early-life exposure of mice to stress (CVS) causes acute insulin resistance but improves long-term insulin sensitivity. 3 months after stress, mice had enhanced adipose glucose uptake and higher skeletal muscle mitochondrial function. Plasma FGF21 and gene expression for formation of brown-like adipocytes were substantially increased long after stress. In humans, serum FGF21 levels were associated with the ability to cope with stress long time after the exposure.
Collapse
Affiliation(s)
- Tomas Jelenik
- Institute for Clinical Diabetology, German Diabetes Center, Medical Faculty, Heinrich Heine University, Leibniz Center for Diabetes Research, Düsseldorf, Germany; German Center for Diabetes Research (DZD), München-Neuherberg, Germany
| | - Matthias Dille
- Institute for Clinical Biochemistry and Pathobiochemistry, German Diabetes Center, Medical Faculty, Heinrich Heine University, Leibniz Center for Diabetes Research, Düsseldorf, Germany; German Center for Diabetes Research (DZD), München-Neuherberg, Germany
| | - Sabrina Müller-Lühlhoff
- Institute for Clinical Biochemistry and Pathobiochemistry, German Diabetes Center, Medical Faculty, Heinrich Heine University, Leibniz Center for Diabetes Research, Düsseldorf, Germany; German Center for Diabetes Research (DZD), München-Neuherberg, Germany
| | - Dhiraj G Kabra
- Institute for Clinical Biochemistry and Pathobiochemistry, German Diabetes Center, Medical Faculty, Heinrich Heine University, Leibniz Center for Diabetes Research, Düsseldorf, Germany; German Center for Diabetes Research (DZD), München-Neuherberg, Germany
| | - Zhou Zhou
- Institute for Clinical Biochemistry and Pathobiochemistry, German Diabetes Center, Medical Faculty, Heinrich Heine University, Leibniz Center for Diabetes Research, Düsseldorf, Germany; German Center for Diabetes Research (DZD), München-Neuherberg, Germany
| | - Christian Binsch
- Institute for Clinical Biochemistry and Pathobiochemistry, German Diabetes Center, Medical Faculty, Heinrich Heine University, Leibniz Center for Diabetes Research, Düsseldorf, Germany; German Center for Diabetes Research (DZD), München-Neuherberg, Germany
| | - Sonja Hartwig
- Institute for Clinical Biochemistry and Pathobiochemistry, German Diabetes Center, Medical Faculty, Heinrich Heine University, Leibniz Center for Diabetes Research, Düsseldorf, Germany; German Center for Diabetes Research (DZD), München-Neuherberg, Germany
| | - Stefan Lehr
- Institute for Clinical Biochemistry and Pathobiochemistry, German Diabetes Center, Medical Faculty, Heinrich Heine University, Leibniz Center for Diabetes Research, Düsseldorf, Germany; German Center for Diabetes Research (DZD), München-Neuherberg, Germany
| | - Alexandra Chadt
- Institute for Clinical Biochemistry and Pathobiochemistry, German Diabetes Center, Medical Faculty, Heinrich Heine University, Leibniz Center for Diabetes Research, Düsseldorf, Germany; German Center for Diabetes Research (DZD), München-Neuherberg, Germany
| | - Eva M J Peters
- Justus-Liebig-University, Department of Psychosomatics and Psychotherapy, Psychoneuroimmunology Laboratory, Gießen, Germany
| | - Johannes Kruse
- Justus-Liebig-University, Department of Psychosomatics and Psychotherapy, Psychoneuroimmunology Laboratory, Gießen, Germany
| | - Michael Roden
- Institute for Clinical Diabetology, German Diabetes Center, Medical Faculty, Heinrich Heine University, Leibniz Center for Diabetes Research, Düsseldorf, Germany; German Center for Diabetes Research (DZD), München-Neuherberg, Germany; Division of Endocrinology and Diabetology, Medical Faculty, Heinrich Heine University, Düsseldorf, Germany
| | - Hadi Al-Hasani
- Institute for Clinical Biochemistry and Pathobiochemistry, German Diabetes Center, Medical Faculty, Heinrich Heine University, Leibniz Center for Diabetes Research, Düsseldorf, Germany; German Center for Diabetes Research (DZD), München-Neuherberg, Germany.
| | - Tamara R Castañeda
- Institute for Clinical Biochemistry and Pathobiochemistry, German Diabetes Center, Medical Faculty, Heinrich Heine University, Leibniz Center for Diabetes Research, Düsseldorf, Germany; German Center for Diabetes Research (DZD), München-Neuherberg, Germany
| |
Collapse
|
28
|
Akhyari P, Oberle F, Hülsmann J, Heid H, Lehr S, Barbian A, Nakanishi S, Aubin H, Jenke A, Lichtenberg A. Characterization of the Epicardial Adipose Tissue in Decellularized Human-Scaled Whole Hearts: Implications for the Whole-Heart Tissue Engineering. Tissue Eng Part A 2018; 24:682-693. [DOI: 10.1089/ten.tea.2017.0107] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
Affiliation(s)
- Payam Akhyari
- Research Group for Experimental Surgery, Department of Cardiovascular Surgery, Medical Faculty, Heinrich Heine University, Duesseldorf, Germany
| | - Fabian Oberle
- Research Group for Experimental Surgery, Department of Cardiovascular Surgery, Medical Faculty, Heinrich Heine University, Duesseldorf, Germany
| | - Jörn Hülsmann
- Research Group for Experimental Surgery, Department of Cardiovascular Surgery, Medical Faculty, Heinrich Heine University, Duesseldorf, Germany
| | - Hans Heid
- Helmholtz Group for Cell Biology, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Stefan Lehr
- Proteomics Group, German Diabetes Center, Duesseldorf, Germany
| | - Andreas Barbian
- Core Facility for Electron Microscopy, Division of Clinical Anatomy, Medical Faculty, Heinrich Heine University, Duesseldorf, Germany
| | - Sentaro Nakanishi
- Research Group for Experimental Surgery, Department of Cardiovascular Surgery, Medical Faculty, Heinrich Heine University, Duesseldorf, Germany
- Department of Cardiac Surgery, Asahikawa Medical University, Hokkaido, Japan
| | - Hug Aubin
- Research Group for Experimental Surgery, Department of Cardiovascular Surgery, Medical Faculty, Heinrich Heine University, Duesseldorf, Germany
| | - Alexander Jenke
- Research Group for Experimental Surgery, Department of Cardiovascular Surgery, Medical Faculty, Heinrich Heine University, Duesseldorf, Germany
| | - Artur Lichtenberg
- Research Group for Experimental Surgery, Department of Cardiovascular Surgery, Medical Faculty, Heinrich Heine University, Duesseldorf, Germany
| |
Collapse
|
29
|
Göddeke S, Knebel B, Fahlbusch P, Hörbelt T, Poschmann G, van de Velde F, Benninghoff T, Al-Hasani H, Jacob S, Van Nieuwenhove Y, Lapauw B, Lehr S, Ouwens DM, Kotzka J. Secretome profiling identifies T-Cadherin as a potential biomarker for adipose tissue plasticity. DIABETOL STOFFWECHS 2018. [DOI: 10.1055/s-0038-1641832] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Affiliation(s)
- S Göddeke
- Deutsches Diabetes-Zentrum (DDZ), IKBP, Düsseldorf, Germany
- Deutsches Zentrum für Diabetesforschung (DZD), Düsseldorf, Germany
| | - B Knebel
- Deutsches Diabetes-Zentrum (DDZ), IKBP, Düsseldorf, Germany
- Deutsches Zentrum für Diabetesforschung (DZD), Düsseldorf, Germany
| | - P Fahlbusch
- Deutsches Diabetes-Zentrum (DDZ), IKBP, Düsseldorf, Germany
- Deutsches Zentrum für Diabetesforschung (DZD), Düsseldorf, Germany
| | - T Hörbelt
- Deutsches Diabetes-Zentrum (DDZ), IKBP, Düsseldorf, Germany
- Deutsches Zentrum für Diabetesforschung (DZD), Düsseldorf, Germany
| | - G Poschmann
- Heinrich-Heine-Universität Düsseldorf, Molecular Proteomics Laboratory, BMFZ, Düsseldorf, Germany
| | - F van de Velde
- Ghent University Hospital, Department of Endocrinology, Ghent, Belgium
| | - T Benninghoff
- Deutsches Diabetes-Zentrum (DDZ), IKBP, Düsseldorf, Germany
- Deutsches Zentrum für Diabetesforschung (DZD), Düsseldorf, Germany
| | - H Al-Hasani
- Deutsches Diabetes-Zentrum (DDZ), IKBP, Düsseldorf, Germany
- Deutsches Zentrum für Diabetesforschung (DZD), Düsseldorf, Germany
| | - S Jacob
- Deutsches Diabetes-Zentrum (DDZ), IKBP, Düsseldorf, Germany
- Deutsches Zentrum für Diabetesforschung (DZD), Düsseldorf, Germany
| | - Y Van Nieuwenhove
- Ghent University Hospital, Department of Gastrointestinal Surgery, Ghent, Belgium
| | - B Lapauw
- Ghent University Hospital, Department of Endocrinology, Ghent, Belgium
| | - S Lehr
- Deutsches Diabetes-Zentrum (DDZ), IKBP, Düsseldorf, Germany
- Deutsches Zentrum für Diabetesforschung (DZD), Düsseldorf, Germany
| | - DM Ouwens
- Deutsches Diabetes-Zentrum (DDZ), IKBP, Düsseldorf, Germany
- Deutsches Zentrum für Diabetesforschung (DZD), Düsseldorf, Germany
- Ghent University Hospital, Department of Endocrinology, Ghent, Belgium
| | - J Kotzka
- Deutsches Diabetes-Zentrum (DDZ), IKBP, Düsseldorf, Germany
- Deutsches Zentrum für Diabetesforschung (DZD), Düsseldorf, Germany
| |
Collapse
|
30
|
Frackenpohl J, Grill E, Bojack G, Baltz R, Busch M, Dittgen J, Franke J, Freigang J, Gonzalez S, Heinemann I, Helmke H, Hills M, Hohmann S, von Koskull-Döring P, Kleemann J, Lange G, Lehr S, Müller T, Peschel E, Poree F, Schmutzler D, Schulz A, Willms L, Wunschel C. Front Cover: Analogues of Abscisic Acid - Insights into their Activity in Vitro and in Vivo (Eur. J. Org. Chem. 12/2018). European J Org Chem 2018. [DOI: 10.1002/ejoc.201800414] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- Jens Frackenpohl
- Research & Development, Weed Control; Bayer AG, CropScience Division; Industriepark Höchst; Geb. G836 65926 Frankfurt am Main Germany
| | - Erwin Grill
- Lehrstuhl für Botanik, Wissenschaftszentrum Weihenstephan; Technische Universität München; Emil-Ramann-Straße 4 85354 Freising Germany
| | - Guido Bojack
- Research & Development, Weed Control; Bayer AG, CropScience Division; Industriepark Höchst; Geb. G836 65926 Frankfurt am Main Germany
| | - Rachel Baltz
- Bayer S.A.S. Centre de Recherche de La Dargoire; 14 Impasse Pierre Baizet 69263 Cedex 09 Lyon France
| | - Marco Busch
- Research & Development, Weed Control; Bayer AG, CropScience Division; Industriepark Höchst; Geb. G836 65926 Frankfurt am Main Germany
| | - Jan Dittgen
- Research & Development, Weed Control; Bayer AG, CropScience Division; Industriepark Höchst; Geb. G836 65926 Frankfurt am Main Germany
| | - Jana Franke
- Research & Development, Weed Control; Bayer AG, CropScience Division; Industriepark Höchst; Geb. G836 65926 Frankfurt am Main Germany
| | - Jörg Freigang
- Research & Development, Research Technology; Bayer AG, CropScience Division; Gebäude 6240, Alfred-Nobel-Straße 50 40789 Monheim Germany
| | - Susana Gonzalez
- Research & Development, Weed Control; Bayer AG, CropScience Division; Industriepark Höchst; Geb. G836 65926 Frankfurt am Main Germany
| | - Ines Heinemann
- Research & Development, Weed Control; Bayer AG, CropScience Division; Industriepark Höchst; Geb. G836 65926 Frankfurt am Main Germany
| | - Hendrik Helmke
- Research & Development, Weed Control; Bayer AG, CropScience Division; Industriepark Höchst; Geb. G836 65926 Frankfurt am Main Germany
| | - Martin Hills
- Research & Development, Weed Control; Bayer AG, CropScience Division; Industriepark Höchst; Geb. G836 65926 Frankfurt am Main Germany
| | - Sabine Hohmann
- Research & Development, Weed Control; Bayer AG, CropScience Division; Industriepark Höchst; Geb. G836 65926 Frankfurt am Main Germany
| | - Pascal von Koskull-Döring
- Research & Development, Weed Control; Bayer AG, CropScience Division; Industriepark Höchst; Geb. G836 65926 Frankfurt am Main Germany
| | - Jochen Kleemann
- Research & Development, Weed Control; Bayer AG, CropScience Division; Industriepark Höchst; Geb. G836 65926 Frankfurt am Main Germany
| | - Gudrun Lange
- Research & Development, Weed Control; Bayer AG, CropScience Division; Industriepark Höchst; Geb. G836 65926 Frankfurt am Main Germany
| | - Stefan Lehr
- Research & Development, Weed Control; Bayer AG, CropScience Division; Industriepark Höchst; Geb. G836 65926 Frankfurt am Main Germany
| | - Thomas Müller
- Research & Development, Weed Control; Bayer AG, CropScience Division; Industriepark Höchst; Geb. G836 65926 Frankfurt am Main Germany
| | - Elisabeth Peschel
- Research & Development, Weed Control; Bayer AG, CropScience Division; Industriepark Höchst; Geb. G836 65926 Frankfurt am Main Germany
| | - Fabien Poree
- Bayer SAS, Toxicology, Toxicology Research; 355, rue Dostoievski, CS 90153 Valbonne, 06906 Sophia-Antipolis Cedex France
| | - Dirk Schmutzler
- Research & Development, Weed Control; Bayer AG, CropScience Division; Industriepark Höchst; Geb. G836 65926 Frankfurt am Main Germany
| | - Arno Schulz
- Research & Development, Weed Control; Bayer AG, CropScience Division; Industriepark Höchst; Geb. G836 65926 Frankfurt am Main Germany
| | - Lothar Willms
- Research & Development, Weed Control; Bayer AG, CropScience Division; Industriepark Höchst; Geb. G836 65926 Frankfurt am Main Germany
| | - Christian Wunschel
- Research & Development, Weed Control; Bayer AG, CropScience Division; Industriepark Höchst; Geb. G836 65926 Frankfurt am Main Germany
| |
Collapse
|
31
|
Frackenpohl J, Bojack G, Baltz R, Bickers U, Busch M, Dittgen J, Franke J, Freigang J, Grill E, Gonzalez S, Helmke H, Hills MJ, Hohmann S, von Koskull-Döring P, Kleemann J, Lange G, Lehr S, Schmutzler D, Schulz A, Walther K, Willms L, Wunschel C. Potent Analogues of Abscisic Acid - Identifying Cyano-Cyclopropyl Moieties as Promising Replacements for the Cyclohexenone Headgroup. European J Org Chem 2018. [DOI: 10.1002/ejoc.201701769] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
- Jens Frackenpohl
- Research & Development, Weed Control; Bayer AG, CropScience Division; Industriepark Höchst 65926 Frankfurt am Main Germany
| | - Guido Bojack
- Research & Development, Weed Control; Bayer AG, CropScience Division; Industriepark Höchst 65926 Frankfurt am Main Germany
| | - Rachel Baltz
- Bayer S.A.S. Centre de Recherche de La Dargoire; 14 Impasse Pierre Baizet 69263 Cedex 09 Lyon France
| | - Udo Bickers
- Research & Development, Weed Control; Bayer AG, CropScience Division; Industriepark Höchst 65926 Frankfurt am Main Germany
| | - Marco Busch
- Research & Development, Weed Control; Bayer AG, CropScience Division; Industriepark Höchst 65926 Frankfurt am Main Germany
| | - Jan Dittgen
- Research & Development, Weed Control; Bayer AG, CropScience Division; Industriepark Höchst 65926 Frankfurt am Main Germany
| | - Jana Franke
- Research & Development, Weed Control; Bayer AG, CropScience Division; Industriepark Höchst 65926 Frankfurt am Main Germany
| | - Jörg Freigang
- Research & Development, Research Technology; Bayer AG, CropScience Division; Gebäude 6240, Alfred-Nobel-Straße 50 40789 Monheim Germany
| | - Erwin Grill
- Lehrstuhl für Botanik, Wissenschaftszentrum Weihenstephan; Technische Universität München; Emil-Ramann-Straße 4 85354 Germany
| | - Susana Gonzalez
- Research & Development, Weed Control; Bayer AG, CropScience Division; Industriepark Höchst 65926 Frankfurt am Main Germany
| | - Hendrik Helmke
- Research & Development, Weed Control; Bayer AG, CropScience Division; Industriepark Höchst 65926 Frankfurt am Main Germany
| | - Martin J. Hills
- Research & Development, Weed Control; Bayer AG, CropScience Division; Industriepark Höchst 65926 Frankfurt am Main Germany
| | - Sabine Hohmann
- Research & Development, Weed Control; Bayer AG, CropScience Division; Industriepark Höchst 65926 Frankfurt am Main Germany
| | - Pascal von Koskull-Döring
- Research & Development, Weed Control; Bayer AG, CropScience Division; Industriepark Höchst 65926 Frankfurt am Main Germany
| | - Jochen Kleemann
- Research & Development, Weed Control; Bayer AG, CropScience Division; Industriepark Höchst 65926 Frankfurt am Main Germany
| | - Gudrun Lange
- Research & Development, Weed Control; Bayer AG, CropScience Division; Industriepark Höchst 65926 Frankfurt am Main Germany
| | - Stefan Lehr
- Research & Development, Weed Control; Bayer AG, CropScience Division; Industriepark Höchst 65926 Frankfurt am Main Germany
| | - Dirk Schmutzler
- Research & Development, Weed Control; Bayer AG, CropScience Division; Industriepark Höchst 65926 Frankfurt am Main Germany
| | - Arno Schulz
- Research & Development, Weed Control; Bayer AG, CropScience Division; Industriepark Höchst 65926 Frankfurt am Main Germany
| | - Kerstin Walther
- Research & Development, Weed Control; Bayer AG, CropScience Division; Industriepark Höchst 65926 Frankfurt am Main Germany
| | - Lothar Willms
- Research & Development, Weed Control; Bayer AG, CropScience Division; Industriepark Höchst 65926 Frankfurt am Main Germany
| | - Christian Wunschel
- Lehrstuhl für Botanik, Wissenschaftszentrum Weihenstephan; Technische Universität München; Emil-Ramann-Straße 4 85354 Germany
| |
Collapse
|
32
|
Frackenpohl J, Grill E, Bojack G, Baltz R, Busch M, Dittgen J, Franke J, Freigang J, Gonzalez S, Heinemann I, Helmke H, Hills M, Hohmann S, von Koskull-Döring P, Kleemann J, Lange G, Lehr S, Müller T, Peschel E, Poree F, Schmutzler D, Schulz A, Willms L, Wunschel C. Insights into the in Vitro and in Vivo SAR of Abscisic Acid - Exploring Unprecedented Variations of the Side Chain via Cross-Coupling-Mediated Syntheses. European J Org Chem 2018. [DOI: 10.1002/ejoc.201701687] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- Jens Frackenpohl
- Research & Development, Weed Control; Bayer AG, CropScience Division; Industriepark Höchst; Geb. G836 65926 Frankfurt am Main Germany
| | - Erwin Grill
- Lehrstuhl für Botanik, Wissenschaftszentrum Weihenstephan; Technische Universität München; Emil-Ramann-Straße 4 85354 Freising Germany
| | - Guido Bojack
- Research & Development, Weed Control; Bayer AG, CropScience Division; Industriepark Höchst; Geb. G836 65926 Frankfurt am Main Germany
| | - Rachel Baltz
- Bayer S.A.S. Centre de Recherche de La Dargoire; 14 Impasse Pierre Baizet 69263 Cedex 09 Lyon France
| | - Marco Busch
- Research & Development, Weed Control; Bayer AG, CropScience Division; Industriepark Höchst; Geb. G836 65926 Frankfurt am Main Germany
| | - Jan Dittgen
- Research & Development, Weed Control; Bayer AG, CropScience Division; Industriepark Höchst; Geb. G836 65926 Frankfurt am Main Germany
| | - Jana Franke
- Research & Development, Weed Control; Bayer AG, CropScience Division; Industriepark Höchst; Geb. G836 65926 Frankfurt am Main Germany
| | - Jörg Freigang
- Research & Development, Research Technology; Bayer AG, CropScience Division; Gebäude 6240, Alfred-Nobel-Straße 50 40789 Monheim Germany
| | - Susana Gonzalez
- Research & Development, Weed Control; Bayer AG, CropScience Division; Industriepark Höchst; Geb. G836 65926 Frankfurt am Main Germany
| | - Ines Heinemann
- Research & Development, Weed Control; Bayer AG, CropScience Division; Industriepark Höchst; Geb. G836 65926 Frankfurt am Main Germany
| | - Hendrik Helmke
- Research & Development, Weed Control; Bayer AG, CropScience Division; Industriepark Höchst; Geb. G836 65926 Frankfurt am Main Germany
| | - Martin Hills
- Research & Development, Weed Control; Bayer AG, CropScience Division; Industriepark Höchst; Geb. G836 65926 Frankfurt am Main Germany
| | - Sabine Hohmann
- Research & Development, Weed Control; Bayer AG, CropScience Division; Industriepark Höchst; Geb. G836 65926 Frankfurt am Main Germany
| | - Pascal von Koskull-Döring
- Research & Development, Weed Control; Bayer AG, CropScience Division; Industriepark Höchst; Geb. G836 65926 Frankfurt am Main Germany
| | - Jochen Kleemann
- Research & Development, Weed Control; Bayer AG, CropScience Division; Industriepark Höchst; Geb. G836 65926 Frankfurt am Main Germany
| | - Gudrun Lange
- Research & Development, Weed Control; Bayer AG, CropScience Division; Industriepark Höchst; Geb. G836 65926 Frankfurt am Main Germany
| | - Stefan Lehr
- Research & Development, Weed Control; Bayer AG, CropScience Division; Industriepark Höchst; Geb. G836 65926 Frankfurt am Main Germany
| | - Thomas Müller
- Research & Development, Weed Control; Bayer AG, CropScience Division; Industriepark Höchst; Geb. G836 65926 Frankfurt am Main Germany
| | - Elisabeth Peschel
- Research & Development, Weed Control; Bayer AG, CropScience Division; Industriepark Höchst; Geb. G836 65926 Frankfurt am Main Germany
| | - Fabien Poree
- Bayer SAS, Toxicology, Toxicology Research; 355, rue Dostoievski, CS 90153 Valbonne, 06906 Sophia-Antipolis Cedex France
| | - Dirk Schmutzler
- Research & Development, Weed Control; Bayer AG, CropScience Division; Industriepark Höchst; Geb. G836 65926 Frankfurt am Main Germany
| | - Arno Schulz
- Research & Development, Weed Control; Bayer AG, CropScience Division; Industriepark Höchst; Geb. G836 65926 Frankfurt am Main Germany
| | - Lothar Willms
- Research & Development, Weed Control; Bayer AG, CropScience Division; Industriepark Höchst; Geb. G836 65926 Frankfurt am Main Germany
| | - Christian Wunschel
- Research & Development, Weed Control; Bayer AG, CropScience Division; Industriepark Höchst; Geb. G836 65926 Frankfurt am Main Germany
| |
Collapse
|
33
|
Göddeke S, Knebel B, Fahlbusch P, Hörbelt T, Poschmann G, van de Velde F, Benninghoff T, Al-Hasani H, Jacob S, Van Nieuwenhove Y, Lapauw B, Lehr S, Ouwens DM, Kotzka J. CDH13 abundance interferes with adipocyte differentiation and is a novel biomarker for adipose tissue health. Int J Obes (Lond) 2018; 42:1039-1050. [PMID: 29467502 DOI: 10.1038/s41366-018-0022-4] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/10/2017] [Revised: 12/13/2017] [Accepted: 12/27/2017] [Indexed: 12/14/2022]
Abstract
BACKGROUND CDH13, an atypical member of the cadherin superfamily, has been identified in adipocyte secretomes of lean mouse models. CDH13 abundance differs in mouse models according to their susceptibility to develop metabolic disorders, but the role of CDH13 in adipose tissue is unknown. METHODS Secreted CDH13 protein levels and mRNA levels in visceral adipose tissue were determined in lean and obese mouse models. In vitro studies were performed in 3T3-L1 adipocytes to determine the role of CDH13 in adipocyte differentiation. The pathophysiological impact of visceral adipose tissue CDH13 mRNA and circulating CDH13 levels were determined in humans (normal-weight men n = 37, obese men n = 109 including n = 51 type 2 diabetes patients) and in obese patients (n = 14) pre- and post-metabolic surgery. RESULTS This study shows that in visceral adipose tissue CDH13 protein secretion and mRNA levels were decreased in obese mouse models. Mechanistically, CDH13 affects lipid metabolism during adipogenesis but not in mature adipocytes. CDH13 knockdown during adipogenesis reduced fatty acid uptake and lipid content in developing adipocytes. Furthermore, CDH13 depletion during adipogenesis lowered the induction of PPARγ and C/EBPα expression. These observations are of pathophysiological impact since visceral adipose tissue CDH13 mRNA and circulating CDH13 levels were decreased in obese men compared to normal-weight controls. Weight loss induced by bariatric surgery restored circulating CDH13 to levels found in normal-weight controls. CONCLUSIONS CDH13 levels in adipose tissue and the circulation are affected by obesity in mouse models and humans and are restored by weight loss in humans. CDH13 interferes with the differentiation potential of adipocytes and therefore is a marker for plasticity of fat tissue that might reflect the health status of adipose tissue.
Collapse
Affiliation(s)
- Simon Göddeke
- Institute of Clinical Biochemistry and Pathobiochemistry, German Diabetes Center at the Heinrich-Heine-University Duesseldorf, Leibniz Center for Diabetes Research, Aufm Hennekamp 65, 40225, Duesseldorf, Germany.,Institute of Clinical Biochemistry and Pathobiochemistry, Medical Faculty, German Diabetes Center at the Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany.,German Center of Diabetes Research Partner, Duesseldorf, Germany
| | - Birgit Knebel
- Institute of Clinical Biochemistry and Pathobiochemistry, German Diabetes Center at the Heinrich-Heine-University Duesseldorf, Leibniz Center for Diabetes Research, Aufm Hennekamp 65, 40225, Duesseldorf, Germany.,German Center of Diabetes Research Partner, Duesseldorf, Germany
| | - Pia Fahlbusch
- Institute of Clinical Biochemistry and Pathobiochemistry, German Diabetes Center at the Heinrich-Heine-University Duesseldorf, Leibniz Center for Diabetes Research, Aufm Hennekamp 65, 40225, Duesseldorf, Germany.,Institute of Clinical Biochemistry and Pathobiochemistry, Medical Faculty, German Diabetes Center at the Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany.,German Center of Diabetes Research Partner, Duesseldorf, Germany
| | - Tina Hörbelt
- Institute of Clinical Biochemistry and Pathobiochemistry, German Diabetes Center at the Heinrich-Heine-University Duesseldorf, Leibniz Center for Diabetes Research, Aufm Hennekamp 65, 40225, Duesseldorf, Germany.,Institute of Clinical Biochemistry and Pathobiochemistry, Medical Faculty, German Diabetes Center at the Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany.,German Center of Diabetes Research Partner, Duesseldorf, Germany
| | - Gereon Poschmann
- Molecular Proteomics Laboratory, Biomedizinisches Forschungszentrum (BMFZ), Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany
| | | | - Tim Benninghoff
- Institute of Clinical Biochemistry and Pathobiochemistry, German Diabetes Center at the Heinrich-Heine-University Duesseldorf, Leibniz Center for Diabetes Research, Aufm Hennekamp 65, 40225, Duesseldorf, Germany.,Institute of Clinical Biochemistry and Pathobiochemistry, Medical Faculty, German Diabetes Center at the Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany.,German Center of Diabetes Research Partner, Duesseldorf, Germany
| | - Hadi Al-Hasani
- Institute of Clinical Biochemistry and Pathobiochemistry, German Diabetes Center at the Heinrich-Heine-University Duesseldorf, Leibniz Center for Diabetes Research, Aufm Hennekamp 65, 40225, Duesseldorf, Germany.,Institute of Clinical Biochemistry and Pathobiochemistry, Medical Faculty, German Diabetes Center at the Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany.,German Center of Diabetes Research Partner, Duesseldorf, Germany
| | - Sylvia Jacob
- Institute of Clinical Biochemistry and Pathobiochemistry, German Diabetes Center at the Heinrich-Heine-University Duesseldorf, Leibniz Center for Diabetes Research, Aufm Hennekamp 65, 40225, Duesseldorf, Germany.,German Center of Diabetes Research Partner, Duesseldorf, Germany
| | - Yves Van Nieuwenhove
- Department of Gastrointestinal Surgery, Ghent University Hospital, Ghent, Belgium
| | - Bruno Lapauw
- Department of Endocrinology, Ghent University Hospital, Ghent, Belgium
| | - Stefan Lehr
- Institute of Clinical Biochemistry and Pathobiochemistry, German Diabetes Center at the Heinrich-Heine-University Duesseldorf, Leibniz Center for Diabetes Research, Aufm Hennekamp 65, 40225, Duesseldorf, Germany.,German Center of Diabetes Research Partner, Duesseldorf, Germany
| | - D Margriet Ouwens
- Institute of Clinical Biochemistry and Pathobiochemistry, German Diabetes Center at the Heinrich-Heine-University Duesseldorf, Leibniz Center for Diabetes Research, Aufm Hennekamp 65, 40225, Duesseldorf, Germany.,German Center of Diabetes Research Partner, Duesseldorf, Germany.,Department of Endocrinology, Ghent University Hospital, Ghent, Belgium
| | - Jorg Kotzka
- Institute of Clinical Biochemistry and Pathobiochemistry, German Diabetes Center at the Heinrich-Heine-University Duesseldorf, Leibniz Center for Diabetes Research, Aufm Hennekamp 65, 40225, Duesseldorf, Germany. .,German Center of Diabetes Research Partner, Duesseldorf, Germany.
| |
Collapse
|
34
|
Strohkamp S, Gemoll T, Humborg S, Hartwig S, Lehr S, Freitag-Wolf S, Becker S, Franzén B, Pries R, Wollenberg B, Roblick UJ, Bruch HP, Keck T, Auer G, Habermann JK. Protein levels of clusterin and glutathione synthetase in platelets allow for early detection of colorectal cancer. Cell Mol Life Sci 2018; 75:323-334. [PMID: 28849249 PMCID: PMC11105233 DOI: 10.1007/s00018-017-2631-9] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2017] [Revised: 07/21/2017] [Accepted: 08/21/2017] [Indexed: 02/06/2023]
Abstract
Colorectal cancer (CRC) is one of the most frequent malignancies in the Western world. Early tumor detection and intervention are important determinants on CRC patient survival. During early tumor proliferation, dissemination and angiogenesis, platelets store and segregate proteins actively and selectively. Hence, the platelet proteome is a potential source of biomarkers denoting early malignancy. By comparing protein profiles of platelets between healthy volunteers (n = 12) and patients with early- (n = 7) and late-stage (n = 5) CRCs using multiplex fluorescence two-dimensional gel electrophoresis (2D-DIGE), we aimed at identifying differentially regulated proteins within platelets. By inter-group comparisons, 94 differentially expressed protein spots were detected (p < 0.05) between healthy controls and patients with early- and late-stage CRCs and revealed distinct separations between all three groups in principal component analyses. 54 proteins of interest were identified by mass spectrometry and resulted in high-ranked Ingenuity Pathway Analysis networks associated with Cellular function and maintenance, Cellular assembly and organization, Developmental disorder and Organismal injury and abnormalities (p < 0.0001 to p = 0.0495). Target proteins were validated by multiplex fluorescence-based Western blot analyses using an additional, independent cohort of platelet protein samples [healthy controls (n = 15), early-stage CRCs (n = 15), late-stage CRCs (n = 15)]. Two proteins-clusterin and glutathione synthetase (GSH-S)-featured high impact and were subsequently validated in this independent clinical cohort distinguishing healthy controls from patients with early- and late-stage CRCs. Thus, the potential of clusterin and GSH-S as platelet biomarkers for early detection of CRC could improve existing screening modalities in clinical application and should be confirmed in a prospective multicenter trial.
Collapse
Affiliation(s)
- Sarah Strohkamp
- Section for Translational Surgical Oncology and Biobanking, Department of Surgery, University of Lübeck and University Medical Center Schleswig-Holstein, Campus Lübeck, Ratzeburger Allee 160, 23538, Lübeck, Germany
| | - Timo Gemoll
- Section for Translational Surgical Oncology and Biobanking, Department of Surgery, University of Lübeck and University Medical Center Schleswig-Holstein, Campus Lübeck, Ratzeburger Allee 160, 23538, Lübeck, Germany.
| | - Sina Humborg
- Section for Translational Surgical Oncology and Biobanking, Department of Surgery, University of Lübeck and University Medical Center Schleswig-Holstein, Campus Lübeck, Ratzeburger Allee 160, 23538, Lübeck, Germany
| | - Sonja Hartwig
- Institute of Clinical Biochemistry and Pathobiochemistry, Leibniz Center for Diabetes Research, German Diabetes Center at the Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany
- German Center for Diabetes Research (DZD), München-Neuherberg, Germany
| | - Stefan Lehr
- Institute of Clinical Biochemistry and Pathobiochemistry, Leibniz Center for Diabetes Research, German Diabetes Center at the Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany
- German Center for Diabetes Research (DZD), München-Neuherberg, Germany
| | - Sandra Freitag-Wolf
- Institute of Medical Informatics and Statistics, University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany
| | - Susanne Becker
- Karolinska Biomics Center, Karolinska Institutet, Stockholm, Sweden
| | - Bo Franzén
- Karolinska Biomics Center, Karolinska Institutet, Stockholm, Sweden
| | - Ralph Pries
- Clinic for Otorhinolaryngology, Head and Neck Surgery, University Medical Center Schleswig-Holstein, Campus Lübeck, Lübeck, Germany
| | - Barbara Wollenberg
- Clinic for Otorhinolaryngology, Head and Neck Surgery, University Medical Center Schleswig-Holstein, Campus Lübeck, Lübeck, Germany
| | - Uwe J Roblick
- Section for Translational Surgical Oncology and Biobanking, Department of Surgery, University of Lübeck and University Medical Center Schleswig-Holstein, Campus Lübeck, Ratzeburger Allee 160, 23538, Lübeck, Germany
| | - Hans-Peter Bruch
- Section for Translational Surgical Oncology and Biobanking, Department of Surgery, University of Lübeck and University Medical Center Schleswig-Holstein, Campus Lübeck, Ratzeburger Allee 160, 23538, Lübeck, Germany
| | - Tobias Keck
- Section for Translational Surgical Oncology and Biobanking, Department of Surgery, University of Lübeck and University Medical Center Schleswig-Holstein, Campus Lübeck, Ratzeburger Allee 160, 23538, Lübeck, Germany
| | - Gert Auer
- Karolinska Biomics Center, Karolinska Institutet, Stockholm, Sweden
| | - Jens K Habermann
- Section for Translational Surgical Oncology and Biobanking, Department of Surgery, University of Lübeck and University Medical Center Schleswig-Holstein, Campus Lübeck, Ratzeburger Allee 160, 23538, Lübeck, Germany.
- Interdisciplinary Center for Biobanking-Lübeck (ICB-L), University of Lübeck, Lübeck, Germany.
| |
Collapse
|
35
|
Knebel B, Göddeke S, Hartwig S, Hörbelt T, Fahlbusch P, Al-Hasani H, Jacob S, Koellmer C, Nitzgen U, Schiller M, Lehr S, Kotzka J. Alteration of Liver Peroxisomal and Mitochondrial Functionality in the NZO Mouse Model of Metabolic Syndrome. Proteomics Clin Appl 2017; 12. [PMID: 29068532 DOI: 10.1002/prca.201700028] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/07/2017] [Revised: 09/15/2017] [Indexed: 12/18/2022]
Abstract
PURPOSE Metabolic syndrome (MetS) consists of five risk factors: elevated blood pressure and fasting glucose, visceral obesity, dyslipidemia, and hypercholesterinemia. The physiological impact of lipid metabolism indicated as visceral obesity and hepatic lipid accumulation on MetS is still under debate. One major cause of disturbed lipid metabolism might be dysfunction of cellular organelles controlling energy homeostasis, i.e., mitochondria and peroxisomes. EXPERIMENTAL DESIGN The New Zealand Obese (NZO) mouse model exhibits a polygenic syndrome of obesity, insulin resistance, triglyceridemia, and hypercholesterolemia that resembles human metabolic syndrome. We applied a multi-omics approach combining lipidomics with liver transcriptomics and top-down MS based organelle proteomics (2D-DIGE) of highly enriched mitochondria and peroxisomes in male mice, to investigate molecular mechanisms related to the impact of lipid metabolism in the pathophysiology of the metabolic syndrome. CONCLUSIONS AND CLINICAL RELEVANCE Proteome analyses of liver organelles indicate differences in fatty acid and cholesterol metabolism, mainly influenced by PG-C1α/PPARα and other nuclear receptor mediated pathways. These results are in accordance with altered serum lipid profiles and elevated organelle functionality. These data emphasize that metabolic syndrome is accompanied with increased mitochondria and peroxisomal activity to cope with dyslipidemia and hypercholesterinemia driven hepatic lipid overflow in developing a fatty liver.
Collapse
Affiliation(s)
- Birgit Knebel
- Institute of Clinical Biochemistry and Pathobiochemistry, German Diabetes Center at the Heinrich-Heine-University Duesseldorf, Leibniz Center for Diabetes Research, Duesseldorf, Germany.,German Center of Diabetes Research Partner, Duesseldorf, Germany
| | - Simon Göddeke
- Institute of Clinical Biochemistry and Pathobiochemistry, German Diabetes Center at the Heinrich-Heine-University Duesseldorf, Leibniz Center for Diabetes Research, Duesseldorf, Germany.,German Center of Diabetes Research Partner, Duesseldorf, Germany.,Institute of Clinical Biochemistry and Pathobiochemistry, German Diabetes Center at the Heinrich-Heine-University Duesseldorf Medical Faculty, Duesseldorf, Germany
| | - Sonja Hartwig
- Institute of Clinical Biochemistry and Pathobiochemistry, German Diabetes Center at the Heinrich-Heine-University Duesseldorf, Leibniz Center for Diabetes Research, Duesseldorf, Germany.,German Center of Diabetes Research Partner, Duesseldorf, Germany
| | - Tina Hörbelt
- Institute of Clinical Biochemistry and Pathobiochemistry, German Diabetes Center at the Heinrich-Heine-University Duesseldorf, Leibniz Center for Diabetes Research, Duesseldorf, Germany.,German Center of Diabetes Research Partner, Duesseldorf, Germany.,Institute of Clinical Biochemistry and Pathobiochemistry, German Diabetes Center at the Heinrich-Heine-University Duesseldorf Medical Faculty, Duesseldorf, Germany
| | - Pia Fahlbusch
- Institute of Clinical Biochemistry and Pathobiochemistry, German Diabetes Center at the Heinrich-Heine-University Duesseldorf, Leibniz Center for Diabetes Research, Duesseldorf, Germany.,German Center of Diabetes Research Partner, Duesseldorf, Germany.,Institute of Clinical Biochemistry and Pathobiochemistry, German Diabetes Center at the Heinrich-Heine-University Duesseldorf Medical Faculty, Duesseldorf, Germany
| | - Hadi Al-Hasani
- Institute of Clinical Biochemistry and Pathobiochemistry, German Diabetes Center at the Heinrich-Heine-University Duesseldorf, Leibniz Center for Diabetes Research, Duesseldorf, Germany.,German Center of Diabetes Research Partner, Duesseldorf, Germany.,Institute of Clinical Biochemistry and Pathobiochemistry, German Diabetes Center at the Heinrich-Heine-University Duesseldorf Medical Faculty, Duesseldorf, Germany
| | - Sylvia Jacob
- Institute of Clinical Biochemistry and Pathobiochemistry, German Diabetes Center at the Heinrich-Heine-University Duesseldorf, Leibniz Center for Diabetes Research, Duesseldorf, Germany.,German Center of Diabetes Research Partner, Duesseldorf, Germany
| | - Cornelia Koellmer
- Institute of Clinical Biochemistry and Pathobiochemistry, German Diabetes Center at the Heinrich-Heine-University Duesseldorf, Leibniz Center for Diabetes Research, Duesseldorf, Germany.,German Center of Diabetes Research Partner, Duesseldorf, Germany
| | - Ulrike Nitzgen
- Institute of Clinical Biochemistry and Pathobiochemistry, German Diabetes Center at the Heinrich-Heine-University Duesseldorf, Leibniz Center for Diabetes Research, Duesseldorf, Germany.,German Center of Diabetes Research Partner, Duesseldorf, Germany
| | - Martina Schiller
- Institute of Clinical Biochemistry and Pathobiochemistry, German Diabetes Center at the Heinrich-Heine-University Duesseldorf, Leibniz Center for Diabetes Research, Duesseldorf, Germany.,German Center of Diabetes Research Partner, Duesseldorf, Germany
| | - Stefan Lehr
- Institute of Clinical Biochemistry and Pathobiochemistry, German Diabetes Center at the Heinrich-Heine-University Duesseldorf, Leibniz Center for Diabetes Research, Duesseldorf, Germany.,German Center of Diabetes Research Partner, Duesseldorf, Germany
| | - Jorg Kotzka
- Institute of Clinical Biochemistry and Pathobiochemistry, German Diabetes Center at the Heinrich-Heine-University Duesseldorf, Leibniz Center for Diabetes Research, Duesseldorf, Germany.,German Center of Diabetes Research Partner, Duesseldorf, Germany
| |
Collapse
|
36
|
Homann S, Grandoch M, Kiene LS, Podsvyadek Y, Feldmann K, Rabausch B, Nagy N, Lehr S, Kretschmer I, Oberhuber A, Bollyky P, Fischer JW. Hyaluronan synthase 3 promotes plaque inflammation and atheroprogression. Matrix Biol 2017; 66:67-80. [PMID: 28987865 DOI: 10.1016/j.matbio.2017.09.005] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2017] [Revised: 09/18/2017] [Accepted: 09/19/2017] [Indexed: 12/22/2022]
Abstract
OBJECTIVE Hyaluronan (HA) is a prominent component of the provisional extracellular matrix (ECM) present in the neointima of atherosclerotic plaques. Here the role of HA synthase 3 (HAS3) in atheroprogression was studied. APPROACH AND RESULTS It is demonstrated here that HAS isoenzymes 1, -2 and -3 are expressed in human atherosclerotic plaques of the carotid artery. In Apolipoprotein E (Apoe)-deficient mice Has3 expression is increased early during lesion formation when macrophages enter atherosclerotic plaques. Importantly, HAS3 expression in vascular smooth muscle cells (VSMC) was found to be regulated by interleukin 1 β (IL-1β) in an NFkB dependent manner and blocking antibodies to IL-1β abrogate Has3 expression in VSMC by activated macrophages. Has3/Apoe double deficient mice developed less atherosclerosis characterized by decreased Th1-cell responses, decreased IL-12 release, and decreased macrophage-driven inflammation. CONCLUSIONS Inhibition of HAS3-dependent synthesis of HA dampens systemic Th1 cell polarization and reduces plaque inflammation. These data suggest that HAS3 might be a promising therapeutic target in atherosclerosis. Moreover, because HAS3 is regulated by IL-1β, our results suggest that therapeutic anti-IL-1β antibodies, recently tested in human clinical trials (CANTOS), may exert their beneficial effects on inflammation in post-myocardial infarction patients in part via effects on HAS3. TOC categorybasic study TOC subcategoryarteriosclerosis.
Collapse
Affiliation(s)
- Susanne Homann
- Institut für Pharmakologie und Klinische Pharmakologie, University Hospital, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany
| | - Maria Grandoch
- Institut für Pharmakologie und Klinische Pharmakologie, University Hospital, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany
| | - Lena S Kiene
- Institut für Pharmakologie und Klinische Pharmakologie, University Hospital, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany
| | - Yanina Podsvyadek
- Institut für Pharmakologie und Klinische Pharmakologie, University Hospital, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany
| | - Kathrin Feldmann
- Institut für Pharmakologie und Klinische Pharmakologie, University Hospital, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany
| | - Berit Rabausch
- Institut für Pharmakologie und Klinische Pharmakologie, University Hospital, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany
| | - Nadine Nagy
- Institut für Pharmakologie und Klinische Pharmakologie, University Hospital, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany; Division of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford Immunology, Stanford, USA
| | - Stefan Lehr
- Institute of Clinical Biochemistry and Pathobiochemistry, German Diabetes Center at the Heinrich-Heine-University Duesseldorf, Leibniz Center for Diabetes Research, Düsseldorf, Germany
| | - Inga Kretschmer
- Institut für Pharmakologie und Klinische Pharmakologie, University Hospital, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany
| | - Alexander Oberhuber
- Department of Vascular and Endovascular Surgery, University Hospital Düsseldorf, Düsseldorf, Germany
| | - Paul Bollyky
- Division of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford Immunology, Stanford, USA
| | - Jens W Fischer
- Institut für Pharmakologie und Klinische Pharmakologie, University Hospital, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany; CARID, Cardiovascular Research Institute Düsseldorf, University Hospital, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany.
| |
Collapse
|
37
|
Knebel B, Goeddeke S, Poschmann G, Markgraf DF, Jacob S, Nitzgen U, Passlack W, Preuss C, Dicken HD, Stühler K, Hartwig S, Lehr S, Kotzka J. Novel Insights into the Adipokinome of Obese and Obese/Diabetic Mouse Models. Int J Mol Sci 2017; 18:ijms18091928. [PMID: 28885548 PMCID: PMC5618577 DOI: 10.3390/ijms18091928] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2017] [Revised: 08/19/2017] [Accepted: 08/21/2017] [Indexed: 12/16/2022] Open
Abstract
The group of adipokines comprises hundreds of biological active proteins and peptides released from adipose tissue. Alterations of those complex protein signatures are suggested to play a crucial role in the pathophysiology of multifactorial, metabolic diseases. We hypothesized that also the pathophysiology of type-2-diabetes is linked to the dysregulation of the adipocyte secretome. To test this, we investigated mouse models with monogenic defects in leptin signaling which are susceptible to adipositas (C57BL/6 Cg-Lepob (obob)) or adipositas with diabetes (C57BL/KS Cg-Leprdb (dbdb)) according to their genetic background. At the age of 17 weeks, visceral fat was obtained and primary murine adipocytes were isolated to harvest secretomes. Quantitative proteome analyses (LC-ESI-MS/MS) identified more than 800 potential secreted proteins. The secretome patterns revealed significant differences connected to the pathophysiology of obese mice. Pathway analyses indicated that these differences focus on exosome modelling, but failed to provide more precise specifications. To investigate the relationship of secretome data to insulin sensitivity, we examined the content of diabetogenic lipids, i.e., diacylglycerols (DAGs), identified as key players in lipid-induced insulin resistance. In contrast to obob mice, fat tissue of dbdb mice showed elevated DAG content, especially of DAG species with saturated fatty acid C16:0 and C18:0, while unsaturated fatty acid C16:1 were only changed in obob. Furthermore, DAG signatures of the models specifically correlate to secreted regulated adipokines indicating specific pathways. In conclusion, our data further support the concept that the fat tissue is an endocrine organ that releases bioactive factors corresponding to adipose tissue health status.
Collapse
Affiliation(s)
- Birgit Knebel
- Institute of Clinical Biochemistry and Pathobiochemistry, German Diabetes Center, Heinrich-Heine-University Duesseldorf, Leibniz Center for Diabetes Research, Aufm Hennekamp 65, 40225 Dusseldorf, Germany.
- German Center for Diabetes Research (DZD), Partner Duesseldorf, 40225 Duesseldorf, Germany.
| | - Simon Goeddeke
- Institute of Clinical Biochemistry and Pathobiochemistry, German Diabetes Center, Heinrich-Heine-University Duesseldorf, Leibniz Center for Diabetes Research, Aufm Hennekamp 65, 40225 Dusseldorf, Germany.
- German Center for Diabetes Research (DZD), Partner Duesseldorf, 40225 Duesseldorf, Germany.
| | - Gereon Poschmann
- Molecular Proteomics Laboratory, Biomedizinisches Forschungszentrum (BMFZ), Heinrich-Heine-University Duesseldorf, 40225 Duesseldorf, Germany.
| | - Daniel F Markgraf
- German Center for Diabetes Research (DZD), Partner Duesseldorf, 40225 Duesseldorf, Germany.
- Institute of Clinical Diabetology, German Diabetes Center at the Heinrich-Heine-University Duesseldorf, Leibniz Center for Diabetes Research, 40225 Duesseldorf, Germany.
| | - Sylvia Jacob
- Institute of Clinical Biochemistry and Pathobiochemistry, German Diabetes Center, Heinrich-Heine-University Duesseldorf, Leibniz Center for Diabetes Research, Aufm Hennekamp 65, 40225 Dusseldorf, Germany.
- German Center for Diabetes Research (DZD), Partner Duesseldorf, 40225 Duesseldorf, Germany.
| | - Ulrike Nitzgen
- Institute of Clinical Biochemistry and Pathobiochemistry, German Diabetes Center, Heinrich-Heine-University Duesseldorf, Leibniz Center for Diabetes Research, Aufm Hennekamp 65, 40225 Dusseldorf, Germany.
- German Center for Diabetes Research (DZD), Partner Duesseldorf, 40225 Duesseldorf, Germany.
| | - Waltraud Passlack
- Institute of Clinical Biochemistry and Pathobiochemistry, German Diabetes Center, Heinrich-Heine-University Duesseldorf, Leibniz Center for Diabetes Research, Aufm Hennekamp 65, 40225 Dusseldorf, Germany.
- German Center for Diabetes Research (DZD), Partner Duesseldorf, 40225 Duesseldorf, Germany.
| | - Christina Preuss
- German Center for Diabetes Research (DZD), Partner Duesseldorf, 40225 Duesseldorf, Germany.
- Institute of Clinical Diabetology, German Diabetes Center at the Heinrich-Heine-University Duesseldorf, Leibniz Center for Diabetes Research, 40225 Duesseldorf, Germany.
| | - Hans-Dieter Dicken
- Multimedia Center, Heinrich-Heine-University Duesseldorf, 40225 Duesseldorf, Germany.
| | - Kai Stühler
- Molecular Proteomics Laboratory, Biomedizinisches Forschungszentrum (BMFZ), Heinrich-Heine-University Duesseldorf, 40225 Duesseldorf, Germany.
- Institute for Molecular Medicine, University Hospital Duesseldorf, Heinrich-Heine-University Duesseldorf, 40225 Duesseldorf, Germany.
| | - Sonja Hartwig
- Institute of Clinical Biochemistry and Pathobiochemistry, German Diabetes Center, Heinrich-Heine-University Duesseldorf, Leibniz Center for Diabetes Research, Aufm Hennekamp 65, 40225 Dusseldorf, Germany.
- German Center for Diabetes Research (DZD), Partner Duesseldorf, 40225 Duesseldorf, Germany.
| | - Stefan Lehr
- Institute of Clinical Biochemistry and Pathobiochemistry, German Diabetes Center, Heinrich-Heine-University Duesseldorf, Leibniz Center for Diabetes Research, Aufm Hennekamp 65, 40225 Dusseldorf, Germany.
- German Center for Diabetes Research (DZD), Partner Duesseldorf, 40225 Duesseldorf, Germany.
| | - Jorg Kotzka
- Institute of Clinical Biochemistry and Pathobiochemistry, German Diabetes Center, Heinrich-Heine-University Duesseldorf, Leibniz Center for Diabetes Research, Aufm Hennekamp 65, 40225 Dusseldorf, Germany.
- German Center for Diabetes Research (DZD), Partner Duesseldorf, 40225 Duesseldorf, Germany.
| |
Collapse
|
38
|
Binsch C, Jelenik T, Pfitzer A, Dille M, Müller-Lühlhoff S, Hartwig S, Karpinski S, Lehr S, Kabra DG, Chadt A, Roden M, Al-Hasani H, Castañeda TR. Absence of the kinase S6k1 mimics the effect of chronic endurance exercise on glucose tolerance and muscle oxidative stress. Mol Metab 2017; 6:1443-1453. [PMID: 29107291 PMCID: PMC5681242 DOI: 10.1016/j.molmet.2017.08.008] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/20/2017] [Revised: 08/22/2017] [Accepted: 08/22/2017] [Indexed: 11/28/2022] Open
Abstract
Objective Ribosomal protein S6 Kinase-1 (S6K1) has been linked to resistance exercise-mediated improvements in glycemia. We hypothesized that S6K1 may also play a role in regulating glycemic control in response to endurance exercise training. Methods S6k1-knockout (S6K1KO) and WT mice on a 60 cal% high-fat diet were trained for 4 weeks on treadmills, metabolically phenotyped, and compared to sedentary controls. Results WT mice showed improved glucose tolerance after training. In contrast, S6K1KO mice displayed equally high glucose tolerance already in the sedentary state with no further improvement after training. Similarly, training decreased mitochondrial ROS production in skeletal muscle of WT mice, whereas ROS levels were already low in the sedentary S6K1KO mice with no further decrease after training. Nevertheless, trained S6K1KO mice displayed an increased running capacity compared to trained WT mice, as well as substantially reduced triglyceride contents in liver and skeletal muscle. The improvements in glucose handling and running endurance in S6K1KO mice were associated with markedly increased ketogenesis and a higher respiratory exchange ratio. Conclusions In high-fat fed mice, loss of S6K1 mimics endurance exercise training by reducing mitochondrial ROS production and upregulating oxidative utilization of ketone bodies. Pharmacological targeting of S6K1 may improve the outcome of exercise-based interventions in obesity and diabetes. Absence of S6k1 upregulates oxidative substrate utilization under HFD consumption. S6k1 knockout mice show enhanced running performance and improved glycemia already in the sedentary state. Aerobic endurance exercise training of S6k1 knockout mice further improves running performance but not glycemia. Metabolic improvements are associated with lower rates of TCA-linked mitochondrial H2O2 production and increased ketogenesis.
Collapse
Affiliation(s)
- C Binsch
- Institute for Clinical Biochemistry and Pathobiochemistry, German Diabetes Center, Düsseldorf, Germany; German Center for Diabetes Research, München-Neuherberg, Germany
| | - T Jelenik
- Institute for Clinical Diabetology, German Diabetes Center, Düsseldorf, Germany; German Center for Diabetes Research, München-Neuherberg, Germany
| | - A Pfitzer
- Institute for Clinical Biochemistry and Pathobiochemistry, German Diabetes Center, Düsseldorf, Germany
| | - M Dille
- Institute for Clinical Biochemistry and Pathobiochemistry, German Diabetes Center, Düsseldorf, Germany; German Center for Diabetes Research, München-Neuherberg, Germany
| | - S Müller-Lühlhoff
- Institute for Clinical Biochemistry and Pathobiochemistry, German Diabetes Center, Düsseldorf, Germany
| | - S Hartwig
- Institute for Clinical Biochemistry and Pathobiochemistry, German Diabetes Center, Düsseldorf, Germany; German Center for Diabetes Research, München-Neuherberg, Germany
| | - S Karpinski
- Institute for Clinical Biochemistry and Pathobiochemistry, German Diabetes Center, Düsseldorf, Germany
| | - S Lehr
- Institute for Clinical Biochemistry and Pathobiochemistry, German Diabetes Center, Düsseldorf, Germany; German Center for Diabetes Research, München-Neuherberg, Germany
| | - D G Kabra
- Institute for Clinical Biochemistry and Pathobiochemistry, German Diabetes Center, Düsseldorf, Germany; German Center for Diabetes Research, München-Neuherberg, Germany
| | - A Chadt
- Institute for Clinical Biochemistry and Pathobiochemistry, German Diabetes Center, Düsseldorf, Germany; German Center for Diabetes Research, München-Neuherberg, Germany
| | - M Roden
- Institute for Clinical Diabetology, German Diabetes Center, Düsseldorf, Germany; Division of Endocrinology and Diabetology, Medical Faculty, Heinrich-Heine University, Düsseldorf, Germany; German Center for Diabetes Research, München-Neuherberg, Germany
| | - H Al-Hasani
- Institute for Clinical Biochemistry and Pathobiochemistry, German Diabetes Center, Düsseldorf, Germany; German Center for Diabetes Research, München-Neuherberg, Germany.
| | - T R Castañeda
- Institute for Clinical Biochemistry and Pathobiochemistry, German Diabetes Center, Düsseldorf, Germany
| |
Collapse
|
39
|
Keipert S, Kutschke M, Ost M, Schwarzmayr T, van Schothorst EM, Lamp D, Brachthäuser L, Hamp I, Mazibuko SE, Hartwig S, Lehr S, Graf E, Plettenburg O, Neff F, Tschöp MH, Jastroch M. Long-Term Cold Adaptation Does Not Require FGF21 or UCP1. Cell Metab 2017; 26:437-446.e5. [PMID: 28768181 DOI: 10.1016/j.cmet.2017.07.016] [Citation(s) in RCA: 96] [Impact Index Per Article: 13.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/08/2016] [Revised: 05/31/2017] [Accepted: 07/18/2017] [Indexed: 11/13/2022]
Abstract
Brown adipose tissue (BAT)-dependent thermogenesis and its suggested augmenting hormone, FGF21, are potential therapeutic targets in current obesity and diabetes research. Here, we studied the role of UCP1 and FGF21 for metabolic homeostasis in the cold and dissected underlying molecular mechanisms using UCP1-FGF21 double-knockout mice. We report that neither UCP1 nor FGF21, nor even compensatory increases of FGF21 serum levels in UCP1 knockout mice, are required for defense of body temperature or for maintenance of energy metabolism and body weight. Remarkably, cold-induced browning of inguinal white adipose tissue (iWAT) is FGF21 independent. Global RNA sequencing reveals major changes in response to UCP1- but not FGF21-ablation in BAT, iWAT, and muscle. Markers of mitochondrial failure and inflammation are observed in BAT, but in particular the enhanced metabolic reprogramming in iWAT supports the thermogenic role of UCP1 and excludes an important thermogenic role of endogenous FGF21 in normal cold acclimation.
Collapse
Affiliation(s)
- Susanne Keipert
- Institute for Diabetes and Obesity, Helmholtz Diabetes Center, German Research Center for Environmental Health (GmbH), Neuherberg, Germany; German Center for Diabetes Research (DZD), Neuherberg, Germany
| | - Maria Kutschke
- Institute for Diabetes and Obesity, Helmholtz Diabetes Center, German Research Center for Environmental Health (GmbH), Neuherberg, Germany
| | - Mario Ost
- German Institute of Human Nutrition, Nuthetal, Germany
| | - Thomas Schwarzmayr
- Institute of Human Genetics, Helmholtz Zentrum München, German Research Center for Environmental Health (GmbH), Neuherberg, Germany
| | | | - Daniel Lamp
- Institute for Diabetes and Obesity, Helmholtz Diabetes Center, German Research Center for Environmental Health (GmbH), Neuherberg, Germany
| | - Laura Brachthäuser
- Institute of Pathology, Helmholtz-Zentrum München, German Research Center for Environmental Health (GmbH), Neuherberg, Germany
| | - Isabel Hamp
- Institute of Medicinal Chemistry, Helmholtz Zentrum München, German Research Center for Environmental Health (GmbH), Neuherberg, Germany; Institute of Organic Chemistry, Leibniz Universität Hannover, Hannover, Germany
| | - Sithandiwe E Mazibuko
- Institute for Diabetes and Obesity, Helmholtz Diabetes Center, German Research Center for Environmental Health (GmbH), Neuherberg, Germany
| | - Sonja Hartwig
- German Center for Diabetes Research (DZD), Neuherberg, Germany; Institute for Clinical Biochemistry and Pathobiochemistry, German Diabetes Center (DDZ), Düsseldorf, Germany
| | - Stefan Lehr
- German Center for Diabetes Research (DZD), Neuherberg, Germany; Institute for Clinical Biochemistry and Pathobiochemistry, German Diabetes Center (DDZ), Düsseldorf, Germany
| | - Elisabeth Graf
- Institute of Human Genetics, Helmholtz Zentrum München, German Research Center for Environmental Health (GmbH), Neuherberg, Germany
| | - Oliver Plettenburg
- Institute of Medicinal Chemistry, Helmholtz Zentrum München, German Research Center for Environmental Health (GmbH), Neuherberg, Germany; Institute of Organic Chemistry, Leibniz Universität Hannover, Hannover, Germany
| | - Frauke Neff
- Institute of Pathology, Helmholtz-Zentrum München, German Research Center for Environmental Health (GmbH), Neuherberg, Germany
| | - Matthias H Tschöp
- Institute for Diabetes and Obesity, Helmholtz Diabetes Center, German Research Center for Environmental Health (GmbH), Neuherberg, Germany; German Center for Diabetes Research (DZD), Neuherberg, Germany; Division of Metabolic Diseases, Department of Medicine, Technische Universität München, München, Germany
| | - Martin Jastroch
- Institute for Diabetes and Obesity, Helmholtz Diabetes Center, German Research Center for Environmental Health (GmbH), Neuherberg, Germany; German Center for Diabetes Research (DZD), Neuherberg, Germany; Department of Animal Physiology, Faculty of Biology, Philipps University of Marburg, Marburg, Germany.
| |
Collapse
|
40
|
Jelenik T, Kaul K, Séquaris G, Flögel U, Phielix E, Kotzka J, Knebel B, Fahlbusch P, Hörbelt T, Lehr S, Reinbeck AL, Müller-Wieland D, Esposito I, Shulman GI, Szendroedi J, Roden M. Mechanisms of Insulin Resistance in Primary and Secondary Nonalcoholic Fatty Liver. Diabetes 2017; 66:2241-2253. [PMID: 28490610 PMCID: PMC5521856 DOI: 10.2337/db16-1147] [Citation(s) in RCA: 104] [Impact Index Per Article: 14.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/22/2016] [Accepted: 04/30/2017] [Indexed: 12/11/2022]
Abstract
Nonalcoholic fatty liver disease is associated with hepatic insulin resistance and may result primarily from increased hepatic de novo lipogenesis (PRIM) or secondarily from adipose tissue lipolysis (SEC). We studied mice with hepatocyte- or adipocyte-specific SREBP-1c overexpression as models of PRIM and SEC. PRIM mice featured increased lipogenic gene expression in the liver and adipose tissue. Their selective, liver-specific insulin resistance was associated with increased C18:1-diacylglycerol content and protein kinase Cε translocation. SEC mice had decreased lipogenesis mediated by hepatic cholesterol responsive element-binding protein and featured portal/lobular inflammation along with total, whole-body insulin resistance. Hepatic mitochondrial respiration transiently increased and declined with aging along with higher muscle reactive oxygen species production. In conclusion, hepatic insulin resistance originates from lipotoxicity but not from lower mitochondrial capacity, which can even transiently adapt to increased peripheral lipolysis. Peripheral insulin resistance is prevented during increased hepatic lipogenesis only if adipose tissue lipid storage capacity is preserved.
Collapse
Affiliation(s)
- Tomas Jelenik
- Institute for Clinical Diabetology, German Diabetes Center, Düsseldorf, Germany
- German Center for Diabetes Research, München-Neuherberg, Germany
| | - Kirti Kaul
- Institute for Clinical Diabetology, German Diabetes Center, Düsseldorf, Germany
- German Center for Diabetes Research, München-Neuherberg, Germany
| | - Gilles Séquaris
- Institute for Clinical Diabetology, German Diabetes Center, Düsseldorf, Germany
- German Center for Diabetes Research, München-Neuherberg, Germany
| | - Ulrich Flögel
- Department of Molecular Cardiology, Medical Faculty, Heinrich-Heine University Düsseldorf, Düsseldorf, Germany
| | - Esther Phielix
- Institute for Clinical Diabetology, German Diabetes Center, Düsseldorf, Germany
- German Center for Diabetes Research, München-Neuherberg, Germany
| | - Jörg Kotzka
- German Center for Diabetes Research, München-Neuherberg, Germany
- Institute for Biochemistry and Pathobiochemistry, German Diabetes Center, Düsseldorf, Germany
| | - Birgit Knebel
- German Center for Diabetes Research, München-Neuherberg, Germany
- Institute for Biochemistry and Pathobiochemistry, German Diabetes Center, Düsseldorf, Germany
| | - Pia Fahlbusch
- German Center for Diabetes Research, München-Neuherberg, Germany
- Institute for Biochemistry and Pathobiochemistry, German Diabetes Center, Düsseldorf, Germany
| | - Tina Hörbelt
- German Center for Diabetes Research, München-Neuherberg, Germany
- Institute for Biochemistry and Pathobiochemistry, German Diabetes Center, Düsseldorf, Germany
| | - Stefan Lehr
- German Center for Diabetes Research, München-Neuherberg, Germany
- Institute for Biochemistry and Pathobiochemistry, German Diabetes Center, Düsseldorf, Germany
| | - Anna Lena Reinbeck
- Institute for Clinical Diabetology, German Diabetes Center, Düsseldorf, Germany
| | - Dirk Müller-Wieland
- Department of Internal Medicine I, University Hospital Aachen, Aachen, Germany
| | - Irene Esposito
- Institute of Pathology, Heinrich-Heine University Düsseldorf, Düsseldorf, Germany
| | - Gerald I Shulman
- Departments of Internal Medicine and Cellular & Molecular Physiology, Howard Hughes Medical Institute, Yale University School of Medicine, New Haven, CT
| | - Julia Szendroedi
- Institute for Clinical Diabetology, German Diabetes Center, Düsseldorf, Germany
- German Center for Diabetes Research, München-Neuherberg, Germany
- Department of Endocrinology and Diabetology, Medical Faculty, Heinrich-Heine University Düsseldorf, Düsseldorf, Germany
| | - Michael Roden
- Institute for Clinical Diabetology, German Diabetes Center, Düsseldorf, Germany
- German Center for Diabetes Research, München-Neuherberg, Germany
- Department of Endocrinology and Diabetology, Medical Faculty, Heinrich-Heine University Düsseldorf, Düsseldorf, Germany
| |
Collapse
|
41
|
Feldmann K, Grandoch M, Kohlmorgen C, Valentin B, Gerfer S, Nagy N, Fender AC, Hartwig S, Lehr S, Fischer JW. Reduced pro-inflammatory macrophage polarization in visceral adipose tissue and atherosclerotic lesions of LDL receptor deficient mice treated with the direct thrombin inhibitor dabigatran. Atherosclerosis 2017. [DOI: 10.1016/j.atherosclerosis.2017.06.114] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
42
|
Gemoll T, Kollbeck SL, Karstens KF, Hò GG, Hartwig S, Strohkamp S, Schillo K, Thorns C, Oberländer M, Kalies K, Lehr S, Habermann JK. EB1 protein alteration characterizes sporadic but not ulcerative colitis associated colorectal cancer. Oncotarget 2017; 8:54939-54950. [PMID: 28903393 PMCID: PMC5589632 DOI: 10.18632/oncotarget.18978] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2017] [Accepted: 06/17/2017] [Indexed: 12/29/2022] Open
Abstract
Background While carcinogenesis in Sporadic Colorectal Cancer (SCC) has been thoroughly studied, less is known about Ulcerative Colitis associated Colorectal Cancer (UCC). This study aimed to identify and validate differentially expressed proteins between clinical samples of SCC and UCC to elucidate new insights of UCC/SCC carcinogenesis and progression. Results Multiplex-fluorescence two-dimensional gel electrophoresis (2-D DIGE) and mass spectrometry identified 67 proteoforms representing 43 distinct proteins. After analysis by Ingenuity Pathway Analysis® (IPA), subsequent Western blot validation proofed the differential expression of Heat shock 27 kDA protein 1 (HSPB1) and Microtubule-associated protein R/EB family, member 1 (EB1) while the latter one showed also expression differences by immunohistochemistry. Materials and Methods Fresh frozen tissue of UCC (n = 10) matched with SCC (n = 10) was investigated. Proteins of cancerous intestinal mucosal cells were obtained by Laser Capture Microdissection (LCM) and compared by 2-D DIGE. Significant spots were identified by mass spectrometry. After IPA, three proteins [EB1, HSPB1, and Annexin 5 (ANXA5)] were chosen for further validation by Western blotting and tissue microarray-based immunohistochemistry. Conclusions This study identified significant differences in protein expression of colorectal carcinoma cells from UCC patients compared to patients with SCC. Particularly, EB1 was validated in an independent clinical cohort.
Collapse
Affiliation(s)
- Timo Gemoll
- Section for Translational Surgical Oncology and Biobanking, Department of Surgery, University of Lübeck and University Hospital Schleswig-Holstein, Campus Lübeck, D-23538 Lübeck, Germany
| | - Sophie L Kollbeck
- Section for Translational Surgical Oncology and Biobanking, Department of Surgery, University of Lübeck and University Hospital Schleswig-Holstein, Campus Lübeck, D-23538 Lübeck, Germany
| | - Karl F Karstens
- Section for Translational Surgical Oncology and Biobanking, Department of Surgery, University of Lübeck and University Hospital Schleswig-Holstein, Campus Lübeck, D-23538 Lübeck, Germany
| | - Gia G Hò
- Section for Translational Surgical Oncology and Biobanking, Department of Surgery, University of Lübeck and University Hospital Schleswig-Holstein, Campus Lübeck, D-23538 Lübeck, Germany
| | - Sonja Hartwig
- Institute of Clinical Biochemistry and Pathobiochemistry, German Diabetes Center at the Heinrich-Heine-University Düsseldorf, Leibniz Center for Diabetes Research, D-40225 Düsseldorf, Germany.,German Center for Diabetes Research (DZD), D-85764 München-Neuherberg, Germany
| | - Sarah Strohkamp
- Section for Translational Surgical Oncology and Biobanking, Department of Surgery, University of Lübeck and University Hospital Schleswig-Holstein, Campus Lübeck, D-23538 Lübeck, Germany
| | - Katharina Schillo
- Section for Translational Surgical Oncology and Biobanking, Department of Surgery, University of Lübeck and University Hospital Schleswig-Holstein, Campus Lübeck, D-23538 Lübeck, Germany
| | - Christoph Thorns
- Department of Pathology, University Hospital Schleswig-Holstein, Campus Lübeck, D-23538 Lübeck, Germany
| | - Martina Oberländer
- Section for Translational Surgical Oncology and Biobanking, Department of Surgery, University of Lübeck and University Hospital Schleswig-Holstein, Campus Lübeck, D-23538 Lübeck, Germany
| | - Kathrin Kalies
- Institute of Anatomy, University of Lübeck, D-23538 Lübeck, Germany
| | - Stefan Lehr
- Institute of Clinical Biochemistry and Pathobiochemistry, German Diabetes Center at the Heinrich-Heine-University Düsseldorf, Leibniz Center for Diabetes Research, D-40225 Düsseldorf, Germany.,German Center for Diabetes Research (DZD), D-85764 München-Neuherberg, Germany
| | - Jens K Habermann
- Section for Translational Surgical Oncology and Biobanking, Department of Surgery, University of Lübeck and University Hospital Schleswig-Holstein, Campus Lübeck, D-23538 Lübeck, Germany
| |
Collapse
|
43
|
Tan K, Ding Z, Steckel B, Hartwig S, Lehr S, Deng X, Schrader J. The Inverted Heart Model for Interstitial Transudate Collection from the Isolated Rat Heart. J Vis Exp 2017. [DOI: 10.3791/55849] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022] Open
|
44
|
Röhling M, Strom A, Bönhof G, Püttgen S, Bódis K, Müssig K, Szendrödi J, Markgraf D, Lehr S, Roden M, Ziegler D. Differential Patterns of Impaired Cardiorespiratory Fitness and Cardiac Autonomic Dysfunction in Recently Diagnosed Type 1 and Type 2 Diabetes. Diabetes Care 2017; 40:246-252. [PMID: 27899499 DOI: 10.2337/dc16-1898] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/02/2016] [Accepted: 11/08/2016] [Indexed: 02/03/2023]
Abstract
OBJECTIVE Both impaired cardiorespiratory fitness (CRF) and heart rate variability (HRV) are predictors of mortality, but their relative roles in recent-onset diabetes are unknown. We determined to which extent CRF and HRV are reduced and interrelated in recent-onset diabetes. RESEARCH DESIGN AND METHODS Participants from the German Diabetes Study with type 1 (n = 163) or type 2 (n = 188) diabetes with known diabetes duration <1 year and two age-matched glucose-tolerant control groups (n = 40 each) underwent spiroergometry and HRV assessment during a hyperinsulinemic-euglycemic clamp. RESULTS Compared with control subjects, patients with type 2 diabetes showed reduced VO2max (median [1st-3rd quartiles] 19.3 [16.5-22.9] vs. 25.6 [20.7-29.9] mL/kg body weight/min; P < 0.05), diminished VCO2max (23.0 [19.1-26.8] vs. 30.9 [24.5-34.4] mL/kg body weight/min; P < 0.05), blunted heart rate recovery after 2 min (-29.0 [-35.0 to -23.0] vs. -36.0 [-42.8 to -28.0] beats/min; P < 0.05), and reduced HRV in four of nine indices, whereas patients with type 1 diabetes had unaltered CRF but reduced HRV in three of nine indices (P < 0.05), indicating diminished vagal and sympathetic HRV modulation. HRV measures correlated with VO2max in patients with type 1 diabetes (r >0.34; P < 0.05) but not in those with type 2 diabetes. CONCLUSIONS CRF is reduced in recently diagnosed type 2 diabetes but preserved in type 1 diabetes, whereas cardiac autonomic function is reduced in both diabetes types but is strongly associated with CRF only in type 1 diabetes. These results support the therapeutic concept of promoting physical fitness in the early course of diabetes.
Collapse
Affiliation(s)
- Martin Röhling
- Institute for Clinical Diabetology, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University Düsseldorf, Düsseldorf, Germany.,German Center for Diabetes Research, München-Neuherberg, Germany
| | - Alexander Strom
- Institute for Clinical Diabetology, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University Düsseldorf, Düsseldorf, Germany.,German Center for Diabetes Research, München-Neuherberg, Germany
| | - Gidon Bönhof
- Institute for Clinical Diabetology, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University Düsseldorf, Düsseldorf, Germany
| | - Sonja Püttgen
- Institute for Clinical Diabetology, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University Düsseldorf, Düsseldorf, Germany
| | - Kálmán Bódis
- Institute for Clinical Diabetology, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University Düsseldorf, Düsseldorf, Germany.,German Center for Diabetes Research, München-Neuherberg, Germany
| | - Karsten Müssig
- Institute for Clinical Diabetology, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University Düsseldorf, Düsseldorf, Germany.,German Center for Diabetes Research, München-Neuherberg, Germany.,Department of Endocrinology and Diabetology, Medical Faculty, Heinrich Heine University, Düsseldorf, Germany
| | - Julia Szendrödi
- Institute for Clinical Diabetology, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University Düsseldorf, Düsseldorf, Germany.,German Center for Diabetes Research, München-Neuherberg, Germany.,Department of Endocrinology and Diabetology, Medical Faculty, Heinrich Heine University, Düsseldorf, Germany
| | - Daniel Markgraf
- Institute for Clinical Diabetology, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University Düsseldorf, Düsseldorf, Germany.,German Center for Diabetes Research, München-Neuherberg, Germany
| | - Stefan Lehr
- German Center for Diabetes Research, München-Neuherberg, Germany.,Institute of Clinical Biochemistry and Pathobiochemistry, German Diabetes Center, Heinrich Heine University Düsseldorf, Düsseldorf, Germany
| | - Michael Roden
- Institute for Clinical Diabetology, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University Düsseldorf, Düsseldorf, Germany.,German Center for Diabetes Research, München-Neuherberg, Germany.,Department of Endocrinology and Diabetology, Medical Faculty, Heinrich Heine University, Düsseldorf, Germany
| | - Dan Ziegler
- Institute for Clinical Diabetology, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University Düsseldorf, Düsseldorf, Germany .,German Center for Diabetes Research, München-Neuherberg, Germany.,Department of Endocrinology and Diabetology, Medical Faculty, Heinrich Heine University, Düsseldorf, Germany
| | | |
Collapse
|
45
|
Berti L, Hartwig S, Irmler M, Rädle B, Siegel-Axel D, Beckers J, Lehr S, Al-Hasani H, Häring HU, Hrabě de Angelis M, Staiger H. Impact of fibroblast growth factor 21 on the secretome of human perivascular preadipocytes and adipocytes: a targeted proteomics approach. Arch Physiol Biochem 2016; 122:281-288. [PMID: 27494767 DOI: 10.1080/13813455.2016.1212898] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
CONTEXT Perivascular adipose tissue (PVAT) is suggested to impact on vascular cells via humoral factors, possibly contributing to endothelial dysfunction and atherosclerosis. OBJECTIVE To address whether the hepatokine fibroblast growth factor (FGF) 21 affects the PVAT secretome. METHODS Human perivascular (pre)adipocytes were subjected to targeted proteomics and whole-genome gene expression analysis. RESULTS Preadipocytes, as compared to adipocytes, secreted higher amounts of inflammatory cytokines and chemokines. Adipocytes released higher amounts of adipokines [e.g. adipisin, visfatin, dipeptidyl peptidase 4 (DPP4), leptin; p < 0.05, all]. In preadipocytes, omentin 1 release was 1.28-fold increased by FGF-21 (p < 0.05). In adipocytes, FGF-21 reduced chemerin release by 5% and enhanced DPP4 release by 1.15-fold (p < 0.05, both). FGF-21 altered the expression of four secretory genes in preadipocytes and of 18 in adipocytes (p < 0.01, all). CONCLUSION The hepatokine FGF-21 exerts secretome-modulating effects in human perivascular (pre)adipocytes establishing a new liver-PVAT-blood vessel axis that possibly contributes to vascular inflammation and atherosclerosis.
Collapse
Affiliation(s)
- Lucia Berti
- a Institute for Diabetes Research and Metabolic Diseases of the Helmholtz Center Munich at the University of Tübingen , Tübingen , Germany
- b Helmholtz Center Munich, German Research Center for Environmental Health, Institute of Experimental Genetics , Neuherberg , Germany
- c German Centre for Diabetes Research (DZD) , Neuherberg , Germany
| | - Sonja Hartwig
- c German Centre for Diabetes Research (DZD) , Neuherberg , Germany
- d Institute for Clinical Biochemistry and Pathobiochemistry, German Diabetes Center, Leibniz Center for Diabetes Research at the Heinrich Heine University Düsseldorf , Düsseldorf , Germany
| | - Martin Irmler
- b Helmholtz Center Munich, German Research Center for Environmental Health, Institute of Experimental Genetics , Neuherberg , Germany
- c German Centre for Diabetes Research (DZD) , Neuherberg , Germany
| | - Bernhard Rädle
- b Helmholtz Center Munich, German Research Center for Environmental Health, Institute of Experimental Genetics , Neuherberg , Germany
- c German Centre for Diabetes Research (DZD) , Neuherberg , Germany
| | - Dorothea Siegel-Axel
- a Institute for Diabetes Research and Metabolic Diseases of the Helmholtz Center Munich at the University of Tübingen , Tübingen , Germany
- c German Centre for Diabetes Research (DZD) , Neuherberg , Germany
- e Department of Internal Medicine , Division of Endocrinology, Diabetology, Angiology, Nephrology, and Clinical Chemistry, University Hospital Tübingen , Tübingen , Germany , and
| | - Johannes Beckers
- b Helmholtz Center Munich, German Research Center for Environmental Health, Institute of Experimental Genetics , Neuherberg , Germany
- c German Centre for Diabetes Research (DZD) , Neuherberg , Germany
- f Chair for Experimental Genetics, Technical University Munich , Neuherberg , Germany
| | - Stefan Lehr
- c German Centre for Diabetes Research (DZD) , Neuherberg , Germany
- d Institute for Clinical Biochemistry and Pathobiochemistry, German Diabetes Center, Leibniz Center for Diabetes Research at the Heinrich Heine University Düsseldorf , Düsseldorf , Germany
| | - Hadi Al-Hasani
- c German Centre for Diabetes Research (DZD) , Neuherberg , Germany
- d Institute for Clinical Biochemistry and Pathobiochemistry, German Diabetes Center, Leibniz Center for Diabetes Research at the Heinrich Heine University Düsseldorf , Düsseldorf , Germany
| | - Hans-Ulrich Häring
- a Institute for Diabetes Research and Metabolic Diseases of the Helmholtz Center Munich at the University of Tübingen , Tübingen , Germany
- c German Centre for Diabetes Research (DZD) , Neuherberg , Germany
- e Department of Internal Medicine , Division of Endocrinology, Diabetology, Angiology, Nephrology, and Clinical Chemistry, University Hospital Tübingen , Tübingen , Germany , and
| | - Martin Hrabě de Angelis
- b Helmholtz Center Munich, German Research Center for Environmental Health, Institute of Experimental Genetics , Neuherberg , Germany
- c German Centre for Diabetes Research (DZD) , Neuherberg , Germany
- f Chair for Experimental Genetics, Technical University Munich , Neuherberg , Germany
| | - Harald Staiger
- a Institute for Diabetes Research and Metabolic Diseases of the Helmholtz Center Munich at the University of Tübingen , Tübingen , Germany
- c German Centre for Diabetes Research (DZD) , Neuherberg , Germany
- e Department of Internal Medicine , Division of Endocrinology, Diabetology, Angiology, Nephrology, and Clinical Chemistry, University Hospital Tübingen , Tübingen , Germany , and
| |
Collapse
|
46
|
Abstract
Investigating complex signatures of biomolecules by mass spectrometry approaches has become indispensable in molecular life science research. Nowadays, various mass spectrometry-based omics technologies are available to monitor qualitative and quantitative changes within hundreds or thousands of biological active components, including proteins/peptides, lipids and metabolites. These comprehensive investigations have the potential to decipher the pathophysiology of disease development at a molecular level and to monitor the individual response of pharmacological treatment or lifestyle intervention.
Collapse
Affiliation(s)
- Stefan Lehr
- a Institute for Clinical Biochemistry and Pathobiochemistry, German Diabetes Center , Duesseldorf , Germany and
| | - Daniel Markgraf
- b Institute for Clinical Diabetology, German Diabetes Center , Duesseldorf , Germany
| |
Collapse
|
47
|
Džinić T, Hartwig S, Lehr S, Dencher NA. Oxygen and differentiation status modulate the effect of X-ray irradiation on physiology and mitochondrial proteome of human neuroblastoma cells. Arch Physiol Biochem 2016; 122:257-265. [PMID: 27615280 DOI: 10.1080/13813455.2016.1218518] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
Cytotoxic effects, including oxidative stress, of low linear energy transfer (LET)-ionizing radiation are often underestimated and studies of their mechanisms using cell culture models are widely conducted with cells cultivated at atmospheric oxygen that does not match its physiological levels in body tissues. Also, cell differentiation status plays a role in the outcome of experiments. We compared effects of 2 Gy X-ray irradiation on the physiology and mitochondrial proteome of nondifferentiated and human neuroblastoma (SH-SY5Y) cells treated with retinoic acid cultivated at 21% and 5% O2. Irradiation did not affect the amount of subunits of OxPhos complexes and other non-OxPhos mitochondrial proteins, except for heat shock protein 70, which was increased depending on oxygen level and differentiation status. These two factors were proven to modulate mitochondrial membrane potential and the bioenergetic status of cells. We suggest, moreover, that oxygen plays a role in the differentiation of human SH-SY5Y cells.
Collapse
Affiliation(s)
- Tamara Džinić
- a Physical Biochemistry, Department of Chemistry , Technische Universität Darmstadt , Darmstadt , Germany
| | - Sonja Hartwig
- b Institute of Clinical Biochemistry and Pathobiochemistry, German Diabetes Center at the Heinrich-Heine-University Düsseldorf, Leibniz Center for Diabetes Research , Düsseldorf , Germany , and
- c German Center for Diabetes Research (DZD) , München , Neuherberg , Germany
| | - Stefan Lehr
- b Institute of Clinical Biochemistry and Pathobiochemistry, German Diabetes Center at the Heinrich-Heine-University Düsseldorf, Leibniz Center for Diabetes Research , Düsseldorf , Germany , and
- c German Center for Diabetes Research (DZD) , München , Neuherberg , Germany
| | - Norbert A Dencher
- a Physical Biochemistry, Department of Chemistry , Technische Universität Darmstadt , Darmstadt , Germany
| |
Collapse
|
48
|
Knebel B, Mack S, Lehr S, Barsch A, Schiller M, Haas J, Lange S, Fuchser J, Zurek G, Müller-Wieland D, Kotzka J. Untargeted mass spectrometric approach in metabolic healthy offspring of patients with type 2 diabetes reveals medium-chain acylcarnitine as potential biomarker for lipid induced glucose intolerance (LGIT). Arch Physiol Biochem 2016; 122:266-280. [PMID: 27373781 DOI: 10.1080/13813455.2016.1197277] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
Abstract
Offspring of type 2 diabetes (T2D) patients have increased risk to develop diabetes, due to inherited genetic susceptibility that directly interferes with the individual adaption to environmental conditions. We characterise T2D offspring (OSP) to identify metabolic risk markers for early disease prediction. Plasma of metabolically healthy OSP individuals (n = 43) was investigated after an oral lipid tolerance test (oLTT) by an untargeted mass spectrometric approach for holistic metabolome analyses. Two subgroups of OSP probands can be separated by oLTT, although not differing in general clinical parameters. Analyses of the plasma metabolome revealed mainly medium-chain acylcarnitines and very long-chain fatty acids with differential abundance in the subgroups. The study presented indicates that metabolically healthy OSP of T2D patients differ upon metabolic challenging in serum metabolite composition, especially medium-chain acylcarnitines. The difference suggest that postprandial lipid induced glucose intolerance (LGIT) may serve as a further valuable marker for early diabetes prediction.
Collapse
Affiliation(s)
- Birgit Knebel
- a Leibniz Center for Diabetes Research, Institute of Clinical Biochemistry and Pathobiochemistry, German Diabetes Center at the Heinrich-Heine-University Duesseldorf , Düsseldorf , Germany
- b German Center for Diabetes Research (DZD), Muenchen-Neuherberg , Germany
| | - Susanne Mack
- c Institute for Diabetes Research, Department of General Internal Medicine, Asklepios Klinik St. Georg, Medical Faculty of Semmelweis University , Hamburg , Germany , and
| | - Stefan Lehr
- a Leibniz Center for Diabetes Research, Institute of Clinical Biochemistry and Pathobiochemistry, German Diabetes Center at the Heinrich-Heine-University Duesseldorf , Düsseldorf , Germany
- b German Center for Diabetes Research (DZD), Muenchen-Neuherberg , Germany
| | - Aiko Barsch
- d Bruker Daltonik GmbH , Bremen , Germany , and
| | - Martina Schiller
- a Leibniz Center for Diabetes Research, Institute of Clinical Biochemistry and Pathobiochemistry, German Diabetes Center at the Heinrich-Heine-University Duesseldorf , Düsseldorf , Germany
- b German Center for Diabetes Research (DZD), Muenchen-Neuherberg , Germany
| | - Jutta Haas
- c Institute for Diabetes Research, Department of General Internal Medicine, Asklepios Klinik St. Georg, Medical Faculty of Semmelweis University , Hamburg , Germany , and
| | - Simone Lange
- c Institute for Diabetes Research, Department of General Internal Medicine, Asklepios Klinik St. Georg, Medical Faculty of Semmelweis University , Hamburg , Germany , and
| | | | | | - Dirk Müller-Wieland
- e Department of Internal Medicine I , University Hospital Aachen , Aachen , Germany
| | - Jorg Kotzka
- a Leibniz Center for Diabetes Research, Institute of Clinical Biochemistry and Pathobiochemistry, German Diabetes Center at the Heinrich-Heine-University Duesseldorf , Düsseldorf , Germany
- b German Center for Diabetes Research (DZD), Muenchen-Neuherberg , Germany
| |
Collapse
|
49
|
Knebel B, Lehr S, Janssen OE, Hahn S, Jacob S, Nitzgen U, Müller-Wieland D, Kotzka J. Association between copy-number variation on metabolic phenotypes and HDL-C levels in patients with polycystic ovary syndrome. Mol Biol Rep 2016; 44:51-61. [DOI: 10.1007/s11033-016-4080-1] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2016] [Accepted: 09/09/2016] [Indexed: 01/08/2023]
|
50
|
Knebel B, Strassburger K, Szendroedi J, Kotzka J, Scheer M, Nowotny B, Müssig K, Lehr S, Pacini G, Finner H, Klüppelholz B, Giani G, Al-Hasani H, Roden M. Specific Metabolic Profiles and Their Relationship to Insulin Resistance in Recent-Onset Type 1 and Type 2 Diabetes. J Clin Endocrinol Metab 2016; 101:2130-40. [PMID: 26829444 DOI: 10.1210/jc.2015-4133] [Citation(s) in RCA: 46] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
CONTEXT Insulin resistance reflects the inadequate insulin-mediated use of metabolites and predicts type 2 diabetes (T2D) but is also frequently seen in long-standing type 1 diabetes (T1D) and represents a major cardiovascular risk factor. OBJECTIVE We hypothesized that plasma metabolome profiles allow the identification of unique and common early biomarkers of insulin resistance in both diabetes types. DESIGN, SETTING, AND PATIENTS Two hundred ninety-five plasma metabolites were analyzed by mass spectrometry from patients of the prospective observational German Diabetes Study with T2D (n = 244) or T1D (n = 127) and known diabetes duration of less than 1 year and glucose-tolerant persons (CON; n = 129). Abundance of metabolites was tested for association with insulin sensitivity as assessed by hyperinsulinemic-euglycemic clamps and related metabolic phenotypes. MAIN OUTCOMES MEASURES Sixty-two metabolites with phenotype-specific patterns were identified using age, sex, and body mass index as covariates. RESULTS Compared with CON, the metabolome of T2D and T1D showed similar alterations in various phosphatidylcholine species and amino acids. Only T2D exhibited differences in free fatty acids compared with CON. Pairwise comparison of metabolites revealed alterations of 28 and 49 metabolites in T1D and T2D, respectively, when compared with CON. Eleven metabolites allowed differentiation between both diabetes types and alanine, α-amino-adipic acid, isoleucin, and stearic acid showed an inverse association with insulin sensitivity in both T2D and T1D combined. CONCLUSION Metabolome analyses from recent-onset T2D and T1D patients enables identification of defined diabetes type-specific differences and detection of biomarkers of insulin sensitivity. These analyses may help to identify novel clinical subphenotypes diabetes.
Collapse
Affiliation(s)
- Birgit Knebel
- Institute for Clinical Biochemistry and Pathobiochemistry (B.Kn., J.K., S.L., H.-A.H.), Institute for Biometrics and Epidemiology (K.S., M.S., H.F., B.Kl., G.G.), Institute for Clinical Diabetology (J.S., B.N., K.M., M.R.), German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University, and Department of Endocrinology and Diabetology (J.S., B.N., K.M., M.R.), Medical Faculty, Heinrich Heine University 40225 Duesseldorf, Germany; German Center for Diabetes Research (B.Kn., K.S., J.S., J.K., M.S., B.N., K.M., S.L., H.F., B.Kl., G.G., H.-A.H., M.R.), 85764 Muenchen-Neuherberg, Germany; and Metabolic Unit (G.P.), Institute of Neuroscience, Research Program on Aging of the Italian Research Council, 35127 Padua, Italy
| | - Klaus Strassburger
- Institute for Clinical Biochemistry and Pathobiochemistry (B.Kn., J.K., S.L., H.-A.H.), Institute for Biometrics and Epidemiology (K.S., M.S., H.F., B.Kl., G.G.), Institute for Clinical Diabetology (J.S., B.N., K.M., M.R.), German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University, and Department of Endocrinology and Diabetology (J.S., B.N., K.M., M.R.), Medical Faculty, Heinrich Heine University 40225 Duesseldorf, Germany; German Center for Diabetes Research (B.Kn., K.S., J.S., J.K., M.S., B.N., K.M., S.L., H.F., B.Kl., G.G., H.-A.H., M.R.), 85764 Muenchen-Neuherberg, Germany; and Metabolic Unit (G.P.), Institute of Neuroscience, Research Program on Aging of the Italian Research Council, 35127 Padua, Italy
| | - Julia Szendroedi
- Institute for Clinical Biochemistry and Pathobiochemistry (B.Kn., J.K., S.L., H.-A.H.), Institute for Biometrics and Epidemiology (K.S., M.S., H.F., B.Kl., G.G.), Institute for Clinical Diabetology (J.S., B.N., K.M., M.R.), German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University, and Department of Endocrinology and Diabetology (J.S., B.N., K.M., M.R.), Medical Faculty, Heinrich Heine University 40225 Duesseldorf, Germany; German Center for Diabetes Research (B.Kn., K.S., J.S., J.K., M.S., B.N., K.M., S.L., H.F., B.Kl., G.G., H.-A.H., M.R.), 85764 Muenchen-Neuherberg, Germany; and Metabolic Unit (G.P.), Institute of Neuroscience, Research Program on Aging of the Italian Research Council, 35127 Padua, Italy
| | - Jorg Kotzka
- Institute for Clinical Biochemistry and Pathobiochemistry (B.Kn., J.K., S.L., H.-A.H.), Institute for Biometrics and Epidemiology (K.S., M.S., H.F., B.Kl., G.G.), Institute for Clinical Diabetology (J.S., B.N., K.M., M.R.), German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University, and Department of Endocrinology and Diabetology (J.S., B.N., K.M., M.R.), Medical Faculty, Heinrich Heine University 40225 Duesseldorf, Germany; German Center for Diabetes Research (B.Kn., K.S., J.S., J.K., M.S., B.N., K.M., S.L., H.F., B.Kl., G.G., H.-A.H., M.R.), 85764 Muenchen-Neuherberg, Germany; and Metabolic Unit (G.P.), Institute of Neuroscience, Research Program on Aging of the Italian Research Council, 35127 Padua, Italy
| | - Marsel Scheer
- Institute for Clinical Biochemistry and Pathobiochemistry (B.Kn., J.K., S.L., H.-A.H.), Institute for Biometrics and Epidemiology (K.S., M.S., H.F., B.Kl., G.G.), Institute for Clinical Diabetology (J.S., B.N., K.M., M.R.), German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University, and Department of Endocrinology and Diabetology (J.S., B.N., K.M., M.R.), Medical Faculty, Heinrich Heine University 40225 Duesseldorf, Germany; German Center for Diabetes Research (B.Kn., K.S., J.S., J.K., M.S., B.N., K.M., S.L., H.F., B.Kl., G.G., H.-A.H., M.R.), 85764 Muenchen-Neuherberg, Germany; and Metabolic Unit (G.P.), Institute of Neuroscience, Research Program on Aging of the Italian Research Council, 35127 Padua, Italy
| | - Bettina Nowotny
- Institute for Clinical Biochemistry and Pathobiochemistry (B.Kn., J.K., S.L., H.-A.H.), Institute for Biometrics and Epidemiology (K.S., M.S., H.F., B.Kl., G.G.), Institute for Clinical Diabetology (J.S., B.N., K.M., M.R.), German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University, and Department of Endocrinology and Diabetology (J.S., B.N., K.M., M.R.), Medical Faculty, Heinrich Heine University 40225 Duesseldorf, Germany; German Center for Diabetes Research (B.Kn., K.S., J.S., J.K., M.S., B.N., K.M., S.L., H.F., B.Kl., G.G., H.-A.H., M.R.), 85764 Muenchen-Neuherberg, Germany; and Metabolic Unit (G.P.), Institute of Neuroscience, Research Program on Aging of the Italian Research Council, 35127 Padua, Italy
| | - Karsten Müssig
- Institute for Clinical Biochemistry and Pathobiochemistry (B.Kn., J.K., S.L., H.-A.H.), Institute for Biometrics and Epidemiology (K.S., M.S., H.F., B.Kl., G.G.), Institute for Clinical Diabetology (J.S., B.N., K.M., M.R.), German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University, and Department of Endocrinology and Diabetology (J.S., B.N., K.M., M.R.), Medical Faculty, Heinrich Heine University 40225 Duesseldorf, Germany; German Center for Diabetes Research (B.Kn., K.S., J.S., J.K., M.S., B.N., K.M., S.L., H.F., B.Kl., G.G., H.-A.H., M.R.), 85764 Muenchen-Neuherberg, Germany; and Metabolic Unit (G.P.), Institute of Neuroscience, Research Program on Aging of the Italian Research Council, 35127 Padua, Italy
| | - Stefan Lehr
- Institute for Clinical Biochemistry and Pathobiochemistry (B.Kn., J.K., S.L., H.-A.H.), Institute for Biometrics and Epidemiology (K.S., M.S., H.F., B.Kl., G.G.), Institute for Clinical Diabetology (J.S., B.N., K.M., M.R.), German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University, and Department of Endocrinology and Diabetology (J.S., B.N., K.M., M.R.), Medical Faculty, Heinrich Heine University 40225 Duesseldorf, Germany; German Center for Diabetes Research (B.Kn., K.S., J.S., J.K., M.S., B.N., K.M., S.L., H.F., B.Kl., G.G., H.-A.H., M.R.), 85764 Muenchen-Neuherberg, Germany; and Metabolic Unit (G.P.), Institute of Neuroscience, Research Program on Aging of the Italian Research Council, 35127 Padua, Italy
| | - Giovanni Pacini
- Institute for Clinical Biochemistry and Pathobiochemistry (B.Kn., J.K., S.L., H.-A.H.), Institute for Biometrics and Epidemiology (K.S., M.S., H.F., B.Kl., G.G.), Institute for Clinical Diabetology (J.S., B.N., K.M., M.R.), German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University, and Department of Endocrinology and Diabetology (J.S., B.N., K.M., M.R.), Medical Faculty, Heinrich Heine University 40225 Duesseldorf, Germany; German Center for Diabetes Research (B.Kn., K.S., J.S., J.K., M.S., B.N., K.M., S.L., H.F., B.Kl., G.G., H.-A.H., M.R.), 85764 Muenchen-Neuherberg, Germany; and Metabolic Unit (G.P.), Institute of Neuroscience, Research Program on Aging of the Italian Research Council, 35127 Padua, Italy
| | - Helmut Finner
- Institute for Clinical Biochemistry and Pathobiochemistry (B.Kn., J.K., S.L., H.-A.H.), Institute for Biometrics and Epidemiology (K.S., M.S., H.F., B.Kl., G.G.), Institute for Clinical Diabetology (J.S., B.N., K.M., M.R.), German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University, and Department of Endocrinology and Diabetology (J.S., B.N., K.M., M.R.), Medical Faculty, Heinrich Heine University 40225 Duesseldorf, Germany; German Center for Diabetes Research (B.Kn., K.S., J.S., J.K., M.S., B.N., K.M., S.L., H.F., B.Kl., G.G., H.-A.H., M.R.), 85764 Muenchen-Neuherberg, Germany; and Metabolic Unit (G.P.), Institute of Neuroscience, Research Program on Aging of the Italian Research Council, 35127 Padua, Italy
| | - Birgit Klüppelholz
- Institute for Clinical Biochemistry and Pathobiochemistry (B.Kn., J.K., S.L., H.-A.H.), Institute for Biometrics and Epidemiology (K.S., M.S., H.F., B.Kl., G.G.), Institute for Clinical Diabetology (J.S., B.N., K.M., M.R.), German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University, and Department of Endocrinology and Diabetology (J.S., B.N., K.M., M.R.), Medical Faculty, Heinrich Heine University 40225 Duesseldorf, Germany; German Center for Diabetes Research (B.Kn., K.S., J.S., J.K., M.S., B.N., K.M., S.L., H.F., B.Kl., G.G., H.-A.H., M.R.), 85764 Muenchen-Neuherberg, Germany; and Metabolic Unit (G.P.), Institute of Neuroscience, Research Program on Aging of the Italian Research Council, 35127 Padua, Italy
| | - Guido Giani
- Institute for Clinical Biochemistry and Pathobiochemistry (B.Kn., J.K., S.L., H.-A.H.), Institute for Biometrics and Epidemiology (K.S., M.S., H.F., B.Kl., G.G.), Institute for Clinical Diabetology (J.S., B.N., K.M., M.R.), German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University, and Department of Endocrinology and Diabetology (J.S., B.N., K.M., M.R.), Medical Faculty, Heinrich Heine University 40225 Duesseldorf, Germany; German Center for Diabetes Research (B.Kn., K.S., J.S., J.K., M.S., B.N., K.M., S.L., H.F., B.Kl., G.G., H.-A.H., M.R.), 85764 Muenchen-Neuherberg, Germany; and Metabolic Unit (G.P.), Institute of Neuroscience, Research Program on Aging of the Italian Research Council, 35127 Padua, Italy
| | - Hadi Al-Hasani
- Institute for Clinical Biochemistry and Pathobiochemistry (B.Kn., J.K., S.L., H.-A.H.), Institute for Biometrics and Epidemiology (K.S., M.S., H.F., B.Kl., G.G.), Institute for Clinical Diabetology (J.S., B.N., K.M., M.R.), German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University, and Department of Endocrinology and Diabetology (J.S., B.N., K.M., M.R.), Medical Faculty, Heinrich Heine University 40225 Duesseldorf, Germany; German Center for Diabetes Research (B.Kn., K.S., J.S., J.K., M.S., B.N., K.M., S.L., H.F., B.Kl., G.G., H.-A.H., M.R.), 85764 Muenchen-Neuherberg, Germany; and Metabolic Unit (G.P.), Institute of Neuroscience, Research Program on Aging of the Italian Research Council, 35127 Padua, Italy
| | - Michael Roden
- Institute for Clinical Biochemistry and Pathobiochemistry (B.Kn., J.K., S.L., H.-A.H.), Institute for Biometrics and Epidemiology (K.S., M.S., H.F., B.Kl., G.G.), Institute for Clinical Diabetology (J.S., B.N., K.M., M.R.), German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University, and Department of Endocrinology and Diabetology (J.S., B.N., K.M., M.R.), Medical Faculty, Heinrich Heine University 40225 Duesseldorf, Germany; German Center for Diabetes Research (B.Kn., K.S., J.S., J.K., M.S., B.N., K.M., S.L., H.F., B.Kl., G.G., H.-A.H., M.R.), 85764 Muenchen-Neuherberg, Germany; and Metabolic Unit (G.P.), Institute of Neuroscience, Research Program on Aging of the Italian Research Council, 35127 Padua, Italy
| | | |
Collapse
|